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Abstract
Evidence is now emerging which suggests that in addition to the ability of integrins to regulate cell 
adhesion through signalling events to other cell surface receptors they may also play a role in the 
regulation of other integrins expressed on the same cell surface. While the data on LFA-1 is limited, 
published reports suggest that this integrin when activated can both down- and up-regulate the 
binding of a4pl and a5(3l to their respective ligands. Using a novel method we expressed a soluble 
form of LFA-1 which was subsequently used to identify a series of constitutively activated forms of 
LFA-1 generated through introduction of novel and published mutations into the I Domain IDAS. 
Having established their increased activity over wild type LFA-1, the mutant foims of LFA-1 were 
used to investigate the ability of full length LFA-1 to regulate the binding of a4pl and aSpi when 
expressed on the same cell surface. While mutations in the LFA-1 I domain currently known to 
promote ligand binding were not sufficient alone to promote integrin crosstalk in either the K562 or 
JB2.7 cell systems, in the presence of mAh KIM127, crosstalk between a5|3l and all forms of K562 
surface expressed LFA-1 was effectively induced. However, the lack of crosstalk with the JB2.7 cell 
line, even in the presence of KIM127, suggests that this phenomenon may be further complicated by 
cell-line specific differences.
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   Chapter 1
Chapter 1 Introduction
1.1 General introduction
Adhesive interactions of cells with other cells and with the extracellular matrix are required for a 
diverse range of physiological processes that include tissue morphogenesis, inflammation, 
immune responses, leucocyte trafficking and regulation of cell growth and differentiation 
(Hynes, 1992; Springer, 1994). Integrins and their ligands play a central role in regulating such 
processes by bridging the gap between the cell cytoskeleton and the extracellular environment, 
mediating both cell adhesion and activation of many intracellular signalling pathways.
Integrins are a protein family of noncovalently associated, type 1 transmembrane a and (3- 
subunits. To date the family consists of 24 members, made up of 18 a-chains and 8 P-chains 
which combine in a partly restricted manner to form the 24 different dimers (Figure. 1.1). Both 
the a and P subunits contain large extracellular domains of more than 940 and 640 residues, 
respectively (Gahmberg et al., 1997(a)) as well as short but functionally important intracellular 
domains of ~50 residues (Figure. 1.2). Integrins bind to a diverse range of ligands, including 
components of the extracellular matrix, cell surface Ig superfamily receptors, components of 
microorganisms, and certain plasma proteins (Ginsberg et al., 1983; Marlin and Springer, 1987). 
Individual integrins can bind more than one ligand, and, although specific ligands can be 
recognised by more than one integrin, differences in affinity ensure that there is very little 
functional redundancy in such interactions.
The integrin of particular interest for this work is LFA-1. LFA-1 (aLp2) is a member of the 
leucocyte-specific branch of the integrin family which also includes aMp2 (Amaout et al., 1988; 
Corbi et al, 1988), aXp2 (p i50, 95) (Sanchez-Madrid et a l, 1983) and aDp2 (Van Der Vieren 
et a l, 1995). While LFA-1 is constitutively expressed on the cell surface, the other family
2
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members require cell activation for expression on the cell surface. Table 1.1 illustrates the 
cellular distribution of the P2 integrins and their known ligands. There is a significant degree of 
overlap in ligand specificity amongst the different p2 integrins, where the predominant ligands 
are members of the Ig superfamily. Although LFA-1 expression is limited to leucocytes, it is 
involved in a broad range of immunological processes including leucocyte extravasation, antigen 
presentation, and T-lymphocyte alloantigen-induced proliferation (Springer et a l, 1987). The 
functional importance of LFA-1 and the other P2 integrins was first recognized by the clinical 
condition LAD-1 (leucocyte adhesion deficiency type 1), where a mutation within the p2 chain 
results in loss of expression of LFA-1 (and other members of the P2 family) leading to a number 
of leucocyte defects including greatly diminished neutrophil emigration into inflammatory sites, 
leaving patients susceptible to life-threatening bacterial infections (Gahmberg, et ah, 1997(b)). 
A wealth of data from knock-out animal and in vivo studies with monoclonal antibodies (mAbs) 
have highlighted the important role LFA-1 plays in both normal and pathological conditions 
(reviewed by de Fougerolles, 2003).
Because of the importance of LFA-1 and integrins in general, both in normal and disease states, 
much research over the last few years has focused on increasing our knowledge of how integrins 
function and the processes that are involved in their activation and regulation. In particular, the 
elucidation of the crystal structure of the extracellular domains of aVp3 integrin heterodimer and 
the crystal structures of I domains complexed with ligand, along with extensive mapping of mAb 
epitopes and mutagenesis studies, have suggested that integrins are molecules in dynamic 
equilibrium at the cell surface, capable of interacting with a wide range of proteins both 
intracellularly and extracellularly.
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Figure 1.1 The Integrin Receptor Family. This figure represents the 24 distinet integrins made up of pairings 
between 18a-subunits and SP-subunits. The family can further be divided into several subfamilies based 
on ligand specificity, and in the case of the P2 and P? integrins, their restricted expression on leucocytes, a 
subunits with hatched lines contain an inserted /I domain. Diagram taken from Hynes (2002).
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domainHy br i d
d o m a i n
Transmembrane Domain
Figure 1.2 Schematic of the overall structure of an I domain containing integrin. This diagram illustrates the 
organisation of the 6 distinct domains of the aL subunit and the 9 distinet domains of the P2 subunit 
within the primary structure of an 1 domain-containing integrin. The blue asterisks depict the MIDAS 
(Metal Ion Dependent Adhesion Site) present in both the I domain and I-like domain. The red 
asterisks depict putative Ca^  ^ binding sites and the yellow asterisk depicts the ADMIDAS (Adjacent 
Metal Ion Dependent Adhesion Site)
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All leukocytes Myeloid cells.
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Macrophages
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Macrophages, 
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Macrophages,
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Monocytes
LIGANDS lCAM-1,
lCAM-2,
lCAM-3,
lCAM-4,
JAM-1
lCAM-1,
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Fibrinogen,
NIF, Factor X,
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FUNCTION Leukocyte
extravasation,
Ag presentation,
T- lymphocyte
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induced
proliferation
Phagocytosis,
leukocyte
extravasation,
chemotaxis,
activation of
neutrophils and
monocytes.
Monocyte adhesion 
and chemotaxis
Table 1.1 Cellular distribution and function of the various P2 integrins. This table describes the cellular
distribution, ligand specificity and major functions of each of the P2 integrins. [ICAM = intracellular 
adhesion molecule; VCAM = vascular cell adhesion molecule 1; NIF = neutrophil inhibitory factor; 
JAM = junction adhesion molecule; TLN = telencephalon]
This introduction will summarise what is known about the general structure of integrins based on 
the X-ray crystal and NMR data published to date. This will be followed by a review of how the 
various integrin and I domain structural conformations can be interpreted to explain integrin 
activation and ligand binding with particular reference to LFA-1. The remainder of the 
introduction will cover in detail the function, ligand binding and activation of LFA-1.
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1.2 General Integrin Structure
For many years the only structural information about integrins came from images generated in 
electron microscopy studies of the extracellular region of allbps (Du et a l, 1993). This showed 
that the extracellular segment consisted of a globular head and two long stalk regions which 
connect the globular head to the cell membrane. However, within the last few years resolution 
of the crystal structure of the extracellular portion of aVp3 (Xiong et a l, 2001, 2002) has greatly 
enhanced our understanding of the overall structure of integrins. In addition to this information 
the high level of sequence homology (the a and P-subunits of all integrins share an overall amino 
acid identity of 25% and 37-45% respectively) and correlation of computer-based predictions of 
several integrin domain structures allows one to use this structure as a representation of a 
composite integrin tertiary structure from which the possible mechanisms of activation can be 
postulated. The crystal structure, resolved to 3.1Â, predicted the presence of 12 domains within 
the ap heterodimer extracellular portion of the integrin (Figure. 1.3). Of these 12 domains, 8, and 
a portion of the ninth were fully resolved. A complementary NMR structure of a P2 integrin 
fragment (Beglova et a l, 2002) later revealed the structure of some of the missing domains and 
helped to further define the overall integrin structure. The structure of the twelve domains (13 
for I domain-containing integrins) that assemble into an ovoid head and two legs will be 
described in detail in the following section.
1.2.1. The a-chain head region
The head region of the a  subunit is formed from a seven bladed P-propeller domain (Tuckwell et 
al, 1994; Springer, 1997) and in 9 out of the 18 integrin a-subunits there is an inserted domain 
(known as the 1 domain) between blades 2 and 3.
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Figure 1.3 Ribbon diagram of the three-dimensional structure of aVp3 and schematic of a general integrin 
with an I Domain based on the aVP3 structure The structure shown on the left hand side is o f the 
unliganded aV p3 structure (Xiong et al., 2001) with the schematic on the right hand side giving a 
clearer view o f  the position o f the domains relative to each other. The schematic also includes an 1 
domain which is not present in the aVP3 integrin. In the crystal structure the integrin is folded over 
with the head region bent over towards the C termini o f  the stalks. The structure o f the PSI domain 
and I-EGF repeats 1 and 2 are not well resolved and are estimates only. Ribbon diagram from Xiong et 
al. (2001). Schematic is based on diagram from Beglova et al. (2002).
1.2.1.1 P propeller
The N-terminal region o f  the a-chain contains 7 weakly homologous segments o f  approximately 
60 amino acids each. The crystal structure shows that P-strands o f  each o f  the seven  
homologous segments are arranged around a central axis like blades resembling a propeller (See  
Figure 1.4). A  P-propeller conformation had previously been predicted by Springer, T.A., 
(1997) and was later confirmed with mAh binding studies which identified several discontinuous 
epitopes in the region (Oxvig and Springer, 1998). The similarity o f the Ca^  ^ binding motifs in 
P-strands 4-7 o f  the propeller to turns between P-strands in domains o f  other proteins such as the
7
Chapter I
trimeric G -protein (3-unit also helped to define the structure (Springer et a l ,  1997, 2000). 
binding sites, all solvent exposed in the Ca^  ^ complexed crystal structure, were also identified in 
the (3-hairpin loops o f blades 4-7 at the bottom o f  the propeller.
w«
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Figure 1.4 Ribbon Structure of a P-propeller. This ribbon structure represents the top (A) and side (B) view o f 
the a4  P-propeller containing seven four stranded P-sheet blades (each in a different eolour arranged 
around a eentral eore. The thiek arrows depict the P-strands. Putative Ca^^ and Mg^^ binding sites are 
represented by gold and silver spheres respeetively. When present, the I domain would be inserted 
between blades 2 and 3. (Springer 1997).
1.2.1.2 I dom ain
Nine o f the known integrin a-subunits, including all those that pair with the p2 subunit, contain 
a 200 amino acid inserted domain, known as the I domain, between blades 2 and 3 o f  the P- 
propeller. Independent crystal structures have now been determined for the I domains o f  aM  
(Baldwin et al., 1998; Lee et a l ,  1995a, 1995b), aL (Kallen et a i ,  1999; Legge et al., 2000; Qu 
and Leahy, 1995, 1996), o2 (Emsley et a l ,  1997, 2000), and a l (Nolte et a l ,  1999) integrin 
subunits. Initial studies showed that all 4 o f  these 1 domains, which have -30%  sequence
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homology adopt the same 3D structure. They consist o f  a dinucleotide-binding or Rossmann 
fold, with a-helices surrounding a central P-sheet containing five parallel and one anti-parallel (3- 
strand (Figure 1.5). The (3-strands and a-helices tend to alternate in the secondary structure, with 
the a-helices wrapping around the domain in a clockwise order. Five residues located in the (31- 
a l ,  a2-a3 and (34-a4 loops on the top face o f  the I domain form a central pocket and their side 
chains coordinate with a Mg^  ^ or Mn^  ^ ion, either directly or via water molecules, to fonu a 
metal ion-dependent adhesion site (MIDAS). The metal-coordinating MIDAS residues, DxSxS, 
are invariant amongst all I domains and mutagenesis o f any o f  these residues has been shown to 
abrogate ligand binding (Edwards et a l ,  1995 & 1998). This data, and ligand binding studies 
with isolated I domains, suggest that this is the major ligand binding site o f I domain-containing 
integrins. This will be discussed in more detail in Section 1.4.
N-terminus C-terminus
Figure 1.5 Ribbon structure of the I domain. This structure shows the tertiary structure o f  the aL  I domain as
determined by X-ray crystallography. The protein adopts a Rossmann fold, with a central sheet o f (3- 
strands surrounded by seven a-helices. The bound cation in the MIDAS is represented by the pink 
sphere (Qu and Leahy, 1995).
For integrins that do not contain an I domain it is proposed that the (3-propeller participates 
directly in ligand binding (Humphries, 2000). Mutagenesis studies initially indicated that ligand 
binding residues cluster at the top and side of the (3-propeller (Kamata, 1995) and the 
aVps/ligand crystal structure data is in agreement with this (discussed in more detail in Section 
1.4).
1.2.2. The p-chain head region
The N-terminal globular head region of the p-chain within the aVp3 crystal structure was shown 
to resemble one of the conformations of the a-subunit I domain and is referred to as the I-like 
domain or A-domain (Xiong et ah, 2000). The existence of an I-like domain which 
approximately spans residues 100-340 of the integrin P-chain had previously been predicted 
based on the conserved DXSXS sequence of the MIDAS motif within the region and a predicted 
secondary structure which had a weak but detectable sequence homology with the a-chain I 
domain (Lee et aL, 1995(a&b); Tuckwell and Humphries, 1997). Epitope mapping with 6 
different mAbs had also suggested a Rossmann-like fold as residues 133 of a-helix 1, and 
residues 332 and 339 of a-helix 6 were predicted to be in close proximity to one another (Huang 
et aL, 2000). The I-like domain MIDAS region contains the same residues as that of the a  I 
domain, except that the threonine is replaced by a glutamic acid residue. This domain appears to 
be involved in binding ligand in integrins that lack I domains, and to indirectly regulate ligand 
binding in integrins that contain I domains.
The I-like domain is connected to its stalk via a hybrid domain which is a P-sandwich fold 
comprised of amino acid segments on either side of the I-like domain (See Figure 1.2). 
Hydrophilic and hydrophobic contacts contributed from residues on two loops of the hybrid
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domain, and residues at the base of the I-like domain form a circular interface between the 2 
domains. Takagi and Springer (2002) suggest that movement of one of these connections 
relative to the other may be an important mechanism for relating conformational change within 
domains. They predict that changes in the orientation of neighbouring domains in both the a and 
P subunits could propagate global conformational changes within the integrin.
1.2.3. Contact points between the a-p subunits of the globular head
Several lines of investigation suggest that there is a large interaction between the P-propeller and 
the I-like domain in all integrins. These include the findings that (a) the anti-LFA-1 mAb YTA- 
1 can recognize an epitope formed by a combination of the integrin aL and p2 subunits of LFA- 
1 but does not see the individual subunits alone (Zang et aL, 2000), (b) the epitopes of the 
allbps mAbs, PAC-1, LJ-CP3 and OP-G2 consist of several discontinuous sites in both the allb 
and p3 subunits (Puzon-Mclaughlin et aL, 2000), (c) several attempts at generating an isolated, 
correctly folded form of the I-like domain without the presence of the P-propeller have been 
unsuccessful, and (d) mutations within the region of the I-like domain which contacts the P- 
propeller including the natural mutations that occur in LAD-1, lead to a lack of association of 
the a  and P subunits (Bilsland and Springer, 1994). Analysis of the crystal structure has 
supported these findings and showed that the interface is largely hydrophobic and has a buried 
surface area of ~1600Â^ which is typical for a large protein-protein interface. In the propeller, 2 
aromatic rings contributed from a conserved OOGlyO motif (0  =aromatic residue) at the 
beginning of each blade appear to form a cup-like structure, which grasp a basic residue 
(arginine in P3) in the I-like domain. This was shown to be further strengthened by extensive 
hydrophobic and hydrophilic contacts surrounding this region (Xiong et aL, 2001).
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Although the solved structure of the aV subunit does not contain an I domain, it is predicted that 
the insertion of this domain would have little effect on the overall structure of the ap globular 
head. Blades 2 and 3 of the p-propeller are positioned away from the P-propeller/I-like domain 
interface and the I domain is thought to loop away from the P-propeller. Although the N 
terminus of the I domain is only separated by a short 3 residue linker from the last p-strand of 
blade 2, which suggests a close association with the p-propeller, the C-terminus has a ~20 amino 
acid linker connecting it with the P-strand 1 in blade 3 of the P-propeller. This much longer 
linker, containing several cysteines, indicates a much more flexible relationship with the 
propeller and may permit conformational movement. It has been suggested that the ‘open’ and 
‘closed’ conformations of the I domain may be regulated by the interaction of the C-terminal 
linker with the P-propeller and /or the I-like domain.
1.2.4. The a-subunit stalk domains
The ~500 residues of the extracellular region of the a-subunit, at the C-terminus of the P- 
propeller domain, make up the stalk region. The aVp3 crystal structure reveals that this region 
consists of a C2-type Ig-like ‘thigh’ domain and two similar P-sandwich domains, named calf-1 
and calf-2. The central axis of the p-propeller is almost perpendicular to the main axis of the 
thigh domain and residues clustered on one side at the bottom of the propeller insert into an 
ovoid groove at the top of the thigh domain. The propeller/thigh interface has a mixed 
hydrophobic and hydrophilic nature but lacks salt bridges suggesting that it has some degree of 
flexibility (Amaout et a l, 2002).
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Calf-1 and -2 make substantial, and largely hydrophobic, interdomain contacts with each other 
but the lack of an intervening amino acid linker suggests that there is little or no interdomain 
movement. The proteolytic cleavage site that generates the heavy and light chains in certain 
integrins is predicted to be located in a loop within calf-2. However, as this region is disordered 
in the crystal structure, structural information of this area is limited. Xiong et al. (2003(b)) 
suggests that in a-chains that do not contain this site (as in I domain containing integrins) the 
structure of this loop may be modified.
1.2.5. The p-subunit stalk domains
The P-subunit leg is formed from a PSI domain and four tandem EGF-like domains. The p 
globular head is preceded in the linear sequence by an N-terminal 54-residue PSI domain 
(plexins, semaphorins and integrins) which, in the 3D structure, lies below the head region (Bork 
et a l, 1999). It contains seven cysteines, six of which are shared with other PSI domains and is 
predicted to have 2 a-helices. Crystallographic structural data for the PSI domain is limited and 
Xiong et al. (2001) suggest that a higher resolution than 3.1 Â is required for interpretation of 
the electron density in this region.
Four cysteine-rich repeats at the C-terminus of the hybrid domain make up the long extracellular 
stalk that connects the headpiece to the membrane. In the aVp3 crystal structure, only repeats 3 
and 4 were clearly resolved and were both shown to assemble into EGF-like folds and to contain 
P-strands, arranged in a rod-like fashion. A subsequent NMR structure of the second and third 
cysteine-rich repeats of P2 (Beglova et al., 2002) confirmed this EGF-like pattern. However, 
definition of these domain boundaries has proved difficult, due in part to the low sequence 
homology between the repeats. Analysis of the recent NMR solution structure of the p2 stalk
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region led Tagaki et al. (2001) to redefine these boundaries as starting one cysteine earlier at 
position 427 (using P2 numbering) than had previously been predicted (Tamkun et al., 1986; 
Kishimoto et al., 1987). If one compares this to the previously accepted alignment, only three of 
the eight cysteines and one of the four disulphide bonds in each domain are equivalently 
assigned (Berg et al., 1999). Domain deletion and mAb studies show good correlation with 
these predictions (Takagi, et al, 2001) and such redefinition has shown statistically significant 
sequence homology to the EOF (epidermal growth factor) domain and EGF-like domains that 
are found in E-selectin, tenascin X, reelin and ADAM-11 (D’Arcangelo et a l, 1995). This 
realignment also results in a shortening of the interdomain linkers between each repeat, greatly 
limiting the potential for interdomain flexibility and suggesting a rigid connection between 
domains.
Contrary to the P2 NMR study which suggests the alternative cysteine pairing, the EGF domains 
3 and 4 in the aVP3 structure also appear to have minor strands that do not fit in with this new 
realignment. Amaout et al. (2002) have therefore proposed another alternative alignment based 
on the crystal stmcture where each of the 4 EGF-like domains contain 7 cysteines, of which 6 
form 3 internal pairs (typical of EGF domains) and the seventh forms an interdomain disulphide 
bridge between consecutive EGF-like domains. These disulphide bridges are thought to 
resemble the calcium ‘ion bridge’ of classical EGF domains and provide a similar rigidity to the 
stalk region as suggested in the Tagaki model. As several mAbs to integrin activation epitopes 
map to these repeats, and are thought to induce activation through conformational changes, it is 
interesting to note that these domains have unique stmctural properties that make the 
interdomain connection rigid and suited for transmission of stmctural motion in signalling 
(Beglova et al, 2002; Takagi et a l, 2001)
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1.2.6. Contact points between the a and p subunits of the stalk region
Small and only moderate hydrophobic interfaces occur between the (3-propeller and hybrid 
domain, calf-1 and EGF-like domain 3, calf-2 and EGF4, & calf-2 and the (3-chain tail domain 
(Amaout, 2002). It is believed that during integrin activation major stmctural rearrangements 
occur in the stalk regions, particularly in the P-subunit, which results in breaking of these contact 
points. Evidence to support this comes from a set of activating mAbs that bind in the P2 stalk 
region which are thought to activate by acting as a wedge to break the a  and P domain-domain 
contacts (Huang, et al. 2000). Such mAbs include KIM 127 (Figure 1.6) which has been studied 
extensively.
P-Propeller
l-domai
>^9h
Calf-1
K1M 127
epitope
Calf-2
Calf-1
KIM127. 
epitope
Calf-2
Figure 1.6 Binding site of KIM127. Schematic o f the approximate spatial relationship among integrin domains 
and the effect the binding o f KIM 127 has on wedging the a  and P stalk regions apart. The KIM 127 
mAb epitope has been mapped to EGF domain 2. This schematic is based on the model from Lu et al. 
(2001(b))
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1.2.7. Transmembrane and Cytoplasmic domains
The cytoplasmic domains of integrin a and P subunits are relatively short (~50 residues). The 
1000 residue cytoplasmic domain of integrin p4 is an exception and contains large fibronectin 
type III domains which are thought to connect to the cytoskeleton (de Pereda et a l, 1999). As a 
soluble form of aVpS lacking its transmembrane domain was used in the elucidation of the 
crystal structure, no structural data for the transmembrane and cytoplasmic domains is provided 
by this study. However, a model of the allbps cytoplasmic tails derived by NMR spectroscopy 
(Vinogradova et aL, 2002) may provide a generalized model for all integrin cytoplasmic tails 
(with the obvious exception of a6p4). The structure reveals multiple hydrophobic and 
electrostatic contacts within the membrane-proximal helices of the a and the p cytoplasmic tails 
that suggest a method of restraining the integrin in a resting state. These interface interactions 
are disrupted by point mutations and by binding of the cytoskeletal protein talin, both of which 
are known to activate the receptor. Conserved sequences of GFFKR in the a subunit (Muir et 
aL, 1994) and LL(XXX)HDR (Hughes et aL, 1996) in the p subunits have been shown to play an 
important role in integrin activation and will be discussed in more detail in Section 1.6.
The transmembrane region of both the a and P chains comprises 23 amino acids that appear to 
directly contact membrane lipids. Recent investigations reported the presence of an invariant 
lysine at the carboxy-terminal of both transmembrane domains which may be important for the 
lateral mobility of integrin subunits in the membrane (Armulik et aL, 1999)
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1.2.8. Overall crystal structure of aVp3
The elucidation of the aVp3 structure has yielded an enormous amount of information on the 
structure and interactions of many of the domains that make up the heterodimer but the most 
surprising revelation was the overall shape of the integrin. The aVp3 crystal structures in the 
presence of both Ca^  ^and Mn% and with Mn^  ^plus ligand, have all revealed the same V-shaped 
organisation, in which the ligand-binding headpiece bends back towards the base of the stalk 
region and is orientated toward the cell membrane (See Figure 1.3), This contrasts dramatically 
with the linear and extended form as depicted in EM images (Du et aL, 1993). This bend in the 
structure occurs at the ‘integrin knees’, between the thigh and calf-1 domains of aV and in the 
second and third-EGF repeats of P3. This results in the membrane-proximal calf-2 domain lying 
at an acute angle to the plasma membrane with the ligand-binding face facing away from the 
membrane and therefore still available for ligand interaction. Interestingly, there is also contact 
between the F strand/a7 helix loop of the 1-like domain and the p3 TD (Tail Domain) although 
this contact is lost on ligand binding. This bent conformation has led many researchers to 
rethink the way in which integrins in general bind ligand and the conformational changes that 
are predicted, by mAb mapping, to take place on ligand binding. Several theories have been put 
forward to address these issues and will be discussed below in the context of LFA-1,
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1.3 LFA-1
1.3.1. LFA-1 Expression
Lymphocyte function-associated antigen (LFA-1) is formed from the association of an ISOkDa 
a  subunit (CD 11 a) with the 95kDa P2 subunit (CD 18). It was originally identified in mice 
(Davignon et al. 1981) and the human homologue was later cloned and expressed by Kishimoto 
et al. (1987) and Larson et al. (1989). LFA-1 is one of the 9 integrins that contains an I domain 
and this domain has been reported by many studies to play a critical role in LFA-1/ ligand 
interactions (see below). Expression of LFA-1 is restricted to leucocytes, being well expressed 
on the surface of neutrophils, monocytes, macrophages, NK cells, and lymphocytes (Rose et aL, 
2002; Gahmberg et aL, 1997(a)), with expression level and function shown to be dependent on 
the state of cellular activation and differentiation (Dustin and Springer, 1989; Larson and 
Springer, 1990)
1.3.2. LFA-1 Function
LFA-1 has been shown to be associated with two major pathways of fundamental importance in 
inflammation and in the control of specific T-cell immune responses. Firstly, the requirement 
for p2 integrin activation in the rapid modulation of adhesion and de-adhesion necessary for 
controlled migration of leucocytes from the bloodstream and across the endothelium, known as 
extravasation, is well established (Butcher et aL, 1999; Imhof and Dunon, 1995). Although 
selectin molecules are generally thought to be responsible for the rolling of leucocytes along the 
endothelium, tethering of the rolling leucocytes to the endothelium is mainly controlled by 
binding of activated integrins, specifically VLA-4 (also shown to mediate rolling) and LFA-1, to
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their vascular ligands. For LFA-1, interactions with members of the ICAM family are most 
relevant in this context. Recent evidence has also suggested the importance of LFA-1 in the 
initiation of migration through the endothelium to the underlying basement membrane once tight 
adhesion has occurred through interactions with another ligand, JAM-1 (Ostermann et al, 2002).
Secondly, LFA-1 has been shown to play an important role in the priming of T Cells by antigen 
presenting cells (APCs). Although MHC class 1 and class 11 molecules play a central role by 
interacting with the T-cell receptor complex (TCR) and forming an immunological synapse, this 
specific event is dependent on low affinity interactions and, therefore, other molecular 
interactions including integrin/ligand interactions are required to initiate, strengthen and regulate 
such adhesion. It has been proposed that ICAM-3, which is highly expressed on T-lymphocytes, 
mediates the initial low affinity interaction of the T cell and the APC by binding to both LFA-1 
and DC-SIGN (Dendritic Cell-specific lCAM-3 grabbing non-integrin) on the APCs (de 
Fougerolles and Springer, 1992; Montoya et al, 2002; Geijtenbeek et al, 2000). Subsequent 
TCR /specific peptide-MHC, CD3/CD28 and CD2/LFA-3 interactions appear to induce 
clustering and high affinity LFA-1/ICAM-1 binding which serves to strengthen the interface 
which can be sustained for up to 20 hours in vitro (Dustin and Springer, 1989; van Kooyk et al, 
1989; Dustin and Cooper, 2000). During this process, LFA-1 and lCAM-1 molecules have been 
shown to initially cluster at the centre of the synapse surrounded by a ring of TCR/MHC peptide 
but, within minutes, they move to the periphery of the ring with the TCR/MHC taking up the 
central position (Dustin et al, 2002).
The functional importance of (32 integrins, and in particular LFA-1, is exemplified by the clinical 
condition known as leucocyte adhesion deficiency type 1 (LAD-1), in which mutations in the 
common (32 subunit result in the absence (or very low levels) of expression of all (32 integrins. 
This lack of expression leads to almost complete lack of neutrophil emigration into 
inflammatory sites, resulting in an increased risk of recurring life-threatening bacterial infections
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(Gahmberg et a l, 1997(a)). Subsequent studies using aL and P2 knockout mice have shown 
that, while aL deficient mice have reduced neutrophil migration (Henderson et a l, 2001), suffer 
from impaired T cell proliferation (Shier et a l, 1996, 1999) and have defective lymphocyte 
homing to peripheral lymph nodes (Berlin-Rufenach et al, 1999), they were not as susceptible to 
bacterial infections as mice lacking the CD 18 subunit (Bouvard et a l, 2001; Scharffetter- 
Kochaneke/a/., 1998).
While LAD-1 highlights the functional importance of LFA-1 in normal immune responses, 
increased levels of the integrin have been detected in a wide variety of auto-immune and 
inflammatory conditions such as arthritis, psoriasis and inflammatory bowel disease (Yusuf- 
Makagiansar et a l 2002; Mazzone et al, 1995). The importance of LFA-1 in models of 
rheumatoid arthritis is supported by studies showing that treatment with aL mAbs reduced 
inflammatory responses and recruitment of cells to sites of inflammation. Other studies using 
blocking anti-aL mAbs have also shown that neutrophil and monocyte trafficking to inflamed 
joints is attenuated in a model of arthritis (Bimer et al, 2000), and can prevent disease 
progression in a collagen induced arthritis model (Kakimoto et a l, 1992). A blocking aL mAb 
has also been shown to be efficacious in treating patients with psoriasis (Gottlieb et a l, 2000). 
Because of these findings, inhibition of LFA-1 function has become a major focus of the 
pharmaceutical industry in recent years.
1.3.3. LFA-1 Ligands
LFA-1 has been shown to bind all five members of the ICAM Ig family. The ICAM family are a 
subgroup of the immunoglobulin (Ig) superfamily all of which contain characteristic Ig folds of 
80-100 amino acids arranged into two p-sheets and held together by a highly conserved
20
Chapter 1
disulphide bridge (Xie et aL, 1995). The ICAM genes are clustered in chromosome region 
19ql3.2 (Trask et aL, 1993; Lewis et aL, 1988), except for ICAM-2, which is found on 
chromosome segment 17q23-25 (Sansom et aL, 1991). The ICAMs are type I transmembrane 
proteins containing between 2 and 9 heavily N-glycosylated Ig domains in their extracellular 
domains and are attached via a transmembrane domain to relatively short, poorly conserved 
cytoplasmic domains (Reilly et aL, 1995; Miller et aL, 1995). Table 1.2 highlights the 
expression profiles and important properties of each of the ICAMs and the domains involved in 
ligand binding.
LFA-1 has a greater affinity for ICAM-1 than that for other members of the ICAM family. 
ICAM-1 exists predominantly as a dimer on the cell surface and studies with soluble forms of 
the integrin show that LFA-1 binds with much higher affinity to the dimeric form than to the 
monomeric form (Casasnovas et ah, 1995). Most cell types, especially endothelial cells and 
mesenchymal cells, express some ICAM-1 at a basal level (Hogg et aL, 1991) but this is strongly 
upregulated in response to agents such as lipopolysccharide (LPS), tumour necrosis factor-1 a  
(TNFa), interleukin-la (IL-la), phorbol-myristate-acetate (PMA) and interferon-y (IFNy) 
(Rothlein eta l, 1986(a&b); Krutmann et aL, 1990).
ICAM-2 is primarily expressed on leucocytes and endothelial cells and is the only ICAM family 
member expressed on platelets (Diacova et aL, 1994). In contrast to ICAM-1, ICAM-2 is 
expressed as a monomer on the cell surface and is not easily upregulated by cytokines (de 
Fougerolles et aL, 1991). The main function of ICAM-2 is to regulate adhesion of leucocytes to 
the resting endothelium, but it may be important in regulating cell-cell interactions elsewhere. 
Recently ICAM-2 has also been shown to be a ligand for DC-SIGN, a C-type lectin expressed 
on dendritic cells that recognises pathogen-derived carbohydrate structures and, upon binding, 
allows internalisation of pathogens for antigen processing and T-cell presentation (Geijtenbeek 
et aL, 2000).
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ICAM-3 is the major ICAM Ig molecule present on resting leucocytes (de Fougerolles and 
Springer 1992) and absent from normal endothelial cells but, like ICAM-1 and ICAM-2, is 
strongly expressed on lymphocytes (Doussis-Anag. et aL, 1993). High expression of ICAM-3 
mRNA has been shown in cell types involved in antigen presentation (Acevedo et aL, 1993) and 
more recently ICAM-3 has been shown to localize at cell-cell contacts during initial cell 
aggregation and its low affinity adhesive interactions with DC-SIGN and LFA-1 appear to 
facilitate the exploration of the APC surface by T-cells (de Fougerolles, et aL, 1994; Bleijs et aL, 
2000).
ICAM-4 is specifically expressed on red cells and carries the LW blood group antigens (Bailly, 
et aL, 1995). It has been proposed that ICAM-4 may be involved in red cell turnover by binding 
to P2 integrins expressed on spleen macrophages in the red pulp, and also in erythroid 
maturation to retain immature erythroid precursors in the bone marrow. However, the relevance 
of ICAM-4 interactions with P2 integrin-expressing cells in vivo is still unknown (Bailly et aL, 
1995; Van Der Vieren et aL, 1995).
ICAM-5 is the most complex member of the ICAM family, containing 9 Ig extracellular 
domains. It is expressed on a subset of neurons, but not on glial cells, within the telencephalon 
of mammalian brains (Yoshihara et aL, 1994). Interactions of T-cells with the somato-dendritic 
regions of hippocampal neurons is thought to be mediated through binding of LFA-1 to domain 
1 of ICAM-5, suggesting a mechanism for immune cell targeting to neurons under normal and 
pathological conditions (Tian et aL, 2000 (a&b)). The sixth domain of ICAM-5 has also been 
shown to bind T cells but in an integrin-independent manner and the ligand has yet to be 
identified.
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Ostermann et al. (2002) have recently identified Junction Adhesion Molecule-1 (JAM-1) as 
another potential ligand for LFA-1. JAM-1 is a transmembrane protein found associated with 
tight junctions via cytoplasmic adaptor proteins and its expression appears to be limited to 
endothelial and epithelial cells. Tight junctions are adhesive complexes consisting of strands of 
tightly opposed plasma membranes on adjacent cells that contribute to the barrier function of the 
endothelium. JAM-1 has been shown to be located at the most apical portion of these junctions 
and is involved in forming close contacts between epithelial cells. Like the ICAM-Ig family, 
JAM-1 is an Ig superfamily member consisting of two domains, of which the membrane 
proximal domain is thought to interact with LFA-1. A detailed analysis of LFA-1 binding site 
on JAM-1 has yet to be carried out.
1.3.4. LFA-1/ ICAM binding interface
Although LFA-1 has been reported to bind all 5 members of the ICAM family, its interaction 
with ICAM-1, ICAM-2, and ICAM-3 are the most studied. Mutational studies on ICAM-1 and 
ICAM-3 identified residues E34 and Q73 in ICAM-1 and the corresponding E37 and Q74 of 
ICAM-3 within domain 1 to be critical for LFA-1 binding (Staunton et al, 1990; Holness et al, 
1995). Other mutations within the first domain of these molecules were also shown to affect 
binding, but loss of reactivity with a panel of mAbs demonstrated that these mutations were 
associated with larger conformational changes in the molecule. The elucidation of the crystal 
structures of the first 2 domains of ICAM-1 (Bella et ah, 1998; Casasnovas et a l, 1998) and 
ICAM-2 (Casasnovas et a l, 1997) and most recently that of the aL I domain complexed with the 
first three domains of ICAM-1, have not only confirmed the importance of the glutamate residue 
but also revealed an atomic view of the LFA-1/ICAM-1 interface (Shimaoka et al., 2003).
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Property
ICAM-1 ICAM-2 ICAM-3 ICAM-4 ICAM-5
(CD54) (CD102) (CD50) (LW) Telencephalin
Mol. Wgt(kDa) 90 55 120 42 150
Cellular Distribution :
Leucocytes
Resting + + +++ - -
Activated +++ +-H- - -
Endothelial cells.....
Resting + ++ - - -
Activated +++ ++ - -
Lymphomas +++ +++ +-H- - -
Red Cells - - -f-f- -
Telencephalon - - - - -H-
Binding Partners LFA-1 
MAC-1 
pi 50,95
LFA-1
MAC-1
LFA-1
adP2,
DC-SIGN
LFA-1
MAC-1
LFA-1
No. of Ig Domain 5 2 5 2 9
Ig Domains important 
for binding
D1 (LFA-1) 
D2(MAC-1)
D1 D1 N.D D1
Tablel.2 Expression profiles of each of the ICAMs and the domains involves in ligand binding.
All four X-ray studies have shown that domains 1 and 2 of ICAM-1 have an extended 
orientation with an obtuse angle between domains 1 and 2 and with no significant rearrangement 
in ICAM-1 when bound to integrin. In the integrin /ligand crystal structure, domain 1 appears to 
lie perpendicular to the ‘top’ face of the I domain of LFA-1 with a portion of the domain sitting 
in the shallow groove created by the MIDAS at the top of the I domain (Figure 1.7). The key 
conserved residues that had previously been shown to interact with the MIDAS, E34 and Q73, 
are located at the ends of the C strand and the beginning of the G strand, respectively, in domain
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1 (Staunton et al., 1990; Casasnovas et al., 1995; Li et al., 1993). In the crystal structure E34 
forms a direct contact through its acidic side chain and interacts with the Mg^ "^  ion held in the I 
domain MIDAS site. Rings of hydrophobic residues surrounding both the Mg^  ^bound to the I 
domain (L204, L305 and M l40) and the E34 of ICAM-1 (P36, Y66, M64 on P-strands C, D and 
F) also make contact, and it is thought that this non-polar environment strengthens the 
electrostatic interaction between E34 and the Mg^  ^of the MIDAS.
Polar interactions involving hydrogen bonds between T35, P36 and N68 in ICAM-1 and Q143, 
T243, and H264 in the I domain, as well as a salt bridge between E241 on the I domain and K-39 
on ICAM-1, appear to orient ICAM-1 for optimal contact with the I domain and further 
strengthen the interaction (Shimaoka et aL, 2003).
Site directed mutagenesis studies suggest that the P2 binding motifs of ICAM-4 differ from 
those of the other ICAMs. In ICAM-4, R52 in domain 1 replaces the conserved glutamate 
residue of the other ICAMs, and mutation of this residue to glutamate has no effect on ICAM 
binding (Hermand et al, 2000). A recent paper from Dianus et al. (2003) has, however, shown 
that an epitope recognised by a mAb (MEM83), known to enhance LFA-1 binding to ICAM-1, 
is also involved in LFA-1/ICAM-4 binding.
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1/
Figure 1.7 Ribbon structure of ICAM-1 binding to the I domain. Ribbon diagram o f one monomeric unit o f 
aL 1 domain (gold) complex with lCAM-1 domains 1-2 (blue). The Mg‘  ^ ion is shown as a magenta 
sphere. 1 domain MIDAS and lCAM-1 Glu-34 side chains are shown as ball-and-stick with red oxygen 
atoms. The interacting P strands C, D, and F o f lCAM-1 are labeled. (Shimaoka et a l, 2003).
1.4 I Domain and Ligand Binding
I domains belong to a family of homologous domains of which von Willebrand factor ‘A’ 
domains are the prototype (Larson et al, 1989). As discussed earlier LFA-1 is one of the 9 
integrins that contains an I domain which is centrally involved in regulating ligand-binding 
activity. The importance of the aL I domain in ligand binding was first illustrated by the 
adverse effect that mutations within this region had on the capability of LFA-1 to bind ligand 
(Edwards, et aL, 1995; Huang and Springer, 1995) and by the fact that the majority of mAbs that 
block the LFA-1/ICAM interaction appear to map to the I domain (Champe et aL, 1995). 
Binding of ICAM-1 to recombinant isolated aL I domain (Randi and Hogg, 1994) also indicated
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that this domain was a major ligand-binding site for p2 integrins. More recently, Shimaoka et 
al. (2001) have shown that an isolated I domain under certain conditions can bind ligand with 
the same specificity as the parental integrin suggesting that LFA-1 ligand binding occurs 
predominantly through interaction with this domain. Along with this biochemical data, great 
strides have been made to elucidate the structure of the aL I domain both in the presence and 
absence of ligand, and the knowledge gained from these studies has further enhanced our 
understanding of LFA-1 activation and function.
The first crystal structure of an I domain was generated by Lee et al. (1995(a)) from the a  
subunit of integrin aM^2. As well as confirming the presence of the classic a/p Rossmann fold, 
it was shown that the I domain contained a Mg^  ^coordination site at the top of the domain with 
one of the coordinating points being a glutamate side chain from another I domain molecule. 
Further structures of the aL and aM I domains with bound Mn^ ,^ and aL I domain in the 
presence of Mg^ ,^ also confirmed the dinucleotide fold and cation binding site (Qu and Leahy, 
1995; Lee et al., 1995(b)). Although comparisons of the crystal structures of the aM  I domain 
with bound Mg^ "^  (Lee et al, 1995(a)) and with bound Mn^  ^ (Lee et ah, 1995(b)) showed 
differences in the residues whose side chains interacted directly with the metal structures, these 
differences were not noted in the two aL structures. Indeed, only minor rearrangements of the 
metal-binding site structure were seen when the structures of aL I domain with and without 
divalent cation were compared and these differences were thought to be the result of normal 
crystal lattice interactions (Qu and Leahy, 1995; 1996). However, a large movement in the 
structure of the aL I domain’s a7 helix was suggested in the presence of Mn^  ^compared to the 
aL I domain in the presence of EDTA. A similar movement of the a7 helix was also noted in 
the aM I domain crystal structures but this was accompanied by alterations in the metal binding 
site not seen in the aL I domain crystals (Figure 1.8). Analysis of these aM structures suggested 
that a glutamate side chain from a neighbouring I domain molecule provided a co-ordination
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point in the crystal lattice, essentially mimicking the integrin-ligand interaction. This crystal 
contact is associated with a change in metal coordination and a shift in the position of the «7 
helix that exposes several buried hydrophobic residues. Although the biological relevance of 
these changes was questioned at the time it was hypothesised that the I domain could exist in 
two confonnations designated as ‘open’ and ‘closed’ dependent on the presence of bound ligand 
(Li et aL, 1998).
Cation bound MIDAS . . .
a? helix
a7 helix
Figure 1.8 aM I domain in open (a) and closed (b) conformations. The two conformations illustrate the shift 
in the a7-helix and the minor shifts in and around the MIDAS (Xiong et al. 2000).
The subsequent elucidation of the a2 I domain crystal structure in the absence and presence of a 
ligand fragment by Emsley et al. (2000) confirmed that ligand binding was coupled to the ‘open’ 
conformation. In this case the ligand itself contributed the sixth coordination position in the 
MIDAS site as seen in the aM /ligand mimetic structure (Lee et aL, 1995(a)). Three loops on 
the upper surface of the I domain were shown to engage with the collagen peptide, with a 
collagen glutamate residue completing the coordination sphere of the metal in the MIDAS. In 
the unliganded structure (‘closed’ conformation), the sixth coordination site was contributed by a 
water molecule. Ligand binding appears to cause a switch in Mg^  ^ coordination in which a
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direct bond to the MIDAS threonine is gained while a direct bond to an aspartic acid is lost. 
These subtle changes in metal coordination were associated with backbone movements of the 
loops containing the coordinating residues. These in turn were linked to structural shifts in 
neighbouring loops on the top of the I domain, and to a-helices on the side of the domain. The 
largest movement in the transition from ‘closed’ to ‘open’ conformations involves a 10Â 
downward shift of the a7 helix which results in a dramatic reshaping of the p6-a7 loop, exposing 
buried residues at the top of the loop (Lee et aL, 1995). These gross structural changes in a 
region distal to the ligand-binding region provide a mechanism to link conformational movement 
in I domains to movements elsewhere in the integrin molecule (discussed in Section 1.5.2).
Subsequently, work from Huth et aL (2000) using 2D NMR analysis also demonstrated that 
ICAM-binding to the aL I domain altered the environment of both the MIDAS and a region 
contained between the p6 strand and a7 helix which has been termed the IDAS (I Domain 
Allosteric Site). Mutational analysis of the IDAS by other members of this group (Lupher et aL, 
2001) suggested that the interactions of the large hydrophobic amino acids 1306,1235 and 1255 
create an energy barrier to conformational change in the I domain thus. stabilising the 
conformation seen in the crystal structures. Alanine substitutions at these positions, which 
presumably reduce this energy barrier, were shown to enhance ligand binding relative to wild 
type. On the other hand, the hydrophilic amino acids K232, K287, Q303, K304 and K305 
present on the surface of the IDAS, appear to stabilize an active state by interacting with other 
amino acids in LFA-1. Alanine substitution of these amino acids decreased the stability of the 
activated state presumably by removing polar interactions. Several small molecular inhibitors 
(Kallen et aL, 1999; Kelly et aL, 1999; Weitz-Schmidt, 2001) of the LFA-1/ICAM-1 interaction 
have also been shown to bind at the IDAS site and, since no alteration in the structural 
arrangement of the MIDAS was shown, these authors concluded that inhibitors block LFA-1 
function by binding to the closed conformation of the I domain and prevent the conformational 
transition to the ‘open’ form that can bind ligand.
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More recently, Shimaoka et al. (2003) have solved crystal structures of various mutant forms of 
aL I domains, unliganded and complexed with a fragment of ICAM-1 containing Ig domains 1- 
3. By mutating certain pairs of residues to cysteines on either side of the p6 strand and a7 helix 
(generating new disulphide bridges), they generated locked ‘open’ (K287C/K294C), locked 
‘closed’ (L289C/K294C) and ‘intermediate’ (L161C/F299C) activation forms of the aL I 
domain. Affinity and kinetic measurements showed that the mutant locked ‘open’ and 
‘intermediate’ aL I domains resulted in a 9000-fold and 400-fold increase in affinity for ICAM-1 
over wild type, respectively. Locking the I domain ‘open’ increased its on-rate, which is 
consistent with the idea that conformational change is rate limiting for ligand binding by wild 
type I domain. The affinity and kinetics of ICAM-1 binding are comparable with that measured 
previously for intact, activated LFA-1 (Labadia et al, 1998). The affinity of the locked-closed 
conformer was similar to unactivated wild type integrin (Shimaoka et al, 2001).
The ‘open’ form of aL I domain crystallized in the presence of ligand confirmed that the metal 
coordination bond between Mg^  ^ and E34 is surrounded on the I domain by a ring of 
hydrophobic residues (L204, L205 and M l40) and the aliphatic portion of T243. 
Conformational shifts at other points in the I domain were also very similar to those observed in 
the transition of the a2 and aM I domains from the ‘closed’ to ‘open’ conformations (Emsley et 
al., 2000; Lee et al., 1995). Unfortunately, due to the presence of the disulphide bonds in the 
‘intermediate’ I domains, the p6-a7 loop did not assume the open conformation as seen with a2 
and aM. Comparisons of the aL, aM, and a2 I domains which appear in the closed form show 
an identical conformation of the p6-a7 loop and likewise, the locked ‘open’ aL I domain had an 
identical open conformation in the (36 strand and the p6-a7 loop as in the ‘open’ aM and a2 I 
domains. However, the conformation of a7 in the locked ‘open’ aL I domain differs markedly, 
presumably due to the constraints of the disulphide bond.
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Shimaoka et al. (2003) argue that the structural details of u7 are not critical as it is the 
conformations of P-strand 6 and the P6-a7 loop at the top of the I domain that dictate the 
alterations in the packing of the hydrophobic core during the transition from ‘closed’ to ‘open’ 
conformations. They further suggest that the conformational changes induced by pulling down 
the P6-a7 loop, as is thought to be the case after signalling to the cytoplasmic tails and mimicked 
in this case by the introduction of the disulphide bridge, are first propagated to the hydrophobic 
core of the I domain and then to the MIDAS loops. They argue that if this were not the case, the 
shift in the position of p6-a7 would just expose the hydrophobic core residues on a l, P4 and P5 
and result in a misalignment of the residues within the MIDAS which would render it unable to 
bind ligand.
They therefore propose that as a result of other conformational changes in the integrin, F292 in 
the P6-a7 loop at the top of the I domain is removed from its hydrophobic pocket between p 
strands 4 and 5 and a l helix by the downward shift of the a l helix. The a l helix then moves 
~2Â towards the centre of the I domain. The change in coordination is also linked to a 
movement in the portion of the p l-al loop containing SI41 of the MIDAS which shifts 2Â to 
bring it into contact with the side-chain of E34 (ICAM-1) and in turn allows the side chain of 
Q143 in the p i-al loop to form a hydrogen bond with the backbone of P36 on ICAM-1. As a 
consequence of the movement of S141, L142 pushes D239 in the p4-a5 loop from the primary to 
the secondary metal coordination sphere. In concert with the movement of the a l helix, there is 
a downward movement of the p6-a7 and p4-a5 loops which fill the space left open by the p6-a7 
loop. The downward movement of F265 in the p6-a7 loop causes a backbone flip of G240 and 
results in a 100° rotation of the E241 side chain which is now capable of forming a salt bridge 
with K39 of ICAM-1, facilitating the positioning of ICAM-1 and the I domain for optimal 
interaction.
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1.4.1. Ligand binding to non-I Domain containing Integrins
In I domain-containing integrins, the I-like domain seems to play predominantly a regulatory 
role. In non-I domain-containing integrins, the I-like domain plays a direct role in ligand 
binding (D’Souza et al, 1988; Smith et al, 1990; Lin et a l, 1997). Despite the structural 
diversity of integrin ligands, all appear to contain an exposed aspartic acid or glutamic acid 
residue, as discussed for I domain-containing integrins, which is critical for recognition by 
integrins. Many integrins that do not contain an I domain appear to bind to aspartic acid-based 
sequences such as the ROD motif found in fibronectin, VCAM-1 and vitronectin (Ruoslahti et 
al, 1996) and crystallisation of the aVps extracellular domains in complex with ROD has for 
the first time provided an atomic basis for cation-mediated binding of aspartic acid based ligands 
to integrins (Xiong et al, 2002). In the structure, RGD was shown to fit into a crevice between 
the P-propeller and the I-like domain of the bent aVp3 conformation. The ligand arginine side- 
chain was shown to insert into a groove formed by loops of interconnecting strands D3, A3 and 
D4, A4 of the P-propeller and is held in place by a salt bridge to D218 at the bottom of the 
groove and another salt bridge to D150 at the rear of the groove. The hydrophobic portion of the 
arginine side-chain also interacts with T178 and A215 that form the walls of the groove. The 
ligand glycine residue contacts the aV subunit via hydrophobic interactions with the carbonyl 
oxygen of R216. The ligand aspartic acid contacts the metal ion within the MIDAS of the I-like 
domain and is stabilised by additional contacts with residues T122, R124 and N125 in the same 
domain. The interaction of the ligand aspartate with the MIDAS is strikingly similar to that seen 
when T243 of the I domain interacts with cation. The I-like domain MIDAS is formed from the 
oxygen -containing side-chains of D-X-S-X-S, D119, an invariant glutamic acid (E220, 
corresponding to the invariant threonine in I domains) and D251. Interestingly, D251 is present 
on the same loop that continues to form the major interface with the propeller, suggesting that 
ligand binding may bring about protein movements at the «P interface.
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Unlike the I domain, the MIDAS site of the I-like domain was shown to be unoccupied in the 
absence of ligand in the aVpS crystal structure. Comparison of the unliganded and liganded 
crystal lattice conformation suggests that in the unliganded state, E220 infringes on the MIDAS 
preventing the binding of cation whereas, on ligand binding, E220 is moved sufficiently to allow 
access. A second site (the ADMIDAS) which is cation bound in the unliganded state remains so 
in the liganded state but changes slightly in its conformation so that it is more closely associated 
with the MIDAS. In addition to incorporation of Mn^  ^at the MIDAS and ADMIDAS, a third 
Mn^  ^ was shown to bind at a site 6Â from the MIDAS. This site, termed the ligand induced 
metal binding site (LIMBS), is formed from a side chain of E220, the side chains of D158, N215 
and D217 and the carbonyl oxygens of D217 and P219. Although the LIMBS Mn^^ does not 
contact the ligand, it appears to be necessary to stabilize the reorientation of E220 and to add 
conformational stability and structural rigidity to the ligand binding face.
As well as the changes seen at the MIDAS, tertiary changes in the I-like domain and small 
quaternary changes to the ap interface are observed in the liganded structure. In the liganded 
state, the A -al loop moved closer to the a2-a3 loop, allowing the MIDAS ion to coordinate 
residues from both. These movements appear to be initiated by the top of the a l  helix moving 
closer to the MIDAS, with the ADMIDAS moving in concert. The ligand specificity region of 
p3 also approaches the ligand, probably as a result of the salt bridge between D179 and R214 in 
the I-like domain. Several epitopes for activating and inhibitory mAbs have previously been 
mapped to these regions, underscoring the functional relevance of the observed structural 
changes. The movements in the A -al and a2-a3 loop are very similar in magnitude and 
direction to those seen when the I domain binds ligand (Emsley et al, 2000). In the I domain, 
movement of the A -al loop causes a buried phenylalanine at the top of the a? helix to beeome 
solvent-exposed which in turn causes a 10Â downward movement of the a? helix. However, in 
the I-like domain because the top of the a? helix is connected through the MIDAS cation to a l
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there is minimal movement of the a7 helix when ligand is bound. Small quaternary changes 
such as the closer interaction of the |3-propeller and the I-like domain around the peptide binding 
site, and rotation at the propeller/thigh interface, are also seen when aV(33 is occupied with 
ROD.
As the conformational changes seen in aVpS appear to be dependent on ligand binding, the 
presence of ligand appears to be the controlling factor in integrin activation. An alternative 
interpretation is that the integrin ectodomain exists in an active /inactive equilibrium and that 
ligand binds to the pre-existing active form and stabilises the active conformation.
1.5 LFA-1 Activation
Leucocytes circulate throughout the body as non-adherent cells and yet become adherent to their 
ligands when they transmigrate across the vasculature or encounter APCs in the lymph nodes. 
Regulation of the activation of integrins, such as LFA-1, on the lymphocyte cell surface has been 
shown to play a central role in controlling cell adhesion (Faull et al., 1994; Dustin and Springer, 
1989; Bazzoni et a l, 1998; Diamond and Springer, 1994). External signals triggered by 
activation of receptors for chemokines, antigens and cytokines can modulate integrin function in 
a process termed ‘inside-out’ signalling. The signals generated within the cell are transduced 
through the integrin cytoplasmic and transmembrane regions to alter the ligand binding capacity 
of the extracellular domain. Signal transduction can also be transmitted in the opposite direction 
and initiated after integrins bind ligand, in a process termed ‘outside-in’ signalling. Like ‘inside- 
out’ signalling, this form of signalling is dependent on the cytoplasmic domains of the integrins 
and their direct or indirect interaction with signalling and cytoskeletal proteins. Integrins can 
also be activated directly from outside the cell by the divalent cation Mn^ ,^ which binds to the
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ectodomain (Dransfield et a l, 1992(b); Tominaga et al, 1998(a)), and after stimulation with 
activating mAbs such as KIM 185 (P2) (Andrew et aL, 1993), KIM 127 (P2) (Stephens et ai, 
1995), NKI-L16 (aL) (van Kooyk et a i, 1991) and MEM83 (oL) (Landis et a i, 1993). The 
mechanisms that initiate activation of integrins are still incompletely understood despite 
considerable research effort. This section will discuss the data and various theories put forward 
to explain the activation of LFA-1 (and integrins in general) and will also discuss the structural 
basis for bidirectional signalling.
1.5.1. Avidity Modulation
Data accumulated over the last 10 years suggests that clustering of integrin receptors in the plane 
of the membrane, which increases the avidity of the integrin/ligand interaction, strengthens cell­
cell adhesion and is a requirement for integrin activation and ligand binding (van Kooyk et ai, 
1994; Stewart et a i, 1998; Yauch et a i, 1997; Grabovsky et a i, 2000). Initial evidence for 
avidity alterations of LFA-1 came from the description of the mAh NKI-L16 which detects a 
Ca^^-dependent epitope and is only expressed when LFA-1 is in a clustered state. Further 
investigations by the same group showed that lymphocytes only bound to ligand when LFA-1 
was clustered on the cell surface, even when the same level of LFA-1 was expressed on different 
cells (van Kooyk et ai, 1994). Increased LFA-1 clustering leading to enhanced avidity is 
considered to be the dominant mechanism controlling lymphocyte adhesion induced by Ca^  ^
mobilizers and TCR/CD3 ligation (Van Kooyk et ai, 1989; Dustin and Springer, 1989; Lub et 
ai, 1995; Stewart et ai, 1996). While the precise mechanism by which integrins become 
clustered remains to be fully clarified, use of agents that disrupt the cytoskeleton such as 
cytochalasin D have indicated that cytoskeletal rearrangement is involved and that, on activation, 
LFA-1 molecules are released from restraint, allowing the molecules to move and cluster (Kucik
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et al., 1996). Introduction of deletion mutations that result in LFA-1 lacking the complete (32 
cytoplasmic tail and/or the conserved KVGFFKR sequence in the aL cytoplasmic tail and hence 
loss of cytoskeletal interaction also resulted in a elustered cell surface distribution of LFA-1 
(Van Kooyk e? a/., 1999).
Studies of lipid raft dynamics also suggest that integrins are regulated through avidity changes 
(Krauss et al., 1999). The distribution of lipid molecules such as glycosphingolipids, GPI- 
anchored proteins and cholesterol in the lipid bilayer is now widely accepted not to be a random 
process, but rather such lipids are organised into microdomains or Tipid rafts’ and appear to be 
important in vesicle transport and sorting of membrane proteins in polarized cells (London and 
Brown, 2000; Cherukuri et al, 2001). At the cell surface, the rafts also serve as platforms for 
signalling molecules such as Src family members, G-proteins, PI3 kinases and adaptor proteins. 
It has recently been demonstrated that, on activation, LFA-1, VLA-4, aVp3 and the pi integrins 
a3pi and a6pi relocate to these highly organised microdomains and, in doing so, enhance 
avidity and increase cell adhesion by means of a high local concentration of the integrin 
(Leitinger et al., 2002; Claas et al., 2001 ; Thome et al., 2000).
1.5.2. Affinity Modulation
By definition, high affinity is the consequence of changes in molecular conformation that results 
in a stable bond between an integrin and its ligand (Chan et al., 2002). Evidence for 
conformational changes following cell activation is primarily derived from the identification of 
mAbs that recognize integrin molecules only when they are in an activated state. The first 
reported activation mAh, PAC-1 (Shattil et ah, 1985), was shown to recognize an epitope on the 
platelet integrin allbp3 only after platelet activation. O’Toole et al. (1990) later described two 
further allbp3 mAbs, mAb62 and P41, which caused both increased binding to fibronectin and a 
distinct change in conformation as evidenced by the binding of PAC-1. A series of antibodies
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described by Luque et al. (1996) have also been shown to bind pi integrins when cells were 
activated.
Several mAbs that recognise only activated LFA-1, termed reporter mAbs, have also been 
identified. The epitope of Mab24, which has recently been mapped to the P2 I-like domain, is 
only induced after ligation of LFA-1 with ICAM-1 and requires the presence of cation (Kamata 
et al., 2002). Data suggests that this mAh prevents deadhesion of receptor/ligand pairs, by 
‘locking’ the integrin into an active state (Dransfield, et ah, 1992(a); Cabanas and Hogg, 1993). 
Two aL mAbs, CBR LFA-1/1 and H i l l  have also been identified as activation-sensitive, 
although both appear to favour the inactive from of LFA-1 as activation by divalent cations 
reduces binding. H i l l  binds to the edge of the MIDAS site on the I domain and CBR LFA-1/1 
maps to residues 310-338, which includes all of the linker and the last two turns of the C- 
terminal a-helix. This reduced binding suggests that a change in the conformation around the 
linker sequence alters the epitope in some way (Ma et a l, 2002). However, it must be noted that 
the affinity changes in LFA-1 reported by these mAbs, and as measured by enhanced binding of 
ICAM-1, were only demonstrated when the LFA-1 ectodomain was modulated directly through 
divalent cation binding, presumably bypassing all intracellular signalling mechanisms. The lack 
of detectable affinity changes in LFA-1 on cellular activation initially suggested that affinity 
regulation did not have a significant role to play in ligand binding.
Development of in vitro and in vivo models of leucocyte recruitment have now allowed for the 
analysis of chemokine-inducible adhesion of leucocytes under flow conditions. Such studies 
have revealed that chemokines such as SLC (CCL21), ELC (CCL19) and SDF-la (CXCL20) 
can induce rapid and transient increases in affinity of LFA-1 for ICAM-1, promote strong 
adhesion, and initiate arrest of rolling naïve T lymphocytes (Campbell et al, 1998; Constantin et 
al, 2000). Interestingly, in his study of rapid lymphocyte arrest, Constantin et al. (2000) 
showed that the mechanism of activation employed appears to be dependent on the local
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concentration of ligand. Under physiological conditions, affinity regulation of LFA-1 appeared 
to be sufficient for lymphocyte arrest on ligand-rieh high endothelial venules (HEVs), whilst 
enhanced mobility of integrin appears to be eritical for lymphocyte adhesion under conditions of 
low ligand density. A similar finding by Leitinger et al. (2002) showed that there is a mixture of 
clustered and high affinity LFA-1 molecules present in lipid rafts, suggesting that both affinity 
and avidity play important and often convergent roles in inducing LFA-1 /ligand interactions. 
This is dependent on the activation signals received and the concentration of the ligand in the 
surrounding environment.
Emerging evidence from crystallographic studies of conformational changes within the I 
domains of aM and a l  on ligand binding does suggest that such conformational changes have a 
role to play in affinity regulation, although crystallographic studies have yet to yield an aL I 
domain in this conformation. Shimaoka et al. (2001) have shown in vitro that conformational 
changes in the aL I domain confer high affinity binding of LFA-1 to ICAM-1. The 
identification of areas of flexibility in both the a  and (3 subunits of the aV(33 integrin also 
suggests that conformational changes within the integrin may take place on ligand binding. 
However, the fact that the aV(33 structure, both in the presence and absence of ligand, remains 
in the bent conformation has led to researchers questioning how this conformational regulation 
of affinity actually takes place. Two groups of researchers have published extensively in this 
area, and have proposed theories on how conformational switching from inactive to active states 
takes place and have attempted to relate the relevance of these findings to integrin activation and 
ligand binding. Both theories are based on accumulated data from X-ray crystallographic and 
NMR studies of integrin structure and mutational analysis of several of the integrin domains. 
Although both theories agree that dynamic movement through the extracellular domains results 
in increased ligand binding, there is a conflicting view on the overall structure that constitutes 
the active state.
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The theory proposed by Amaout (Xiong et ah, 2003(b)) is based on the crystal structure of 
aV(33 in the presence of ligand which they believe is representative of the active form of the 
integrin, even though it remains in the bent conformation. To explain how the activation process 
takes place, the analogy of a ‘deadbolt’ is employed. A bolt firmly in the latch represents the 
interaction of the (33 tail domain (bolt) with the F/a7 loop of the I-like domain (clasp) which 
occurs in the resting state on the cell surface. This interaction locks the I-like domain in an 
inactive state by preventing the flip of the F/a7 loop required for the movement of the a l helix 
which occurs on activation. On transmission of signals through the cytoplasmic domains, 
movement of the P-tail helices distances the TD domain from the F/a7 loop of the I-like domain 
and weakens the interactions between the two domains. This renders the integrin competent to 
bind ligand, causing complete unlocking of the adjacent ‘deadbolt’. The authors suggest that the 
reason one does not observe extensive contacts between the (3-tail domain and the I-like domain 
in the erystal structure is because it is already in the active form due to its truncation before the 
transmembrane domain. This model, where a movement of ~0.3nm could switch the integrin 
from active to inactive, is also an attractive explanation for the speed at which some integrins are 
activated. From their analysis of epitopes recognized by activating mAbs, which are known to 
bind to various ^-subunit C-terminal regions, Amaout also proposes such mAbs would still be 
available to bind in this model and could act by unlocking the deadbolt without necessarily 
straightening the integrin. Analysis by Calzada et al. (2002) of epitopes seen by both activating 
and inactivating allb(33 mAbs also suggests that the structure of the integrin does not appear to 
require linearisation in order to become active. In conclusion, Amaout and colleagues suggest 
that the bent conformation represents the active form of the integrin and extension at the knees is 
not required for ligand binding but, rather, is a post-binding event linked to extracellular signals.
An altemative model of integrin activation has been proposed by Springer et al. (2002) and 
referred to as the ‘switchblade’ model. In this model, the bent conformation of aV(33 is 
considered to represent the inactive state and activation is associated with the opening of a
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“switchblade” which allows the ligand headpiece to move away form the plasma membrane and 
the legs to separate. Using the aVp3 structure, superimposed with the p2 I-EGF modules 2 and 
3 determined by Beglova et al. (2002), Shimaoka et al. (2002(b)) have shown the epitopes of 
mAbs that bind in the stalk region and activate the integrin would be inaccessible if the bent 
conformation represented the active high affinity ligand binding conformation. The bent 
structure shows that residues in the P2 I-EGF3, which are involved in the aP stalk interface that 
restrains integrins in the inactive state, are on the face pointing toward calf-1 domain of the a- 
subunit stalk. This being the case, the epitopes of activating mAbs such as KIM 127 and 
MEM 148 on I-EGF3 are masked in this conformation, contradicting Amaout’s claim. On 
transmission of signals to the cytoplasmic domains. Springer’s model suggests that the resultant 
separation of membrane proximal domains leads to the dislocation of the I-EGF3 contact with 
calf-1 domain. This in tum triggers the ‘switch blade’-like opening, which is linked to a change 
in conformation of the I-like domain. This interpretation fits with the EM images of ligand- 
bound integrins (Weisel et al., 1992; Du et al., 1993) which show the integrin as an extended 
stmcture. Epitope mapping studies (Takagi et al., 2001), which demonstrate that mAbs to 
specific residues in I-EGF repeats 2 and 3 would be buried in the bent conformation, also add 
weight to this theory. Furthermore, Takagi et al. (2002) have shown by EM that integrins 
clamped in the inactive state adopt a bent conformation whereas integrins aetivated by Mn^^ or 
cyelic peptides are presented predominantly in the extended form. They have also presented 
evidence that tethering of the inactive form to the cell surface using disulphide bridges within 
the cytoplasmic tails causes the integrin to remain in an inactive state upon cell activation. In I 
domain-containing integrins. Springer suggests that the conformational change in the I-like 
domain causes movement of the I domain C-terminal linker sequence, resulting in a downward 
shift of the a7 helix of the I domain. The consequence of this movement within the I domain 
was discussed in Section 1.3.
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1.5.3. Cations
It is well-established in the integrin field that the divalent cations Mn^  ^and Mg^  ^are required to 
activate integrins and make them competent to bind ligand, whilst Ca^  ^ generally has an 
inhibitory effect on this binding (Marlin and Springer, 1987; Michishita et ah, 1993; Larson et 
a\., 1989; Perruzzelli 1995; Van Kooyk et al., 1994). Although the divalent cation requirements 
for LFA-1 / ligand interactions have been extensively studied, and several metal binding 
domains have been identified on both the a  and (3 subunits, the relative importance of the 
various sites and how the relative site occupancy by cations is regulated in vivo is still unclear.
Crystallographic studies have shown that the overall extracellular structure of aV(33 contains 8 
potential cation-binding sites with five on the a  subunit and three on the p-subunit (Xiong et al., 
2001, 2002). Within the a-subunit, four cation-binding sites are located in the hairpin loops of 
the P-propeller with the fifth located at a novel site in the a  knee region. In the P subunit all 3 
sites are located at the top of the I-like domain in close proximity to each other. Crystallisation 
of aVpS in the presence of Mn^  ^showed that all sites were cation bound while in the presence 
of Ca^  ^only six out of the eight sites were occupied. The two sites that remained unbound in the 
presence of Ca^ "^  were the P-chain I-like domain MIDAS (Metal Ion Dependent Adhesion Site) 
and LIMBS (Ligand-associated Metal Binding Site) sites.
The binding of both Mn^  ^and Mg^  ^ to LFA-1 has been suggested to induce a high affinity 
conformation that promotes ligand binding. This high affinity conformation has been monitored 
by the binding of certain mAbs known as activation reporter antibodies. These mAbs such as 
mAb24 appear to only bind to LFA-1 after it has undergone conformational change. Binding of 
Ca^  ^ however, does not induce the mAh epitope (Dransfield et al., 1989; Dransfield et al., 
1992(a +b)). While Mg^ "^  in the MIDAS site is a requirement for ligand binding, it appears to
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only enhance binding in response to activation following intracellular signalling or binding of 
activating mAbs when millimolar levels of Ca^ "^  are also present. In contrast, Mn^  ^ in the 
presence of low millimolar levels of Ca^  ^is able to stimulate binding of LFA-1-bearing cells to 
ligand in the absence of additional stimuli (Dransfield et a l, 1992(b); Smith 1994; Michishita et 
al., 1993). It has been suggested that the difference in the ability of Mg^  ^and Mn^  ^to activate 
LFA-1 is dependent on the affinity of the cations for the MIDAS site. However, Springer e/ al. 
(2002) have recently suggested that binding of Mn^  ^to a cation site other than the MIDAS site is 
the controlling factor for the increased activation over Mg^ "^ , and have proposed the P-I like 
domain MIDAS site as a potential Mn^  ^binding site in LFA-1 since this site does not appear to 
bind Ca^  ^ and hence could be specific for Mn^ .^ They argue that while there are clear 
differences in the crystal structures of the aM I domain in the presence of Mn^^ compared with 
Mg^ "^  which in tum has lead to the suggestion that the I domain has a higher affinity for Mn^  ^
when both compete for the same site, the conformation of the aL I domain does not appear to be 
altered by changes in metal ion binding (Qu and Leahy, 1996). Additionally, the isolated 
locked-open aL I domain, which they generated to mimic an activated I domain, shows 
equivalent adhesiveness in the presence of Mg^  ^ or Mn^  ^ in their studies. This led them to 
propose that the activating effects of Mn^  ^may in fact be through its binding to one of the other 
cation binding sites found within the integrin extracellular domains such as the p-I like domain 
MIDAS site.
Although Mn^  ^ is routinely used to aetivate integrins in vitro, its interaction with cell surface 
receptors and extracellular matrix proteins (ECM) in vivo has received relatively little attention, 
and Mg^  ^is thought to be the relevant divalent cation that activates integrins in vivo. The theory 
proposed above, however, suggests that Mn^  ^ may indeed have a role in vivo. The 
concentrations of Mn^  ^in most adult tissues range between 3-20|iM (Chan, A, et al., 1992) and 
this divalent eation is known to be a required cofactor of important regulatory kinases and 
phosphatases and can regulate a number of Mn^^-dependent nuclear enzymes, including
42
(Zhapüer 1
endonucleases, nucleotideases, and ribonucleases, required for DNA synthesis and repair 
(reviewed by Roth et al, 2003).
The data from the aVp3 crystal structure has also lead to speculation that the ADMIDAS 
represents a high affinity Ca^  ^binding site and recently published work from Mould et a l (2003) 
supports this theory. Using the interaction between a5pl and fibronectin as a model system, 
they showed that mutation of residues that form the ADMIDAS site inhibit ligand binding. This 
effect could, however, be partially rescued by the use of activating monoclonal antibodies. 
Mutation of the ADMIDAS residues also reduced the inhibition of Mn^^-supported ligand 
binding by Ca^ ,^ suggesting that the ADMIDAS is a Ca^^-binding site involved in the allosteric 
inhibition of Mn^^-supported ligand binding. Mutations of the ADMIDAS site also perturb 
transduction of a conformational change from the MIDAS through the C-terminal helix region of 
the (3 I-like domain to the underlying hybrid domain, implying an important role for this site in 
receptor signalling.
Under normal physiological conditions, the concentration of extracellular Mg^  ^and Ca^  ^in vivo 
is reported to be approximately 1.5mM and 2.5mM respectively (Olinger, 1989). However, 
during the early phase of repair following cutaneous injury, levels of Mg^ "^  have been shown to 
increase significantly with a similar corresponding decrease in the concentration of Ca^ "^ . These 
changes in cation concentrations correlate with increased migration of inflammatory cells, such 
as fibroblasts and kératinocytes to the site of injury which is known to be integrin-dependent 
(Grzesiak and Pierschbacher, 1995). Several other studies (Labadia et al, 1998; Rothlein and 
Springer, 1986; Stewart et a l, 1996) also suggest that the affinity of LFA-1 for ICAM-1 is finely 
tuned through subtle alterations in the concentrations of Mg^  ^and Ca^ .^
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Using surface plasmon resonance, Labadia et al. (1998) showed that whilst micromolar 
concentrations of Ca^  ^ enhance ICAM-1 binding in the presence of Mg^ ,^ increasing Ca^ "^  into 
the millimolar concentration range results in decreased ICAM-1 bindings At low Ca^  ^
concentrations, binding in the presence of Mg^ "^  appears to be synergistic as evidenced by the 
affinity measurements of Mg^  ^ in the presence and absence of Ca^ "^  (160pM and 12pM, 
respectively). However, at high Ca^  ^concentrations, Ca^  ^could competitively displace the Mg^ "^  
which leads to a form of LFA-1 with a low affinity for ICAM-1 thus suggesting that Ca^  ^ can 
bind at the MIDAS site and reduce ligand binding dramatically.
A similar study by Griggs et al. (1998) investigating the relationship between Ca^  ^ and Mn^ "^ , 
using isolated ocL I domain, showed that while the I domain preferentially bound Mn^ "^  over most 
cations, this interaction was inhibited by Ca^  ^and to a lesser extent with other divalent cations. 
They estimated Kd values of 56|iM and 1.4|iM for Ca^  ^and Mn^  ^respectively, and these values 
suggest that the MIDAS site may be complexed with Ca^ "^  at physiological concentrations but if 
the concentration of Ca^ "^  is greatly reduced following cutaneous injury as suggested by Grzesiak 
and Pierschbacher (1995), then it is possible that Mn^  ^could bind and initiate integrin-mediated 
adhesion events.
The LIMBS site could also be a potential Mn^  ^activation site as it too lacks the presence of a 
cation in the Ca^  ^ crystal structure. It also contains residues that are conserved in all (3 I-like 
domains and appears to add structural stability to the ligand-binding surface. The other cation 
sites at the base of the |3-propeller and in the knee region of the a-subunit could also have 
potentially important roles to play in the activation of integrins although further research in this 
area is required before definite roles can be assigned to each of these sites.
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1.6 LFA-1 Signalling and Crosstalk
As discussed above, LFA-1 interaction with the ICAMs, like other integrin ligand interactions, 
requires a signal-induced activation event which causes a transient increase in the capacity of the 
integrin to bind ligand. Several mutagenesis studies have shown that activation of both avidity 
and affinity changes appear to be propagated through the cytoplasmic tails. The cytoplasmic tails 
of most integrins share a similar organisation of polar and apolar amino acids and the conserved 
sequences of GFFKR in the a subunit (Muir, et al., 1994) and LLxxxHDR in the p subunits 
appear to form a structural constraint that locks the integrin naturally in a low affinity 
conformation and, on activation, the two chains separate (Hughes et ah, 1996; Ginsberg et al., 
2001). Truncation before the GFFKR motif, complete deletion of the motif itself, or point 
mutations of the individual residues in the motif, results in a constitutively active integrin which 
is independent of the cell type studied or signalling pathways (O’Toole, et al., 1994; Lu and 
Springer, 1997). Lu et al. (2001(a)) have also shown that replacement of the aL and P2 
cytoplasmic domains with acidic and basic peptides that form an a-helical coiled coil cause 
inactivation of LFA-1, whereas replacement of both tails with basic peptides that prevented 
formation of an a-helical coiled coil resulted in a constitutively active LFA-1. Induction of 
ligand binding by the mutated activated cytoplasmic domains also correlated with the induction 
of activation epitopes in the extracellular domain.
The association of integrin a  and p cytoplasmic tails with cytoskeletal proteins appears to be one 
mechanism by which intracellular signalling events can control the conformation of integrin 
extracellular domains and promote integrin clustering. Several studies suggest that LFA-1 on 
lymphocytes is constrained by the actin cytoskeleton in resting cells (Stewart et al., 1998; Kucik 
et al., 1996). On Ca^^-mediated cell activation, the enzyme calpain releases LFA-1 from this 
constraint and allows the integrin to cluster (Stewart et al., 1998). Similarly, a study by Sampath
45
Chapter I
et al. (1998) using neutrophils suggested that talin also tethers P2 integrins to the cytoskeleton 
and, following activation, proteolysis of talin causes release of integrins from the actin 
cytoskeleton. PMA- and TCR- induced activation of LFA-1 on T cells, and LPS-induced LFA-1 
activation on monocytes, have also been shown to result in association of the protein cytohesin-1 
with LFA-1 (Geiger et al., 2000). This appears to be brought about by the activation of PI-3- 
Kinase through H-ras and Rac pathways which results in phosphoinositide (3,4,5)-triphosphate 
binding to cytohesin-1 which in tum binds to the cytoplasmic tail of p2 and initiates activation. 
The KALI motif on the P2 tail has been proposed as a possible binding site for such interactions. 
Binding of cytohesin and Rac-1 (involved in the PKC intracellular pathway) have both been 
shown to increase ligand binding following interactions with this motif (Geiger et al, 2000; 
Valmu et al, 1991; Nagel et al 1998).
The precise molecular mechanisms mediating the transduction of signals to the cytoplasmic 
domains following activation is still unclear, but investigators have identified several signalling 
pathways that affect both the affinity and avidity of LFA-1 and transmit signals from LFA-1 
back into the cell. These transduction events serve to modulate many aspects of cell behaviour 
including proliferation, shape change, motility, gene expression, and differentiation.
Signalling pathways that are initiated by the upregulation of chemokines have emerged as major 
activators of integrin activation. Through their interaction with heterotrimeric G protein-coupled 
receptors (GPCRs) the chemokines SLC (CCL21), ELC (CCL19) and SDF-la (CXCL20) can 
rapidly and transiently stimulate an increase in the affinity of LFA-1 for ICAM-1 to promote 
strong adhesion and induce arrest of rolling naïve T lymphocytes (Campbell et al, 1998). 
Binding of interleukin-8 (IL-8) to CXCRl and CXCR2 has also been shown to lead to an 
increase in intracellular calcium flux, which in tum signals cell shape change, integrin activation 
and adhesion during the extravasation process (Wolf et al, 1998). In contrast to this transient 
activation, RANTES and MCP-3 have been shown to trigger prolonged expression of a aM|32
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activation epitope on eosinophils (Weber et al, 1996) suggesting that chemokines can activate 
(32 integrins through both affinity and avidity changes.
Activation of protein kinases such as Syk, src family tyrosine kinases, and FAK have also been 
identified as some of the initial signalling events that are triggered by p2 integrin ligation on 
leucocytes which ultimately lead to P2 integrin-dependent modulation of the cytoskeleton (Berg 
& Ostergaard, 1997; Fagerholm et a l, 2002; Rodriguez-Femandez et al, 1999). TCR-associated 
signalling through Lck/Zap70 phosphorylation events have been shown to be initiated at the 
early stages of synapse formation (Dustin et al, 2002) while blocking FAK activity by over­
expression of a FAK tyrosine phosphatase results in a strong reduction of LFA-1 and TCR co­
localization. Antibody-induced clustering of P2 integrins on PMNs has also been shown to 
trigger an association of Fgr and Hck with PI-3 kinase.
1.6.1. Cross talk
Evidence is now emerging which suggests that, in addition to the effects on other receptors on 
the cell surface, outside-in signals can also alter the activity of neighbouring integrins in a 
process termed ‘crosstalk’ (Blystone et al, 1994; Leitinger and Hogg, 2000). This provides an 
additional level of complexity at the cellular level and allows one to explain the functional 
interactions between members of the integrin family. Blystone et a l (1994) first noted the 
‘crosstalk’ phenomenon whilst investigating the influence integrins have on the phagocytic 
ability of cells. Using an aVp3-transfected K562 cell line which endogenously expresses aSpi, 
aVp3 ligation was shown to be capable of inhibiting phagocytic function of a5pi for 
fibronectin-opsonized beads without affecting low affinity, a5pi-mediated adhesion. They went 
on to show that the P3 cytoplasmic tail was both necessary and sufficient for this effect (Blystone
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et al., 1995). Further investigation suggested that the mechanism involves calcium- and 
calmodulin-dependent protein kinase II (CamKII). CamKII is now known to be an important 
regulator of a5pi-mediated phagocytosis and migration, and co-ligation of aVp3 or exposure of 
the isolated p3 tail prevents a5pi-induced CamKII activation (Blystone, et al., 1999). 
Interestingly, a very recent study by Ly et al. (2003) showed, using a COS cell expression 
system, that de novo expression of a5pi was capable of suppressing aVp3-mediated adhesive 
functions and this inhibition was modulated through the a5 integrin cytoplasmic tail.
Pacifici et al. (1994) also showed that fibronectin binding to a5pi was able to induce 
intracellular signals which increased a2pi-dependent adhesion of monocytes to collagen without 
modifying a2pi expression. The a2pi integrin also induces the release ofIL-1 in these cells, an 
event that is also potentiated by the binding of fibronectin to the a5pi. By using mAbs against 
the intracellular region of the a5 subunit and specific inhibitors of PKC, the authors showed that 
the potentiating effects of fibronectin on monocyte IL-1 production and their adherence to 
collagen was dependent on an intact a5 subunit cytoplasmic domain. Although a2pi could be 
activated by several intracellular second messengers, including protein kinase A and intracellular 
calcium, the potentiating effect of fibronectin was mediated only by PKC. A similar study by 
Diaz-Gonzalez et al. (1996) showed that binding of ligand to integrin allbp3 inhibited the 
function of other target integrins such as a5pl and a2pi by blocking their ability to signal.
Turning our attention to ‘crosstalk’ involving LFA-1, the first observations were made by Van 
Kooyk et al. (1993) whilst investigating LFA-1/ICAM-1 and VLA-4/VCAM-1 mediated 
adhesion of T cells to endothelial cells. Using blocking mAbs to both LFA-1 and VLA-4, they 
observed that the binding of activated T cells to endothelial cells was normally mediated through 
LFA-1 and not through VLA-4. However, when LFA-1 was not expressed or non-functional, as 
is the case with several T-cell leukaemia cell lines, VLA-4 was able to mediate adhesion, 
suggesting that LFA-1 may normally down-regulate VLA-4 although the mechanism has yet to
48
Chapter 1
be identified. Initial work by Porter and Hogg (1997) on LFA-1-mediated crosstalk in primary T 
cells also showed that the interaction of LFA-1 with ICAM-1 decreased adhesion mediated by 
VLA-4 and, to a lesser extent, aSpi. Whilst binding studies with mAh 24 suggested that LFA-1 
needed to be in the active state for its suppressive effect, ligand binding or prolonged activation 
of pi integrins has no effect on LFA-1-mediated adhesion to ICAM-1. However, using a 
different cell system, the same group published apparently opposing results showing that 
activation of LFA-1 enhances rather than inhibits the binding of both aSpi and VLA-4 to their 
respective ligands (Leitinger & Hogg, 2000). In this study, LFA-1 was expressed without an I 
domain but appeared to retain features of an activated integrin. Jurkat cell lines expressing this 
I-domain-less LFA-1 (LFA-1 Al and referred to as JB2.7AiDomain in the remainder of this study) 
demonstrated increased aSpi- and VLA-4- mediated adhesion, and addition of activating P2 
mAbs actually enhanced this binding further. In the case of VLA-4, the increased binding likely 
results from integrin clustering rather than affinity changes since no increase in availability of 
activation epitopes was observed. The presence of this ‘active’ LFA-1 in lipid rafts was also 
shown to promote the movement of VLA-4 into the rafts (Leitinger et al, 2002).
In contrast to the studies above, several researchers have investigated ‘cross-talk’ leading to
LFA-1 activation. May et al. (2000) have shown that both LFA-1 and aMp2 became activated
when VLA-4 was ligated by soluble VCAM-l-Fc or by P1 mAbs, leading to rapid induction of
adhesion of myelomonocytic cells (HL60, U937) to HUVECs. The activation of the P2 integrins
by VLA-4 in this system was further shown to require the presence of the urokinase receptor
(uPAR) as depletion of uPAR from the cell surface by phosphatidylinositol-specific
phospholipase C reduced cell adhesion dramatically. Chan et al. (2000) also showed that
treatment of Jurkats or PBMCs with soluble, cross-linked VCAM-1 or activating VLA-4 mAbs,
significantly increased adhesion to ICAM-1. Interestingly, as shown with the LFA-1-mediated
VLA-4 adhesion described above, this enhanced ICAM-1 binding appeared to be brought about
by integrin clustering rather than induction of a high affinity state as evidenced by the lack of
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Mab24 binding. Cytochalasin D prevented VLA-4-mediated up regulation of LFA-1 suggesting 
that rearrangement of the cytoskeleton was involved in the process. That VLA-4 is capable of 
stimulating LFA-1-dependent ligand binding is further supported by the findings of Rose et al. 
(2001) showing that LFA-1-dependent cell migration is dramatically reduced in a VLA-4- 
defective Jurkat cell line relative to a cell line expressing normal levels of VLA-4.
The limited data on integrin crosstalk published so far highlights inconsistencies in terms of 
hierarchy between individual integrins and, indeed, whether the integrin has a positive or 
negative effect on the function of other integrins. Diaz-Gonzalez et al. (1996) suggest that 
negative versus positive regulation is dependent on the levels of expression of the integrins 
involved, with negative regulation controlled by high expression of the dominant integrin. 
Another controlling factor may be the availability of adaptor proteins for cytoskeletal 
connections or components of critical signalling pathways. Leitinger et al. (2002) have 
suggested that in their initial study which showed negative regulation of VLA-4, the high 
concentration of LFA-1 on cultured T-cells might sequester such essential adaptor or signalling 
molecules, whereas in their latter study where there was a low level of LFA-1 expression, the 
adaptor or signalling molecules would be available for binding to other integrins and hence 
positively regulate VLA-4.
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1.7 Aim of Project
Leitinger et al. (2002) reported that the introduction of an I domain-deleted version of LFA-1 
into a cell system resulted in crosstalk with other integrins. The authors suggested that the I 
domain deletion resulted in an LFA-1 molecule that in someway mimicked an active form of the 
integtin and this resulted in intracellular interactions that enhanced binding through other cell 
surface integrins. Since an I domain deletion of LFA-1 is unlikely to exactly reproduce the 
conformation adopted by an activated LFA-1 molecule it was felt that a better picture of integrin 
crosstalk could be achieved by more subtle alterations of the LFA-1 conformation. The aim of 
this project was therefore to generate a series of LFA-1 constructs that contained mutations 
within the I domain which would lead to a more active form of LFA-1. These mutations would 
be initially characterized in a cell free soluble system to confirm that they did enhance ligand 
binding. A series of these advantageous mutations would then be transferred into cells to 
investigate their effects on other endogenous integrins.
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Chapter 2 Materials and Methods
2.1 Materials
2.1.1 Reagents and Equipment
Chemical and biological reagents, unless otherwise stated, were obtained from Sigma-Aldrich 
(UK). Tissue culture components, gel electrophoresis materials and equipment and were obtained 
from Invitrogen Ltd., (UK). Plastic consumables were obtained from Falcon, BD Biosciences (UK) 
with the exception of ELISA plates which were Nunc^^ brand products, supplied by Fisher 
Scientific (UK).
Restriction enzymes, AmpliTaq DNA polymerase, T4 DNA ligase and CIP were purchased from 
Boehringer Mannheim Ltd., (Lewes, East Sussex), New England Biolabs (Beverly, Mass., USA) or 
Roche Molecular Biochemicals, UK. Antibodies (unlabelled or HRP-, FITC- and PE-labelled) 
were obtained from Chemicon International Ltd., (Harrow, UK), Cambridge Bioscience 
(Cambridge, UK) and Jackson Immuno Research, Inc.
The Bio-Rad gene puiser unit and cuvettes were obtained from BIO-RAD (Hemel Hempstead 
Hertfordshire, UK). FACScalibur was supplied by Becton Dickinson (San Jose CA, USA). Plate 
washers and plates readers were supplied by Labsystems, UK. All standard curves were 
constructed and data analysed using Genesis II software (Labsystems, UK). Small-scale 
centrifugation was carried out using an Eppendorf 5415D benchtop microfuge (Eppendorf Ltd, 
Germany). Large-scale centrifugation was carried out using a Beckman RC3B or RC5B (Beckman 
Instrumentation Ltd., CA., USA)
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2.1.2 Buffers and Solutions
PBS 120mM NaCl, 2.7mM KCl, lOmM phosphate buffered salts, pH7.4
TBS 20mM Tris-HCl, 150mM NaCl, pH7.4
L-Broth 1% (w/v) Bactotryptone, 0.5% (w/v) Bacto-yeast extract, 17mM NaCl, pH7.4
SOC 2% Bactotryptone (w/v), 0.5% (w/v) Bacto-yeast extract, lOmM NaCl, 25mM KCl, lOmM 
MgCh, lOmM MgSO/t, 20mM glucose, pH7.4
TE 1 OmM Tris-HCl pH 7.4, 1 mM EDTA
TAB 40mM Tris-acetate pH8, ImM EDTA
TMB 0.1 mg/ml 3,3,5,5'-tetramethylethyene benzidine 0.004%(v/v) hydrogen peroxide in O.IM 
acetate-citrate buffer pH 6
FACS Buffer PBS, 5%(v/v) PCS, 0.02% (v/v) Sodium Azide, pH7.4
Electrophoresis Buffer 2.9g/L Tris Base, 14.4g/L Glycine, Ig/L SDS, pH 8.3
Tris Glycine Blotting 
Buffer
12g/L Glycine, 3g/L Tris Base, pH 8.3
Blocking Buffer 20mM Tris-HCl, 150mM NaCl, ImM MnCh, i.o% (v/v) Tween, 3% (w/v) BSA, pH7.4
Conjugate Buffer 20mM Tris-HCl, 150mM NaCl, ImM MnCh, 0.1%(v/v) Tween, 0.3%(w/v) BSA, pH7.4
Wash Buffer 20mM Tris-HCl, 150mM NaCl, ImM MnCl2,pH7.4
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2.1.3 Bacterial Strains
XL-1 Blue subcloning grade competent cells (Stratagene, CA) were used for most transformations. 
For site directed mutagenesis transformations, XL-Blue supercompetent grade cells (Stratagene,
CA) were used. Where transformations required the use of a dam host, competent GM242 cells 
(M.Cockett, Celltech) were used.
2.1.4 Vectors
EE6hCMV«eo is a derivative of EE6hCMV (Stephens and Cockett, 1989) carrying a G418 
resistance marker. EE12.2 is also a derivative of EE6hCMV but carries a GS selection marker. 
pEE12.2mFc has a Sal I site in the vector removed and replaced by a Not I site. It also contains the 
mouse Fcyl, Sal I / EcdRX gene fragment (Takahashi et a l, 1982) (Figure3.3). pV16mFc is also a 
derivative of pEE6 hCMV in which a Sal I site has been removed and replaced with a/Votl site and 
a second Not I site introduced at the 5’ end of the HCMV promoter fragment. This vector also 
contains the mouse Fcyl, Sal I / EcoRl gene fragment (Figure 3.3).
2.1.5 Antibodies
The name, subclass, host etc. of all antibodies used are described in the table below.
Antibody Subclass Host species Reactivity Source
M0PC21 IgGl monoclonal unknown ATCC
6.5E IgGl monoclonal hCD18 Celltech
KM185 IgGl monoclonal hCD18 Celltech
KIM127 IgGl monoclonal hCD18 Celltech
DA36 IgGl monoclonal hCD lla Celltech
AB38 lgG2a monoclonal hCD lla Chemicon
AB38-PE lgG2a monoclonal hCD lla Chemicon
MEM83 IgGl monoclonal hCD lla V.Horejsi
MEM95 IgGl monoclonal hCD lla V.Horejsi
MEM48 IgGl monoclonal hCD18 V.Horejsi
RRl lgG2a monoclonal hICAM-1 Chemicon
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H Illl-P E IgGl monoclonal hCD lla AutogenBioclear
JBIA IgGl monoclonal hCD29 Chemicon
HA5 IgGl monoclonal a5 Chemicon
Mab24 IgGl monoclonal hCD18 N. Hogg
KIM215 IgGl monoclonal hCD18 Celltech
KIM202 IgGl monoclonal hCD18 Celltech
MCA1485 IgGl monoclonal hICAM-3 Serotec
MCA1140 IgGl monoclonal hICAM-2 Serotec
15.2 IgGl monoclonal hICAM-1 Serotec
BR-IC2/2 lgG2a monoclonal hICAM-2 Biosource
152-2D11 lgG2a monoclonal hICAM-3 Biosource
Y9A2 IgGl monoclonal ha9pl Chemicon
SAM-1 lgG2a monoclonal ha5 Celltech
MAX68P IgGl monoclonal ha4 Celltech
HA5 lgG2b monoclonal hCD29 Chemicon
BHA2.1 IgG monoclonal ha2(3l Chemicon
TS2/7 IgG monoclonal ha l Serotec
C3II.1 IgG monoclonal ha3 Pharmingen
TS2/16 IgGl monoclonal hpl T. Springer
LM609 IgG monoclonal havp3 Chemicon
E7P9 IgGl monoclonal havp3 Chemicon
7E3 IgG monoclonal allbp3 Celltech
AMF-7 IgG monoclonal hCD51(aV) Immunotech
BP6 IgG monoclonal h|37 A. Law
LF61 IgGl monoclonal hocE Serotec
R7.1 IgGl monoclonal hCD lla Biosource
KIM247 IgGl monoclonal hCDllb Celltech
KIM249 IgGl monoclonal hCDllb Celltech
KIM75 IgGl monoclonal hCDllb Celltech
aD IgGl monoclonal haD Y.Van Kyook
15.2 IgGl monoclonal hICAM-1 Biosource
MCA1140 IgGl monoclonal hICAM-2 Serotec
MCA1485 IgGl monoclonal hICAM-3 Serotec
Cal3.10 IgGl monoclonal hICAM-3 R&D
IG ll IgGl monoclonal VCAM-1 Celltech
UPC 10 IgG2a monoclonal unknown Sigma
CRB-IC/2 IgG2a monoclonal ICAM-2 Biosource
M EM lll IgG2a monoclonal ICAM-1 V.Horejsi
P1D6 IgG3 monoclonal ha5 Chemicon
SC6597 goat polyclonal ha6 Santa Cruz
SC6638 goat polyclonal ha8 Santa Cruz
SC6628 goat polyclonal ha4 Santa Cruz
Ab3.9 IgG monoclonal CD llc N. Hogg
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2.1.6 Low Molecular Weight Antagonist
Lovastatin was purchased from Sigma-Aldrich (UK) and was kept as frozen stock solution at a 
concentration of 5OmM in DMSO. Structure is shown below.
HO
Me
Me
Lovastatin
2.1.7 Cell lines
The mouse myeloma cell line NSO was obtained from C. Milstein (Cambridge) and has previously 
been described (Galfre and Milstein, 1982).
The cell line CHO-761H was obtained from Celltech (Cockett et al., 1991).
The human erythroleukaemic cell line K562 was obtained from the European collection of Animal 
Cell Cultures (No.CCL243). The KL4 cell line was obtained from Celltech (Ortlepp et al. 1995).
The JB2.7, J B 2 . 7 l f a - i w t  and JB2.7AiDomain cell lines were obtained from N. Hogg (London) with 
kind permission from L. Klickstein.
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2. 1.8 Assay Reagents
ICAM-lhFc, ICAM-2hFc, ICAM-3hFc and VCAM-lhFc had previously been expressed and 
purified in house (Celltech) with the original ICAM-Fc fusion genes obtained from D. Simmons.
2.1.9 Oligonucleotides
Vector Primers
HCMVMIE Promoter Primer
Sequence:
1053 (5* hCMVregion)
GCTGACAGACTAACAGACTGTTCC
Murine yf Fc Primer V9011 (3* niFc region)
Sequence: CGTCTGAGCTGTGTGCACCTCCAC
CD lla Primers
CD lla Primer 1 
Sequence:
B3609 (Primer to introduce 3’ Sal I site) 
’^CCAAGGGTCGACCTGCTTCTCATACACCACGTCAAC
Sail
CDlla Primer 2: B6112 (470-^)
Sequence: ’^CTGTGTTACCTCTTCCGCCAG
CDlla Primer 3: B8553 (855^)
Sequence:  ^ACCAAAGTGCTTATCATCATC
CDlla Primer 4; B8549 (810 ^ )
Sequence:  ^CGCGACATAATTGATGGCACC
CDlla Primer 5: B8550 (1200<—)
Sequence: ^GGCTCCTACTGCCCCCACGAC
CDlla Primer 6: B8554 (1560->)
Sequence: ^ACACCAGAAGTGAGAGCAGGC
CDlla Primer 7: B8551 (1200<—)
Sequence:  ^TCTCTGCTCCCCATAGAACAG
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CDlla Primer 8: B8555 (1680->)
Sequence:  ^GCTCTGACAGACATCAACGGC
CDlla Primer 9: B8552 (2000<-)
Sequence: ^GGAGCACTCCACTTCATGCAC
CDlla Primer 10: 
Sequence:
B8556 (2070->)
’^t a c c c c c a g t t c c a a g g c c g c
CDlla Primer 11 : 
Sequence:
B8557 (2370<-)
’^CGAGTGCAGGGAGGGTCTCAG
CDlla Primer 12:
Sequence:
B8559 (2450->)
’^CCTGCAAGATCCAGAGCCCTG
CDlla Primer 13: 
Sequence:
B8558 (2730<-)
’^CTGTATTAAACATCATCTGCAG
C D lla Primer 14: 
Sequence:
B3606 (2790->)
’^TGTAACAATGAGGACTCAGACCTC
CDlla Primer 15: 
Sequence:
B3607 (3085^)
’^CACTATGAGGATCTGGAGAGGCTC
CDlla Primer 16: 
Sequence:
B3608 (3200<-)
’^CAGAGTCCCGATCACTTGGACGAG
Other primers used in the cloning of the various forms of LFA-1 are described in Appendices 1 and 
2 and Chapter 3
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2.2 Molecular Biology
2.2.1 Gene Cloning by PCR
Approximately 50 ng of template DNA (either cDNA or plasmid DNA) was mixed with 10 pmoles 
of the appropriate oligonucleotides, and lunit of AmpliTaq® DNA polymerase, in a PCR buffer 
containing 0.25mM dNTP (dATP, dCTP, dGTP, dTTP), 50mM KCl, lOmM Tris-HCl pH 8.3, 
1.5mM MgCli, and 0.01% (w/v) gelatin. The reaction was amplified for 30 cycles of 94°C, 
1 minute; 55°C, 1 minute; ITC , 1-3 minutes; followed by a 15 minute cycle at 72°C, in a T3 
thermocycler (Biometra). Samples were then analysed by agarose gel electrophoresis (See Section 
2.2.4).
2.2.2 Quick Change Site Directed Mutagenesis
Site directed mutagenesis was carried out using Stratagene’s QuikChange® Mutagenesis Kit 
according to the manufacturer’s instructions.
2.2.3 Agarose Gel Electrophoresis
Horizontal submerged gel electrophoresis was carried out as described by Sambrook et al. (1989) 
on 0.5%-1.5% (w/v) agarose gel (depending on fragment size) in TAB buffer containing 0.5pg/ml 
ethidium bromide. Electrophoresis was typically carried out at 4-6V/cm and the DNA bands were 
visualised using a 254nm UV light. Agarose gel electrophoresis was used both analytically and 
preparatively, the latter for purification of fragments after restriction enzyme digestion, prior to 
ligation. To minimise DNA damage, recovery of DNA fragments for cloning and ligation was 
carried out using a 366nm wavelength UV light.
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2.2.4 Purification of DNA fragments from an agarose gel
DNA fragments were isolated from agarose gel using the Qiaquick® Gel Extraction Kit (QIAGEN 
Ltd., UK) according to the manufacturer’s instructions.
2.2.5 Analysis of DNA by restriction enzyme digest
For general restriction enzyme analysis, 500ng - 2|ig DNA was added to the appropriate supplied
enzyme buffer with 2-10 units of enzyme for 1 hour at the appropriate temperature.
2.2.6 Phosphatase Treatment
When vector fragments had compatible restriction enzyme overhangs the 5’-phosphate groups were 
removed by treatment with calf intestinal alkaline phosphatase to prevent self-ligation. Typically, 1 
unit of enzyme was added per 1 OOpmoles of DNA and incubated in the recommended buffer at 
37°C for ISmins.
2.2.7 Ligation of DNA fragments
Ligations were carried out using the Roche (Germany) DNA Rapid Ligation Kit® according to the
manufacturer’s instructions.
2.2.8 Transformation of E'.co//
A small aliquot (2-5pl) of the ligation mixture was transformed into XL-1 Blue sub-cloning grade 
competent cells (Stratagene, CA) according to the manufacturer’s instructions, then plated onto L- 
broth agar plates containing the appropriate antibiotic selection and propagated over-night in a 37°C 
incubator.
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2.2.9 Transformed E.coli / Construct DNA Analysis by PCR
The length of DNA inserts within vectors was estimated by agarose gel electrophoresis following 
PCR. Appropriate oligonucleotides designed to hybridise in the area flanking the DNA insert were 
used. A small sample of each colony was inoculated into a PCR reaction mix (0.25mM dNTP 
(dATP, dCTP, dGTP, dTTP), 50mM KCl, lOmM Tris-HCl pH8.3, 1.5mM MgCb, 0.01%(v/v) 
gelatin, 2-20pmol oligo primers, and lunit of AmpliTaq® DNA polymerase) and the reaction was 
amplified for 30 cycles of 94®C, 1 minute; 55°C, 1 minute; 72°C, 1-3 minutes; followed by a 15 
minute cycle at ITC , in a T3 thermocycler (Biometra). Samples were then analysed by agarose gel 
electrophoresis.
2.2.10 Plasmid DNA preparation from transformed E.coli
Single colonies were picked and grown overnight in the appropriate volume of L-broth containing 
antibiotic selection. For small scale plasmid DNA preparation, QIAprep® spin miniprep kits 
(QIAGEN Ltd., UK) were used and for large scale QIAfilter plasmid maxi kits (QIAGEN Ltd., UK) 
were used, both according to manufacturer’s instructions.
2.2.11 Optical Density quantitation of DNA
The concentration of DNA was determined using a Beckmann DU-8 spectrophotometer at 260nm, 
assuming an OD of 1.0 represents a concentration of 50pg/ml of DS DNA for a 1cm path length.
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2.2.12 Automated DNA Sequencing
Plasmid DNA was sequenced with the appropriate primers as described in Section 2,1.7 using the 
Applied Biosystem 373A XL automated sequencer according to the to manufacturer’s instructions. 
Data was analysed by ABIPRISM^^ autoassembler software (Perkin Elmer).
2.3 Cell Culture Methods
2.3.1 Mammalian Cell lines
Mammalian cell lines were cultured in either RPMI 1640 or DMEM each supplemented with 10% 
(v/v) PCS, 2mM glutamine and SOpg/ml penicillin and SOpg/ml streptomycin. For growth of CHO 
cells l%(v/v) NEAA was also added. Transfected K562 cells were maintained in media (DMEM) 
supplemented as above and with 1 mg/ml G418. The JB2.7wr and JB2.7AiDomain cells (received from 
N. Hogg) were maintained in 250|iig/ml Zeocin (Invitrogen).
Suspension cells were passaged by diluting 1:10 into fresh growth media (as above). Adherent cells 
were treated with trypsin/EDTA before passage.
For long term storage, cells in PCS containing 10% (v/v) DMSO were stored in liquid nitrogen. 
Cells were counted using a Neubauer haemocytometer.
2.3.2 Transient Expression in CHO cells
To test for the integrity and expression of the mutated aL genes, the cxL containing vectors were 
transiently co-transfected with the (32 vector into CHO-761H cells using GenePorter 2000™ 
according to manufacturer’s instructions. For soluble receptors, the supernatants were harvested 
after 5 days and assayed for the presence of the construct by ELISA. In the case of surface-
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expressed receptors, cells were harvested after 2 days and analysed on a fluorescent activated cell 
sorter (FACScan, Becton Dickinson)
2.3.3 Stable Expression of LFA-lmFc in CHO cells
The generation of stable cells lines expressing the various LFA-1-mFc mutants was performed as 
above for, transient expression using GenePorter 2000™ with the exception, that after 24hrs, the 
media was replaced with GS selective media, SGMEM + 25|iM MSX, and was subsequently 
replaced every 4-5 days until single colonies of viable cells were visible. These single colonies 
were then transferred into individual wells using small squares of trypsin-soaked sterilized blotting 
paper. The most productive clones were identified using mFc assays and assembly ELIS As.
2.3.4 Stable Transfection of K562 Cells
To generate stable K562 cell lines expressing the full-length LFA-1 genes, cells were transfected by 
electroporation. Using a Bio-Rad gene pulsar unit, 1x10  ^ cells were transfected with 40|ig of 
linearised DGV plasmid DNA and subjected to 1 pulse at 450volts and 960|iF. Transfectants were 
then selected by addition of 1 mg/ml G418 (Sigma).
2.3.5 Transfection of JB2.7 Cells
Stable JB2.7 cell lines were generated by electroporation as described by Weber et al. (1997). 
1x10  ^ cells were transfected with 25|ig of linearised plasmid DNA and subjected to 1 pulse at 
240volts and 960pF. Transfectants were then selected by addition of 1 mg/ml G418.
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2.3.6 FACs Analysis
For FACs analysis, 2-5x10^ cells were incubated with lOOpl of FACs buffer containing 20|ig/ml of 
the appropriate labelled antibody at 4°C for 1 hour. Cells were washed twice with FACS buffer and 
if the labelling antibody was unconjugated, subjected to a further incubation with a second, 
conjugated antibody for 30 mins, and washed again. Cells were resuspended in 500|xl FACS buffer 
and analysed using a FACScalibur flow cytometer (BD Biosciences). Data was acquired and 
analysed with CellQuest software (BD Biosciences).
2.4 Soluble Protein Assays
2.4.1 Mouse IgG ELISA
The concentration of LFA-1-mFc fusion proteins in culture supernatants was measured as follows: - 
Nunc^^ 96 well plates were coated with lOOpl of 5pg/ml of goat anti-mouse IgG Fc antibody in 
PBS overnight at 4°C (or 3hrs at room temperature). After washing twice with TBS pH 7.4 using a 
Wellman Plate washer, plates were blocked with 200|il/well 2% (w/v) BSA, 1% (v/v) Tween20 in 
TBS for 1 hour at room temperature. Plates were washed again, then purified Max68P (used as 
standard) at a starting concentration of lOOng/ml, along with sample supernatants, were titrated 
across the plate in diluent buffer (0.2% (w/v) BSA, 0.1% (v/v) Tween20 in 20mM TBS, pH 7.4) 
with doubling dilutions. Following 1 hour incubation at room temperature the plates were washed 
again and lOOpl/well anti mFc-HRP 1:10000 dilution in diluent buffer was added across the plate 
and incubated for 1 hour at room temperature. Following a final wash step, the extent of binding 
was revealed with addition of 100|il/well TMB and plates read at 630nm with final concentrations 
calculated using Genesis V3.05 software (Labsystems).
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2.4.2 Heterodimer Assembly Assay
To estimate the concentration of correctly assembled aL and (32 heterodimer in culture supernatant 
and to be able to compare all the mutant forms of LFA-1, a series of assembly ELISAs were 
developed: the heterodimer was captured by an antibody to one subunit and revealed by another 
mAb specific for the other subunit or by an antibody that recognises a combinatorial epitope.
Nunc^^ 96 well plates were coated with lOOp.1 of 5|ig/ml solutions of one of the following mAbs: 
Ab38, 6.5E, KIM 185 or MEM83 in PBS overnight at 4°C. After washing twice with TBS pH 7.4 
using a Wellman Plate washer, plates were blocked with 200p.l/well 2% (w/v) BSA, 1% (v/v) 
Tween20 in TBS for 1 hour at room temperature. Plates were washed again and the sample 
supernatant was titrated down the plate in diluent buffer (0.2% (w/v) BSA, 0.1% (v/v) Tween20 in 
TBS, pH 7.4) with doubling dilutions. Following a 1 hour incubation at room temperature the 
plates were washed again and lOOpl/well of one of the following biotinylated mAbs at lOpg/ml: 
6.5E, KIM 185, DA36, in diluent buffer was added across plate. After incubation for 1 hour at room 
temperature plates were washed and lOOpl/well of 1:1500 dilution of streptavidin-peroxidase in 
diluent buffer was added across the plate and incubated for 30 mins at room temperature. 
Following a final wash step, the extent of binding was revealed with addition of 100|il/well of TMB 
and plates read at 630nm.
2.4.3 Ligand- hFc Binding Assays
Nunc™ 96 well plates were coated with lOOpl goat anti-mouse IgG Fc antibody at 5|ig/ml in PBS 
overnight at 4®C. After washing twice with TBS pH 7.4 using a Wellman Plate washer, plates were 
blocked with 200pl/well 2% (w/v) BSA, 1% (v/v) Tween20 in TBS for 1 hour at room temperature. 
Plates were washed again and the integrin sample supernatants (containing the mFc fusion protein) 
were titrated down the plate in diluent buffer (0.2% (w/v) BSA, 0.1% (v/v) Tween20 in TBS, pH
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7.4, ImM Mn^Q with doubling dilutions. Following a 1 hour incubation at room temperature the 
plates were washed again and 100|il/well 200-1 OOOpg/ml sICAM-1, -2, -3hFc diluted in diluent 
buffer was added across the plate and incubated for 3 hours at room temperature. After washing, 
1 OOpl/well anti-hFc-HRP 1:5000 dilution in diluent buffer was added across the plate and 
incubated for 1 hour at room temperature. Following a final wash step the extent of binding was 
revealed with addition of lOOpl/well of TMB and plates read at 630nm.
2.4.4 Cation Titration Assays
Nunc™ 96 well plates were coated with lOOp.1 of goat anti-mouse IgG Fc antibody at 5|ig/ml in 
PBS overnight at 4°C. After washing twice with TBS pH 7.4 using a Wellman Plate washer, plates 
were blocked with 200|xl/well 2% (w/v) BSA, 1% (v/v) Tween20 in TBS for 1 hr at room 
temperature. lOOpl of LFA-lmFc supernatants was added per well and incubated for 2 hours at 
room temperature. Plates were washed three times in TBS, 20mM EDTA Buffer followed by three 
washes in TBS Buffer. 50|xl of 2x cation solution were titrated down the plate with tripling dilutions 
and 50pl of ICAM-lhFc at 0.5|ig/ml was added across the plate. After incubation for 3 hours wells 
were manually washed twice in the corresponding cation concentration buffer and 100|il/well anti 
hFc-HRP 1:5000 dilution in the corresponding cation concentration buffer was added across plate 
and incubated for 1 hour at room temperature. Following a final wash step with cation buffer the 
extent of binding was revealed with addition of lOOpl/well of TMB and plates read at 630nm.
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2.5 Cell Binding Assays
2.5.1 Rose Bengal 1C AM binding Assays
Nunc^^ 96 well plates were coated with lOOpl of goat anti human IgG Fc antibody (Jackson) at 
5pg/ml in PBS overnight at 4°C. After washing twice with TBS using a Wellman Plate washer, 
plates were blocked with 200pl/well 2% (w/v) BSA, 1% (v/v) Tween20 in TBS for 1 hour at room 
temperature. lOOpl ICAM-1, -2, -3 or VCAM-lhFc diluted in diluent buffer (0.2% (w/v) BSA, 
0.1% (v/v) Tween20 in 20mM TBS, pH 7.4) was added across the plate and incubated for 2hours at 
room temperature. Plates were washed three times in TBS before addition of lOOjil 5x 10"* cells / 
well in warm cell culture media (DMEM with glutamine). MAbs (final concentration 20p.g/ml), 
PMA (final concentration 100 ng/ml), cytochalasin D (final concentration 5|ig/ml) were added to 
cells to stimulate / inhibit cell adhesion. After incubation at 37°C for 45mins plates were washed 
with media (DMEM with glutamine) using a multi-channel pipette. lOOpl 100% methanol was then 
added to each well and incubated at room temperature for lOmins followed by a gentle PBS wash. 
lOOpl 0.25% (w/v) Rose Bengal (Sigma R4507) in PBS was then added and plates incubated for 5 
mins at room temperature. Following intensive gentle washing in PBS to remove all excess stain, 
lOOpl 1:1 PBS: ethanol solution was added and plates were placed in a shaking incubator 
undercover for 1 hour. Plates were then read at 570nm.
2.5.2 Rose Bengal Fibronectin Assays
Fibronectin binding assays were carried out as described above in Section 1.5.1 with one exception. 
Plates were coated directly with 500ng/ml Fibronectin (SIGMA F0895) diluted in PBS and 
incubated overnight at 4°C before being blocked as above.
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2.6 Immunoprécipitation and Western Blotting of mFc-tagged 
proteins
Western blotting was carried out to confirm the expression of recombinant LFA-lmFc proteins and 
to ascertain whether the a  and P chains were in heterodimeric or homodimeric forms. LFA-lmFc 
supernatant volumes equivalent to 75ng and 50ng protein (determined by mFc ELISA) for non­
reduced and reduced samples, respectively, were incubated with 50|il protein Sepharose A beads in 
50mM Tris-HCl, 4M NaCl pH 8 overnight at 4°C. Beads were washed four times in 50mM Tris- 
HCl, l%(v/v) NP-40, pH 8, followed by two washes in TBS pH 7.4 and finally suspended in 30|il 
of TBS containing reduced / non-reduced sample buffer. Samples were heated to 70°C for 5mins 
and the total sample was loaded onto No vex Tris/Glycine Gels and run at 100mA for the required 
time for separation. Proteins were transferred to a nitrocellulose membrane for 3 hours using a 
Novex Mini Cell System in a Tris/Glycine Running Buffer. Following blocking with 5% (w/v) 
non-fat milk powder in TBS/0.1% NP40 for 1 hour, the membrane was incubated with HRP - 
labelled-goat anti-mouse IgG Fc antibody at 1:2000 dilution in TBS /0.1% (v/v) NP40 for 1 hour. 
After extensive washing with TBS/0.1% (v/v) NP40 the bound antibody was detected by non­
isotopic enhanced chemiluminescence assay (ECL Kit, Amersham, UK).
2.7 Statistical Analysis of Results
Where appropriate, statistical analysis of data was performed using Graphpad-Prism Version 3 
(Graphpad Software, San Diego, CA). To determine if parametric or non-parametric analysis of 
data was required, Bartletts test of homogeneity of variance was performed. According to this 
result, either parametric analysis of variance (ANOVA) or non-parametric Kuskal-Wallis ANOVA 
was performed. For sample comparisons, data was analysed using a two-tailed student’s T-test to 
which a P value of =< 0.05 was assigned as significant.
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Chapter 3 Mutation Selection, Vector Design and Molecular Cloning
3.1 Introduction
At the time the work described in this thesis was started, two different conformations of the aM  
and a2 I domains (‘open’ and ‘closed’) had been observed in X-ray crystal structures (See 
Section 1.4). The ‘open’ conformation involved a change in metal ion coordination and a shift 
in the position of the C-terminal a-helix that exposed several buried hydrophobic residues (See 
Figure 1.8). Several X-ray studies of the aL I domain, with and without Mn^^ or Mg^ ,^ had also 
been undertaken but no structural changes in the MIDAS or conformational changes of the 
buried hydrophobic residues were observed, although a shift in the position of the a7 helix was 
apparent (Qu and Leahy 1995; 1996). Kallen et al. (1999) had also shown that Lovastatin, a 
small molecular inhibitor of LFA-1, binds in a cleft adjacent to the a7 helix, which became 
known as the IDAS site. Moreover, since the binding of Lovastatin had no effect on the 
structural arrangement of the MIDAS site, the authors suggested that inhibition of ICAM-1 
binding was through an indirect mechanism. Huth et al. (2000) went onto characterise the 
effects of a series of mutations within the IDAS and identified several residues that were 
important for ligand binding. Therefore, this data, combined with the I domain X-ray results, 
suggest that a conformational change in a region distal to the MIDAS is involved in regulating 
ligand binding. Further investigation of the IDAS site was warranted to determine what 
influence the position and charge of a selection of residues along the a7 helix had both on 
conformational change within the IDAS as well as on the activation state of LFA-1. We 
postulated that it was also possible that a constitutively active form of LFA-1 could be generated 
by mutations within the IDAS and that this mutated form of LFA-1 would be a useful tool to 
characterise the interaction of LFA-1 with its ligands.
71
UianWr .1
Also at this time, Stephens et al. (2000) expressed the integrin VLA-4 as a soluble, active, 
heterodimeric immunoglobulin fusion protein. Using a novel approach, the cDNAs encoding the 
extracellular domains of the integrin a4 and (31 subunits were fused with the human yl 
immunoglobulin Fc domain. Stable heterodimerisation of the a  and p chains was brought about 
by the dimérisation of the CH3 domains and maintained by the formation of disulphide bridges 
in the hinge region between the CHI and CH2 domains of the Ig. In addition, the introduction of 
specific mutations in the Fc region of the molecules helped to induce heterodimeric formation 
and reduce homodimeric formation. Comparison of this soluble form of VLA-4 with native 
cell derived VLA-4 showed that the apparent Kd for VCAM-1 binding was similar for both 
forms of the integrin.
Using this method, it was proposed that it was feasible to generate a soluble form of LFA-1, as 
previous efforts within this laboratory to generate soluble forms of LFA-1 without some form of 
tail were unsuccessful (S. Ortlepp personal communication). A soluble form of LFA-1 would 
allow the study of the function of this integrin in a cell-free system, independent of influences 
such as signal transduction and clustering. Additionally, we wanted to investigate the possibility 
of generating a constitutively active form of the integrin by incorporating a series of mutations in 
and around the IDAS of the LFA-1 I domain. Mutations that conferred an increase in ligand 
binding in the soluble system would then be introduced into LFA-1 expressed on the cell surface 
to determine if altering the structure of the a l  helix contained within the IDAS had effects on 
ligand binding in the presence of cytoplasmic restraints.
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3.2 Mutation Selection
Following analysis of the 3D structure of the aL I-domain and information from the literature, 
the residues listed below were identified as candidates for mutation. Some of the residues 
chosen were based on mutational analysis of the aL I domain described in the literature, where 
an increase in activation was observed compared with wild type, when the I domain was 
expressed in the context of the whole integrin on the cell surface or as an isolated domain. Such 
mutations were selected to act both as controls to validate the expression systems to be used in 
this study and as comparisons for the other selected mutations. The other residues selected for 
mutational analysis were identified based on sequence analysis of other P2 integrin a-subunits 
and on analysis of the amino acid composition of the a l  helix. Figure 3.1 highlights the 
positions of the amino acids chosen for mutational analysis within the I domain 3D structure.
I235A: The 235 isoleucine residue is located at the centre of the IDAS cleft on the p i
strand in the I domain and was previously shown by Huth et al. (2000) to increase the binding of 
CHO-expressed LFA-1 to ICAM-1 when the residue was mutated to alanine. Huth et al. 
suggested that replacement of the large hydrophobic isoleucine residue created a cavity in the 
protein that lowered the energy barrier for conformational change in the I domain. The 
increased activity seen with the 1235A mutation was greater than that seen for the Gly-Ala 
mutation in the GFFKR motif located in the aL cytoplasmic domain, which when expressed in 
CHO cells had been shown to also yield a constitutively active LFA-1 phenotype (Lu and 
Springer, 1997). Interestingly, when the 1235A mutation was expressed in a lymphocyte-like 
cell line (JB2.7), the constitutive activity of the 1235A mutant was lost, although increased 
binding to ICAM-1 was shown at low PMA concentrations relative to wild type (Huth et al., 
2000). This result suggested that the cytoplasmic domain also plays a role in the activation state 
of the integrin.
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Figure 3.1 3D-view of sites chosen for mutational analysis within the IDAS site of the aL I 
domain. Four o f the residues 1306, F299, L295 and K294 are located along the length 
o f the a l  helix; F292 is located on the turn between the a l  helix and the P6 strand with 
L289 and K287 located on the ^6- strand. 1235 also within the IDAS pocket is located 
on the P-1 strand. This image was created using the SYBYL6.9 graphics package 
(Tripos Inc) with kind help from D.Athwal (Celltech).
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K287F: Sequence comparison of all the p2 integrins showed that position 287 in all the
a-chains contains a conserved phenylalanine except for aL, which contains a lysine residue. 
Substituting this lysine residue in aL to phenylalanine would introduce a bulky hydrophobic 
group into the IDAS pocket, which we predicted would induce interactions with side chains of 
other residues to stabilise the ‘closed’ form of the I domain by increasing the energy barrier for 
conformational change. This novel change would, therefore, behave in the opposite manner to 
the alanine substitution at residue 1235. Since LFA-1 has a much higher affinity for each 
member of the ICAM family compared to other members of the P2 family, substitution of a 
phenylalanine residue for a lysine residue at this position might also highlight the influence this 
residue has on the affinity of LFA-1 for its ligands.
F292A: F292 is a large hydrophobic residue situated at the top of the p6-a7 helix loop
and is analogous to residue F302 in the aM I domain. Previously, Li et al. (1998) expressed an 
isolated aM I domain containing a F302^W  mutation which was shown to increase ligand 
binding over the wild type version. A similar study of the same mutation by Shimaoka et al.
(2000) also demonstrated a slight increase in binding of aM^2 to i3Cb compared to wild type 
binding. However, two crystallographic studies of aM containing this mutation conducted by 
the same group (Li et al., 1998; Xhiong et al., 2000) gave conflicting results concerning whether 
or not this residue was important in converting the I domain from the ‘closed’ to ‘open’ 
conformation. In the first, F302^W  was buried in the ‘closed’ conformation and exposed in the 
‘open’ conformation. In the second study, however, the F302—>W mutant crystallised in the 
‘closed’ conformation in the presence and absence of cation and W302 was shown to be buried 
in both cases. Mutational analysis by Huth et al. (2000) and other work by Li et al. (1998) have 
suggested that hydrophilic residues in this area should favour the ‘open’ conformation. 
Therefore, in this study F292 was mutated to alanine rather than tryptophan as in the previous
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studies. This would allow one to determine if a hydrophilic residue at this position (that is also 
much smaller in size than a phenylalanine residue) would favour the ‘open’ ligand binding 
conformation.
L295A: Like F292, L295 is located at the top of the p6-a7 helix loop and hence could
also be involved in conformational changes that take place subsequent to integrin activation. 
The leucine at this position is hydrophobic and may form polar interactions with surrounding 
residues, which could stabilise the I domain in either an ‘open’ or ‘closed’ conformation. We 
predicted that substituting this residue to alanine would remove such interactions allowing more 
flexibility and movement of the helix. It was therefore of interest to establish whether this novel 
substitution would stabilise either the ‘open’ or ‘closed’ conformation, leading to an increase or 
decrease in ligand binding.
F299A: A further novel substitution was introduced at position F299. This
phenylalanine residue is approximately one-third of the way down the a l  helix and its bulky 
hydrophobic nature suggests that it is involved in interactions with the side chains of other 
residues, possibly favouring the ‘closed’ conformation. Substitution of this residue to alanine 
could alter these side chain interactions and may favour the ‘open’ conformation as suggested by 
Huth et al. (2000) and Li et al. (1998) based on the data where a hydrophobic residue was 
replaced with a hydrophilic residue.
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I306A: 1306 is located at the tail of the C-terminal a-helix of aL. It corresponds to
1316 in the aM I domain, which has been shown to stabilise the ‘closed’ conformation of aM  by 
fitting into a hydrophobic pocket between the C-terminal a-helix and the opposing p-sheet of the 
IDAS site (Xiong et al., 2000). Consistent with these observations, substitution of aL  1306 with 
alanine was shown to increase the adhesion of CHO cells to ICAM-1 relative to wild type. 
Interestingly, however, the level of binding was not increased to the same extent as the 1235 
mutation which was also analysed in the same study (Huth et al., 2000). Since this mutation was 
previously shown to activate LFA-1, inclusion of the same substitution in this study would serve 
as a control in the soluble Fc system.
L295A + I306A
These residues are at opposite ends of the a7 helix and, whilst it was unknown how the 295 
substitution would behave, we predicted that substituting this residue to alanine would allow 
more flexibility and movement of the helix. As an alanine substitution at residue 1306 has 
previously been shown to increase the activity of LFA-1, pairing it with A295 may increase the 
overall flexibility of the a-helix, further enhancing the activation state of the integrin.
F292A + L295A + I306A
As with the double mutation described above, it was of interest to see if removal of a second 
large hydrophobic group on the a7 helix had an additive effect on the activation state of LFA-1 
by further lowering the energy barrier required to shift the a7 helix from the ‘closed’ to the 
‘open’ form. Alternatively, it was possible that substitution of both the 292 and 295 residues to 
alanine would remove important structural elements within the I domain required for ligand 
binding.
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Other Mutations
Subsequent to identifying the above residues as potential sites for mutational analysis, Shimaoka 
et al. (2001) recently showed that by introducing disulphide bonds at several positions within the 
IDAS, bracketing the loop between the C-terminal a-helix and the preceding (3-strands, an aL I 
domain in both the ‘open’ and ‘closed’ forms could be generated. Introduction of disulphide 
bonds within the IDAS appeared to lock the aL I domain into conformations similar to that seen 
in the aM ‘open’ and ‘closed’ crystal structures (See Figure 3.2). Mutation of K287 on the (36 
strand to a cysteine residue and K294 on the a7 helix also to a cysteine allowed for the 
formation of a disulphide bridge between (36 and a l. This locked the I domain in an ‘open’ 
conformation, as evidenced by high affinity binding to ICAM-1 when expressed as an isolated I 
domain. By comparison, a disulphide bridge introduced by mutating both L289 and K294 to 
cysteine residues appeared to present the I domain in a locked ‘closed” conformation. This 
construct was shown to behave in a similar manner to wild type I domain in ICAM-1-binding 
experiments.
Taking into account Shimaoka findings, both of these pairs of mutations and mutations that 
contained single K294—>C and K287—>C substitutions were also incorporated into this study. 
We also included a double alanine substitution of residues K287 and K294, to confirm that the 
presence of cysteine bonds rather than the mutations themselves were responsible for the 
increased activity. We were interested to know if soluble-expressed integrin containing these 
mutations behaved in a similar manner to the isolated I domains used in the Shimaoka study
(2001), and if this locked ‘open’ conformation was capable of overriding all other restraints 
imposed by the other domains of the integrin when expressed on the cell surface. These 
mutations would also act as controls with which to compare other introduced mutations not 
previously investigated.
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open model closed structure
C294
C287
C289
C294
Figure 3.2 Locked ‘open’ and ‘closed’ forms of the aL I domain. The above illustration taken 
from Shimaoka et al. (2001 ) depicts the conformational changes that are thought to take 
place within the I domain on activation o f the integrin. These were mimicked by 
Shimaoka et al. by the introduction o f cysteine mutations at residues K287/L289 which 
when paired with a cysteine substitution o f residue K294 locks the I domain in an ‘open’ 
or ‘closed’ form.
3.3 Generation O f Soluble mFc Constructs
For the generation of soluble integrin murine Fc constructs, two vectors had previously been 
designed based on the pEE12.2 and pV16 vectors. Both the pEE12.2mFc and pVlbmFc vectors 
contain a murine yl Fc domain cloned in as a Sal l-Eco RI cDNA fragment encoding 9 residues 
of the upper hinge, the entire hinge and the constant CH2 and CH3 domain regions (Stephens et 
al, 2000) (Figure 3.3). To increase the likelihood of stable heterodimerisation of the a  and (3 
chains, specific mutations were introduced into the CH3 domains of the murine Fc by 
oligonucleotide directed PCR mutagenesis creating a ‘knob’ and ‘hole’ as described by 
Ridgeway e/fl/. (1996).
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A nucleotide change was introduced into the vector which resulted in an amino acid substitution 
of T-^Y (knob) at position 366 in the mFc region of the pEE12.2 vector designed to contain the 
(3 integrin subunit and a T—>Y substitution (hole) at position 407 in the mFc region of the pV16 
vector designed to contain the a  integrin subunit. The ‘knob’ mutation in the mFc tail of the |3 
subunit would help prevent homodimerisation by causing a misalignment of the two CH3 
domains whilst the ‘neat fit’ between the ‘knob’ and ‘hole’ would encourage heterodimer 
formation.
'hole' EcoRI (2 ) 
mFc \  /  SV40 PolyA
Safl (7 6 4 0 ) \  N o n  (2 5 4 )
H in d lll  (76227 B a m  HI (701)
EcoRl (2)
hCMV
M lu l  (5 5 5 0 )
intron + PolyA
pEEll.mFcvector
8 4 7 0  bp
P vu  I (2 2 9 0 )  
Ampr
K pn  /(4 3 0 9 )
A v r  II (3 4 0 7 )  
SV40L
GScDNA
'knob' polyA
mFc N oû  (254)
50/1(5589)
H indlll (5569)
Bam HI (705)
pV16mFc
6419 bp
hCMV
Ampr
P v u l(2294)
M M  (3487) A urll (3093)
Figure 3.3 Vector maps of pV16mFc and pEE12.2mFc. pV16mFc contains the murine yl Fc 
cDNA, an ampicillin resistance marker for selection in a bacterial host (Am p7, and a 
transeription unit for the expression o f foreign genes. The transcription unit consists o f 
a human cytomegalovirus (hCMV) major immediate early promoter, a polylinker {Hind 
IIl-EcoR 1) into which the sequence for the mFc region was later inserted, and the SV40 
polyadenylation signals. pEE12.2mFe eontains the murine yl Fc cDNA, an ampicillin 
resistance marker for selection in a bacterial host (Amp"^), an SV40 origin for replication 
in eukaryotic cells, an SV40 late promoter (SV40L) to drive the GS cDNA, the GS 
cDNA for selection and amplification in mammalian cells and a transcription unit for 
the expression o f foreign genes. The transcription unit consists o f  an hCM V major 
intermediate early promoter, a polylinker {Hind lII-EcoR 1) into which the sequenee for 
the mFc has been inserted and the S V40 polyadenylation signals.
80
Chapter 3
3.3.1. Cloning and Assembly of the Extracellular Domain of |32 into an Expression 
Plasmid
In order help with describing the manipulations of the CD 18 cDNA its sequence and oligos used 
to generate the various constructs are shown in Appendix 1. Full length CD 18 (2100bps) had 
previously been cloned into the pEE6hCMV neo vector by S.Ortlepp (1997) as a Hind lll-Bcl 1 
fragment. In order to generate a soluble form of this integrin subunit, the 5’ region of CD 18 was 
excised as a Hind \l\-Sfu 1 fragment (1900bps). The remainder of the extracellular portion of the 
CD18 sequence was generated by PCR using primers B3611, which incorporated a Sal 1 site at 
the 3’ end of CD 18 directly after the end of the extracellular domain sequence, and B3610 which 
covered the region incorporating the Sfu 1 site. The junction of the extracellular domain and 
transmembrane domain was predicted based on hydrophobicity plots using Mac Vector (See 
Figure 3.4). Following digestion with the appropriate restriction enzymes, the Hind lll-Sfu 1 
(1900bps) and Sfu 1- Sal 1 (200bps) fragments were subcloned into the Hind 111 - Sal 1 backbone 
region of the pV16 vector (Figure 3.6) to generate the V16p2soimFc vector. A PCR screen using 
primers B3610 and V9011 (reverse primer to the mCHl region with in the vector backbone) 
verified the ligation of all three fragments. Further DNA sequencing of both strands in this 
region revealed that the sequence was the same as that published by Amaout et al. (1988) and 
S.Ortlepp (1997).
T ransmembi ane
CD 18 Extracellular Domain Domain
DESRECVAGPNIAAIVGCTVAG-^
ytoplasmic
Insertion of Sal I  site
Figure 3.4 Predicted GDIS extracellular -  Transmembrane Interface.
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3.3.2. Cloning and Assembly of the Extracellular Domain of C D lla  into an 
Expression Plasmid
In order help with describing the manipulations of the CDl la gene its sequence and oligos used 
to generate the various constructs are shown in Appendix 2. Full length CDl la (3600bps) had 
also previously been cloned into the pEE12.2 vector (pEE12.2CDllaFL) in this laboratory as a 
Hind Hl-Bcl I fragment. In order to generate a soluble form of the subunit, the 5’ region of 
C D lla was excised as a Hind Wl-BamE. 1 fragment (2870bps). The remainder of the 
extracellular portion of the sequence was generated by PCR using primers B3609, which 
incorporated a Sal 1 site at the 3’ end of C D lla directly after the end of the extracellular domain 
sequence, and B3606 which covered the region encoding the BamB. 1 site. The junction of the 
extracellular domain and transmembrane domain was predicted based on hydrophobicity plots 
using Mac Vector (See Figure 3.5). Following digestion with the appropriate restriction 
enzymes the Hind Wl-BamB 1 (2870bps) and BamB 1- Sal 1 (400bps) fragments were subcloned 
into the Hind 111 - Sal 1 backbone region of the pEE12.2 vector to generate the new vector 
(pEE12.2aLsoimFc) (Figure 3.7). A PCR screen using primers B3606 and V9011 verified the 
ligation of all three fragments. Further DNA sequencing (Primers listed in Chapter 2 Section 
1.1.7) of both strands in this region revealed that the sequence was the same as that published by 
Larson et al. (1989).
Transmembranc Cytoplasmic
C D lla Extracellular Domain Domain Domain
" ' W M KVDVVYEKOM  LYLYVLSGl
Insertion of Sal I  site
Figure 4.5 Predicted C D lla  Extracellular -  Transmembrane Interface
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3.3.3. Leader Sequence Substitution
Because of low expression levels of soluble LFA-1 after coexpression of the P2 and aL vectors 
in CHO cells the original leader sequences were substituted with murine antibody light chain 
(aL) and heavy chain ((32) leader sequences, which had previously been shown in this laboratory 
to greatly increase integrin expression levels in CHO cells.
1.3.3.1 pEE12.2ocLsoimFc Vector with Ab Leader Sequence
A PCR fragment that incorporated the S'Hind III site at the start of the aL construct and the 
murine K chain leader sequence of the antibody B72.3 (King et al, 1992) was generated by 
using a 90mer primer (B6114) and a 3’ oligo (B6109) which incorporated a Nar I site 
approximately 530bps distal to the Hind III site (See Appendix 2). The original leader sequence 
from pBE12.2aLsolmFc was excised using Hind III and Nar I restriction enzymes and the 
remaining backbone as Nar \-Not I and Not \-Hind III fragments were re-ligated with the Hind 
\\\-Nar I Ab leader PCR fragment to generate the pEE12.2aLabisoimFc vector with the Ab leader 
sequence (See Figure 3.7).
CD lla Primer 1
Sequence:
B6114 (Primer to introduce 5* Antibody Leader Sequence)
Kozak Sequence
’^g g c c a a g c t t c c g c c a c c a t g g c t t g g g t g t g g a a c
H ind  III Antibody Leader Sequence
TTGCTATTCCTGATGGCAGCTGCCCAAAGTGCCCAA
GCATACAACCTGGACGTG
CDlla Sequence ^
CD lla Primer 2:
Sequence:
B6109 (560 <-)
CAGGTCTACGTTGCCCTTGATAC
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Bell (3)
Poly A
Bam HI (241)
SV40 E Promoter
3KI168261
rl (6761)
pEEohCMVneoCDloFL
8297 bp
16099) 
I (5924)
BcoRI (2)
Bell (10) 
polyA
NoO. (254)
A vril (570)
Bglll (593)
Narl (755)
Neomycin
Sail (1760)
Notl (2335;
Ampr
Paul (3000)
50/1(7684)
5^(1 (7483)
CD18
Bco RI (6474)
ATarl (6409)
Ba?u HI (5747)
abl sequence
H m dlll (5569)
hCMV
pV16CD18mFc
8514 bp
Bglll (3786) 
Mlul (3852)
hCMV
Bam HI (705)
Narl (738)
Narl (759)
Narl (872) 
S fu l (990) 
Syiil(i020) 
5^1/1(1050)
Ampr
Paul (2294;
A arll (3093) 
Mlul (3 4 8 7 )
Notl (3578)
\
Figure 3.6 Plasmid Maps of pEE6hCMVneoCD18FL and pV16CD18mEc
EEôhCMV neo contains an ampicillin resistance marker for selection in a bacterial host 
(Amp"^), a gene encoding neomycin resistance (neo) for selection in mammalian cells 
and a transcription cassette for foreign gene expression. The transcription unit consists 
o f a human cytomegalovirus (hCMV) major immediate early promoter, a polylinker 
(Hind Ul-Bcl I) into whieh the sequenee for the CD 18 full-length gene has been 
inserted, and the SV40 spliee and polyadenylation signals.
The pV lbC D lSm Fe vector backbone is as described above in Figure 3.3 with the cDNA 
o f  the extraeellular region o f CD 18 inserted as Hind Wl-Sfu 1 and Sfu l-Sal I fragments. 
The antibody leader sequence (abl) was ineorporated into the vector as a Hind \U-BamH  
1 PCR fragment at the 5 ’ end o f CDl 8 to generate the pV lbC D l 8ablmFc vector.
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E co  R I (2) 
B el I (10) 
/  PolyA
\a m H l  (10483)
N o t l  (254)
B a m  HI (701)
N a r  I (734) 
N a r  I (755) 
iV ar 1 (868 )
CD11
(9 3 4 6 )
(9015) pEE12.2CDllaFL
11702
(8 6 0 5 )
(8045)
d l l l  (7622)
NoÜ (11715) 
B ell (11471) 
£coRI (11463)
mFc
Bam  HI (452)
/  IVdrl (485)
S a li  (10631) 
Bam HI (10234)
P vu  1 (2 2 9 0 )
Ampr
hCMV
,BcoRI (9097)
CD11a
S a li  (8766) 
A v r  II (3407) B g lïl  (8356) 
B glll (8330)
G ScD N A
K pn 1 (4 3 0 9 ) 
B g l  II (4637) 
intron + PolyA
Mlu I (5550)
N arl (7796)
abl sequence
HmdlII (7373)
_  N arl (506)
iVarl (619)
pEE12.2aLmFc
11722 bp
P v u l (2041
Ampr
hCNIV
Am’II (3 
GScDNA
K p n l (4060) 
B g lll  (4 3 8 8 )
intron + PolyA
M lul (5301)
Figure 3.7 Vector Maps of pEE12.2CDllaFL and pEE12.2aLmFc. The pEE12.2 C D llaF L  
vector contains the C D l la  gene ligated into the pEE12.2 backbone as a Hind  III -  Bel I 
fragment. For expression o f the soluble aL  extracellular fragment fused with a mFc tail, 
the 5 ’ end o f the this region was excised as Hind 111 -  BamW I fragment and the 3 ’ end 
incorporating a Sal I site was generated by PCR. These two fragments were then ligated 
into an empty pEE12.2mFc vector cut with Hind 111 and Sal I.
The antibody leader sequence (abl) was incorporated into the vector as a Hind Ill-Aot I 
PCR fragment at the 5 ’ end o f  CDl la  sequence to generate the pEE12.2aLablm Fe 
vector.
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1.3.3.2 pV16p2soimFc Vector with Ab Leader Sequence
A PCR fragment that incorporated the S'Hind III site at the start of the P2 construct and a heavy 
chain antibody leader sequence also from the antibody B72.3 was generated by using a 108bp 
primer (B6113) and a 3’ oligo (B6110) which incorporated a BamH I site -200bps distal to the 
Hind ///s ite  (See Appendix 1). The original leader sequence from pV16p2soimFc vector was 
excised using Hind III and BamH I restriction enzymes and the remaining backbone as BamH I-  
Sal I and Sal l-Hind III fragments were religated with the Hind \\\-BamH I Ab leader PCR 
fragment to generate the pV16p2soimFc vector with the Ab leader sequence (See Figure 3.6).
CDl8 Primer 1 B6113 (Primer to introduce Antibody Leader Sequence)
Kozak Sequence
Sequence:  ^GGCCAAGCTTCCGCCACCATGGGCATCAAGATGGAG
HindlW  Antibody Leader Sequence
TCACAGACCCAGGTCTTTGTATACATGTTGCTGTGGT
TGTCTGGTGTTGATGGACAGGAGTGCACGAAGTTC
GDI 8 sequence—*
CDIS Primer 2 B6110 (320^)
Sequence: ^GTCTTCCTGGGTTTCAGCGAG
3.3.4. Incorporation of IDAS Substitutions into the pEE12.2aLsoi Vector System
The various amino acid substitutions were incorporated into the pE E12.2aLsoiabiniFc vector by 
site directed mutagenesis using the Stratagene’s QuikChange® Mutagenesis Kit. Figure 3.8 
illustrates the steps involved in the procedure. The method involves designing two primers both 
containing the desired mutational change which are complementary to opposite strands of the 
region of interest within the vector. See below for the list of primers used to incorporate the 
selected IDAS mutations into the p E E 12.2aLsoiabimFc vector. During temperature cycling, 
PfuTurbo DNA polymerase extended these primers to generate a mutated plasmid containing 
staggered nicks. Following temperature cycling, the product was treated with Dpn /. The Dpn I
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restriction enzyme (target 5’ Gm6ATC-3’) is specific for methylated and hemi-methylated DNA 
and is used to digest the parental DNA template to select for mutation-containing PCR 
synthesised DNA. The vector DNA containing the desired mutations was then transformed into 
competent cells in which the nicks were repaired. Plasmid DNA was prepared from the 
transformants and analysed by DNA sequencing (Chapter 2 Section 2.1.9 for list of primers 
used) to select clones containing the desired mutation within the aL region. This plasmid was 
then digested with Hind III and BamH I restriction enzymes to excise the region containing the 
mutation and religated into an original Hind IW-BamH I backbone vector preparation {BamH I- 
Eco RI and Eco Rl-Hind III fragments) which had not been subjected to the mutagenesis 
procedure to ensure that random mutations that may have been introduced elsewhere in the 
vector during the PCR reaction were not carried through. Plasmid preparations of the final 
construct were also sequenced to confirm the presence of the desired mutation.
I-DOMAIN cloning Oligos
I  Domain Primer 1:
Sequence:
I  Domain Primer 2:
Sequence:
I  Domain Primer 3:
Sequence:
I  Domain Primer 4:
Sequence:
I  Domain Primer 5:
Sequence:
I  Domain Primer 6:
Sequence:
I235A-^
^'ACCAAAGTGCTTGCTATCATCACGGATGGG
Ala
I235A
^'CCCATCCGTGATGATAGCAAGCACTTTGGT
Ala
L287F-
5’GCGAGCGAGTTTGTGTTTATTCTGGACACA
Phe
L287F<-
^'TGTGTCCAGAATAAACACAAACTCGCTCGC
Phe
L287C-^
^'GCGAGCGAGTTTGTGTTTATTCTGGACACA
Cys
L 287C ^
^'TGTGTCCAGAATACACACAAACTCGCTCGC
Cys
I  Domain Primer 7:
Sequence:
F292A-^
^'ATTCTGGACACAGCCGAGAAGCTGAAA
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Ala
I  Domain Primer 8: F292A<^
.yegrMg/zcg; ^TTTCAGCTTCTCGGCTGTGTCCAGAAT
Ala
I  Domain Primer 9: K294C
\.CATTTGAG
Cys
^GACA TGTCTGAAAGATCTATTC
I  Domain Primer 10: K294C
TAGATCTTTCAG,
Cys
^'GAA ACACTCAAATGTGTC
I  Dont ain Prim er 11: L295A-^
^'ACATTTGAGAAGGCCAAAGATCTATTC
Ala
I  Domain Primer 12: L295A <—
^GAATAGATCTTTGGCCTTCTCAAATGT
Ala
1 Domain Primer 13: F299A-^
5'egweMcg; ^'CTGAAAGATCTAGCCACTGAGCTGCAG
Ala
1 Domain Primer 14: F299A -e—
j'ggwgMce; ^'CTGCAGCTCAGTGGCTAGATCTTTCAG
Ala
I  Domain Primer 15: 1306A
CAGAAGAAG
Ala
^'CTG GCCTATGTCATTGAG
1 Domain Primer 16: 1306A <—
^'CTCAATGACATAGGCCTTCTTCTGCAG
Ala
1 Domain Primer 17: L295A/I306A—^
^ACATTTGAGAAGGCCAAAGATCTATTCACTGAGCTG
Ala
CAGAAGAAGGCCTATGTCATTGAG
Ala
1 Domain Primer 18: L295A/I306A-(—
.yegwewce; ^'CTCAATGACATAGGCCTTCTTCTGCAGCTCAGTGAA
Ala
TAGATCTTTGGCCTTCTCAAATGT
Ala
1 Domain Primer 19: L287A/K294A-^
^GAGTTTGTGGCTATTCTGGACACATTTGAGGCTCTG
Ala Ala
AAAGAT
I  Domain Primer 20: L287A/K294A *—
/yggrwgTzce; ^ATCTTTCAGAGCCTCAAATGTGTCCAGAATAGCCAC
Ala Ala
AAACTC
lia pier
I  Domain Primer 21: L287C/K294C-^
S'ggweMce; ^GAGTTTGTGTGTATTCTGGACACATTTGAGTGTCTGA
Cys Cys
AAGAT
/  Domain Primer 22: L287C/K294C <—
^ATCTTTCAGACACTCAAATGTGTCCAGAATACACAC
Cys Cys
AAACTC
1 Dom ain Prim er 23: L289A/K294A
AATTÇ ___
Ala Ala
5'TTTGTGAA TTGCGGACACATTTGAGGCGCTGAAA
GATCTA
1 Domain Primer 24: L289A/K294A
^'TAGATCTTTCAGCGCCTCAAATGTGTCCGCAATTTTC
Ala Ala
ACAAA
IDomain Primer 25: L289C/K294C-*
^TTTGTGAAAATTTGTGACACATTTGAGTGTCTGAAAG
Cys Cys
ATCTA
1 Domain Primer 26: L289C/K294C *—
^TAGATCTTTCAGACACTCAAATGTGTCACAAATT
Cys Cys
TTCACAAA
3.3.5. Génération of (xLp2 Double Gene Vectors
The use of DGVs (double gene vectors) containing both integrin subunits had previously been 
shown to increase expression by up to 3-fold over co-transfection of SGVs (personal 
communication, P.E. Stephens). A single Not I site that had previously been engineered into the 
pEE12.2 vector allowed for linearisation of this vector and two Not I sites engineered into the 
pV16 vector just before the hCMV region and after the polylinker sequence respectively allowed 
the entire transcription unit of the P2 gene to be excised as one fragment. Following
linearisation and phosphatase treatment of the p E E 1 2 .2 a L a b is o im F c  vector and excision of the
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SOOObp Not \-Not I pVlbpiabisoimFc fragment, both Not I fragments were ligated. Figure 3.9 
illustrates the procedure. Following plasmid preparation, diagnostic digestion with a panel of 
restriction enzymes were carried out to determine that both the aL and P2 genes were present 
and in the correct orientation.
Step I
Plasmid preparation
Step 2
Temperature Cycling
Step 3
Digestion
Gene in plasmid with the target site for mutation 0 )
During this step dénaturation of the plasmid ) 
and the annealing of the primers containing the 
desired mutations take place
The PfuTurbo DNA polymerase extends and 
incorporates the mutatgenic primers resulting 
in nicked circular strands (— >  )
In this step the methylated, non-mutated parental 
DNA template is digested with Dpn I
After transformation, the XLl-Blue supereompetent 
cells repair the nicks in the mutated plasmid
Figure 3.8 Overview of the QuikChange® site-directed mutagenesis method.
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B a m  H I  (2176) 
H in  d i l l  (1998)
:d i 8 
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Eco RI (4944)
S a l  I (4113)
N o t  I (5194)
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Ai t  II (3158) ^
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S a il  (16071) 
CD18
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H in d lll  (1 3956) '
E co  RI (2) 
polyA
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m Fc
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G ScD N A
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B g l  II (4 6 3 7 )  
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/  / 
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Figure 3.9 Generation of the DGV containing the CDl 8  and CDl la  extracellular domain gene 
regions fused with mFc tails. Digestion o f the pEE12.2aLablm Fc vector with Not I  
results in linearisation o f the molecule while the Not I  fragment o f  the pV16P2ablmFc 
vector contains only the hCMV and the CD 18 gene transcription unit. The DGV also 
contains the GS gene system for selection in mammalian cell systems and the Amp*  ^
gene for selection in bacterial systems.
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3.4 aL And p2 Vectors For K562 Transfection And Expression
In order to express LFA-1 on the K562 cell surface, both the aL and (32 full-length genes were 
required to be transfected into the cell line. Previous work within this laboratory had shown that 
transfection using a DGV was more efficient than transfection of both integrin chains as SGVs 
(single gene vectors). The full length CD 18 gene was already available in the EE6hCMVneo 
vector system (Figure 3.2), which contained the neomycin resistance gene allowing for positive 
selection using G418 selection. This vector also contained a unique Not I site enabling 
linearisation of the vector for DGV generation. The V I6 vector which contained two Not 1 sites 
was therefore used as the carrier vector for the aL  full-length gene.
To incorporate the various IDAS mutations into the full-length version of the aL gene. Hind III- 
Sal I fragments of the 5’ end of the aL gene containing the mutated regions were excised from 
the pEE12.2aLabisoimFc vectors. These fragments were ligated with a Sal l-Bcl I fragment 
containing the remaining 3’ end of the aL gene which had been excised from the original 
pEE 12 .2 C D 11 aFL(see Figure 3.7), and an empty pV16 vector cut with Hind III and Bel I to 
generate a series of pV16aLmutFL vectors (Figure 3.10). Prior to generation of fragments which
required cutting with the Bel I restriction enzyme, the plasmids were grown in the GM242 dam
E.coli strain. Following identification of correctly incorporated sequences by DNA sequencing, 
vectors were transiently co-transfected with pEE6«eo|32FL into CHO cells and expression was 
detected by FACs analysis using aL and (32 mAbs. Full-length aL(32 DGV generation was as 
described for the DGV containing the soluble constructs as both the pVlbaLmutFL vectors and 
pEE6neoP2FL contain the Not 1 restriction sites in similar positions (See Figure 3.11).
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H ind m - B c l  I 
bacJvbonc fragment 
from \ I 6 a l.„
A m pr
hCMV
Figure 3.10 Cloning Strategy to Generate a Vector containing a Full Length version of aL with 
mutations. The aL  full-length gene containing mutations within the I domain was 
inserted into the Hind III-5c/1 backbone fragment o f pV 16aLFL using a 3-way ligation 
with an aL  5 ’ Hind lll-Sal I fragment from the pEE12.2aLablmFc vector and a 3 ’ Sal I 
- Bel 1 fragment from the pEE12.2CDl la  FL vector.
B a m H I (14106) 
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hCMV
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Figure 3.11 Vector map of DGV used for K562 stable transfection. The DGV was generated by 
linearising the pEE6hCMV«eo vector with Not I and inserting a Not I-Not I fragment o f 
the pV16aLmutFLvector containing only the hCMV to drive the CDl la  transcription 
unit. The DGV also contains the neomycin gene for selection in mammalian cell 
systems with G418 and the Amp"  ^gene for selection in bacterial systems.
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3.5 aL Vectors For JB2.7 Transfection And Expression
Characterisation of the JB2.7 cell line, which is deficient in aL, by Weber et al. (1997) showed 
that the P2 subunit was synthesised and detectable by immunoprécipitation. The (32 subunit 
however was not expressed on the cell surface but transfection of the cell line with aL cDNA 
restored surface expression of LFA-1. Therefore, only single gene vectors containing the 
various full-length aL cDNAs were required to restore functional LFA-1 cell surface expression 
on JB2.7 cells. As the pVlbaLmutPL SGVs generated for the K562 expression system did not 
contain a selection marker for positive clonal selection, the aLmutPL genes were excised from the 
pVlbaLniutPL SGVs as Hind III-.Bc/1 fragments and ligated into an empty pEE6«co vector cut 
with Hind III and Bel I restriction enzymes (Figure 3.12). Following plasmid preparation, 
diagnostic digestion with a panel of restriction enzymes to determine the presence of the aL 
gene and DNA sequencing of the I domain region was carried out to ensure the presence of all 
the mutated forms of aL.
3.6 Discussion
A panel of expression constructs were generated to give functional vectors capable of either 
expressing the full length LFA-1 gene or a soluble entity comprising of the extracellular CDl la 
and CD 18 domains fused to murine Fc domains. The inclusion of selection markers such as the 
neomycin resistance gene for selection in both K562 and JB2.7 cells allowed for an efficient 
method of identification of cells transfected with the LFA-1 genes. Use of the Stratagene’s 
QuikChange® Mutagenesis Kit enabled the generation of several mutant forms of LFA-1 and 
proved to be very efficient at incorporating the required mutations without introducing other 
undesirable mutations. These expression plasmids were then used to transfect mammalian cells 
to make stable LFA-1 expressing CHO, K562 or JB2.7 cell lines.
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Figure 3.12  Vector Map of pEE6 hCMVneoCDllaFL SGV used for JB 2 .7  stable transfection.
The transcription unit o f pEE6hCMV n e o  consists o f a human cytomegalovirus (hCM V) 
m ajor immediate early promoter, a polylinker {Hind Ill-Bcl I) in to which the sequence 
for the CD 11 a full length gene has been inserted as a Hind \W-Bcl 1 in 2-way ligation, 
and the SV40 splice and polyadenylation signals. The SGV also contains the neomycin 
resistance gene for selection in mammalian cell systems with G418 and the Amp"  ^gene 
for selection in bacterial systems from the pEE6 vector.
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Chapter 4 Soluble integrin expression and analysis
4.1 Introduction
Studies using both isolated I domain constructs and cell surface expressed I domain-less LFA-1 
have shown that the ligand binding site of LFA-1 appears to be solely contained within the I 
domain (Randi and Hogg, 1994; Leitinger et aL, 2000; Shimaoka et al., 2001, 2002). This 
finding is also supported by work from several other groups, which have shown that mutations 
within the I domain can dramatically affect the ability of the isolated I domain and LFA-1 
expressed on the cell surface to bind ligand. Much of the initial mutational analysis 
demonstrated the importance in ligand binding of the DXSXS motif within the MIDAS site, and 
residues surrounding it (Michishita et al., 1993; Edwards et al., 1995 & 1998; Kamata, 1995; 
Huang and Springer, 1995). This was recently confirmed following the elucidation of a crystal 
structure of the aL I domain in complex with the first two domains of ICAM-1 (Shimaoka et al, 
2002), which demonstrated that residues within the MIDAS of aL and the E34 residue in 
domain 1 of ICAM-1 form the main point of interaction. Evidence is now emerging that a 
second region within the I domain, known as the IDAS (I Domain Allosteric Site), also plays a 
major role in activation and ligand binding. Introduction of select mutations within this region 
of the I domain have been shown to either abrogate or enhance ligand binding and, in crystal 
structures of I domains complexed with ligand, a 10Â downward shift of the I domain a7 helix, 
which forms part of the IDAS, has been observed relative to the unliganded structure. 
Shimaoka’s group have reported the generation of a conformation containing such a 10Â 
downward shift of the a7 helix by introducing a restraining disulphide bond in the loop between 
the C-terminal a-helix and the preceding (3-strand of the aL IDAS. Such a mutation increases 
binding of the isolated aL I domain by 9000 fold relative to wild type I domain (Shimaoka et al, 
2001). As this site is distal to the MIDAS, its influence on ligand binding is suggested to be 
through allosteric changes rather than through direct contact with the ligand.
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Using isolated I domains to investigate the role of the IDAS in ligand binding, the influence that 
other extracellular domains, especially the ^-propeller, have on I domain mutations cannot be 
examined. In contrast, in studies using LFA-1 expressed on the cell surface, the influence that 
signalling molecules and the cytoskeleton have on integrin activation must also be taken into 
account. As part of this thesis, a soluble form of LFA-1 has been generated which allows one to 
investigate the role of the IDAS in regulating integrin/ligand interactions in the context of other 
LFA-1 domains but, importantly, also in a cell free system. The previous chapter, in part, has 
described the generation of this soluble integrin construct, which contains the extracellular 
domains of the a  and P chains of LFA-1 fused with mouse Ig-Fc domains. This chapter will 
focus on the expression and characterisation of the LFA-1- mFc construct in relation to ligand 
binding and cation requirements. In order to investigate further the role of the I domain in ligand 
binding and its influence on other features of the full length integrin, various mutations within 
the IDAS domain, some novel and some previously described by other researchers, have also 
been included in the study (described in Section 3.1).
4.2 Expression of soluble LFA-1 mFc
Initial co-transfection of the single gene vectors described in Chapter 3 containing aL with and 
without I domain mutations and P2 extracellular domain cDNAs was carried out in a CHO 
transient system to check that the appropriate protein was produced. The plasmids containing 
the various mutated forms of aLmFc and the p2mFc were introduced into CHO cells using the 
GenePORTER^*^ system. GenePORTER^"^ is a formulation of the lipid dioeoyl 
phosphatidylethanolamine (DOPE) and a cationic lipid that associates with the negatively 
charged nucleic acids. The resulting positively-charged complex allows for interaction with the 
negatively charged cell membrane and, after endocytosis, the nucleic acids are released from 
endosomes and delivered to the nucleus.
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Two days after transfection, the culture supernatant was harvested and assayed for mFc 
expression by mIgG ELISA and heterodimer formation by sandwich ELISA. The sandwich 
ELISA involved capturing the soluble integrin with a mAh coated on the plate that recognised 
the aL subunit and revealing the captured integrin with a mAh that recognised the p2 portion of 
the integrin. Once it was established that aP heterodimer was detectable in the transient 
supernatant, work was undertaken to generate stable cell-lines in order to provide a constant 
supply of material. Although NSO stable transfection of the LFA-1 mFc constructs was 
unsuccessful, stably-transfected CHO cell lines generated nanograms per millilitre quantities of 
each the constructs and further large-scale production using this system generated sufficient 
quantities for this study. Each construct was re-sequenced directly before transfection using an 
altered version of the GenePORTER™ protocol (see Section 2.3.2) to ensure that it contained the 
correct mutation. Supernatants from the selected clones were concentrated 10-fold in an 
Amicon^ i^^  stirred cell system with a 10 kDa cut off membrane and concentrates were analysed 
by ELISA which measured the concentration of immunoglobulin Fc (See Section 2.4.1). 
Verification of the presence of heterodimer was carried out using sandwich ELIS As. Table 4.1 
shows the typical results obtained from an IgG assay before concentration. The introduction of 
select mutations within the IDAS appears to have an advantageous effect on the expression of 
the LFA-1 mFc construct relative to wild type. This could be due either to increased expression 
of the aL chain or to more efficient combining of the heterodimer.
To check the integrity of the integrin portion of the fusion proteins and to verify the formation of 
heterodimer, reduced and non-reduced Western blotting analysis of the samples was carried out 
using an anti-mFc-HRP detection system. Due to the low concentrations of protein in some of 
the samples, immunoprécipitation using Protein Sepharose A was first carried out. Figure 4.1 
shows a reduced and non-reduced blot of several of the constructs. Under non-reducing 
conditions the cysteine bond holding the two mFc regions together remains intact and therefore 
the heterodimer runs as a single high molecular weight species just above the 250kDa marker.
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In the presence of a reducing agent, the disulphide bond is reduced and the individual aL and (32 
subunits run at approximately 210kDa and 190kDa, respectively.
Construct Concentration (ng/ml)
WT 30 ng/ml
I235A 15 ng/ml
287C 20ng/ml
287F 20ng/ml
292A 200ng/ml
294C 50 ng/ml
295A 120 ng/ml
299A 50 ng/ml
306A 30 ng/ml
287C294C 30 ng/ml
287A294A 40 ng/ml
289C294C 200 ng/ml
295A306A 250 ng/ml
Table 4.1 Expression of LFA-lmFc fusion proteins in CHO Cells quantitated by Ig ELISA.
Typical results o f  IgG ELIS As to measure the concentration o f  LFA -lm Fc fusion 
protein in CHO cell supernatant. The concentration o f  the mouse IgG, standard (Ab 
Max68P, Celltech) used was from 0-200ng/ml. For each LFA -lm Fc sample the top 
concentration was neat cell supernatant followed by seven 1:2 dilutions (n=2). These 
results are representative o f  6 or more experiments.
Although the blotting data, which must be noted is only semiquantitative, shows that most of the 
constructs express the aL and (32 fusion proteins at similar levels, some of the mutants exhibited 
markedly reduced expression levels. Whilst alanine substitution at residues 295 and 306 show 
comparable expression to sLFA-lwrmFc, pairing these substitutions in one construct appears to 
dramatically affect aL subunit expression. In light of the reduced aL 29SA306A mFc expression it 
is not surprising that expression of aL292A295A306A mFc is also significantly reduced. 
Interestingly, in both of these samples, homodimers of the excess P2 subunit appear to form. A 
minor band at a similar position in samples containing other constructs suggests that some 
homodimerisation does occur regardless of the expression levels of both subunits. The blots also
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highlight that the level of expression of both the ^2 subunit, which is invariant in all constructs, 
and the various aL subunits appears to vary from construct to construct, with some of them 
containing a much higher proportion of P subunit over a  subunit. There are also significant 
quantities of free mFc (~25kDa on non-reduced gel; ~50kDa on reduced gel) as well as other 
inFc-containing breakdown products present in each of the samples. The presence of varying 
levels of heterodimer, homodimer and free Fc in samples suggests that using the mFc ELISA as 
a quantification method may not truly quantitate the concentration of functional heterodimer in 
each sample.
mFc
Reduced Gel Non - Reduced Gel
mF
2 3 4 5 6 7 8 9 10 11 12 Mol.
Weight
4-20% Tris/Glycine Gel M arkers
f ' # -  250
1 2 3 4 5 6 7 8 9 10 11 12 .  Mol
Weight
4- 12% Tris/Glycine Gel M arkers
sL FA -l235AmFc
294C
235A
sLFA-Lo.f^ mFc
1.
4.
7.
10. sLFA-1
SLFA-I306A mFc
287C294C mFc
2. sLFA-l287c mFc 
5. sLFA-1 
8 . sLFA-1
295A mFc
295A306A
ll.sL F A -1 289C294C
mFc
mFc
3. SLFA-I2 92 mFc 
6. sLFA-l299AmFc 
9. sLFA-1292A29SA306.A mFc
12. sLFA-lyyj mFc
Figure 4.1 Western blot of immunoprecipated sLFA-lmFc constructs in the presence and 
absence of reducing agent. 50ng/mFc (using IgG ELISA) o f each sample was used for 
each immunopercipitation using 50pl Protein A Sepharose beads in the presence o f 
4mM NaCl. After incubation overnight at 4°C beads were washed extensively and on 
addition o f sample buffer +/- reducing agent, samples were boiled and loaded onto gels. 
Following electrophoresis, gels were Western blotted on to nitrocellulose paper 
overnight at 150mAmps. After blocking and washing, nitrocellulose sheets were 
incubated with 1:5000 dilution anti-mFc-HRP polyclonal Ab for 1 hour. Following 
extensive washing blots were revealed with an ECL kit and developed as an 
autoradiograph.
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4.3 Assembly Assays
In light of the Western blotting results, a more accurate method of quantifying the heterodimeric 
content in the supernatants was required. A series of ELISAs, where the ap heterodimer was 
captured using an immobilized LFA-1-speeifie mAb and revealed with a different biotinylated- 
LFA-1 speeifie mAh, were therefore developed. Although efforts were made to select 
antibodies whose binding would not be affected by different I domain mutations it is generally 
accepted that integrins undergo considerable conformational change on aetivation. Therefore in 
order to minimise any effeets that this might have on antibody binding and subsequent 
quantitation, six different pairs of antibodies were used in two site ELISA assays (See Table 
4.2).
KIM185 has been mapped to the C-terminal half of the cysteine-rich domain at positions 522- 
612 in the stalk region of the p2 subunit (Huang et al, 2000). Although it is known to activate 
LFA-1, Huang et a l (2001) suggests that KIM185 binds in a similar manner to both the active 
and inactive form of the integrin and hence this faetor would not affeet its ability to capture or 
reveal the P-chain in this assay. Both DA36 and Ab38 map to the I domain and, although the 
exact epitopes have not been identified, their ability to completely block ligand binding by all of 
the LFA-lmFc mutants suggests that the epitopes recognized by these mAbs are not affeeted by 
the mutations. Huang et a l  (2000) have also mapped the 6.5E epitope to the I-like domain and 
shown that although it binds both LFA-1 wt and the loeked ‘open’ form of LFA-1 to the same 
extent, this mAh is unable to bloek ICAM-1 binding by locked ‘open’ LFA-1. This mAb is 
therefore a useful tool for detecting correctly folded heterodimer.
Figure 4.2 illustrates two representative titrations of the LFA-lmFc supernatants. In most cases 
the supernatants were titrated from neat and the dilution factor of supernatant for individual 
mutants that was required to give equal optieal density readouts was noted from eaeh 
experiment. The average dilution factor of each mutant supernatant compared to wild type from
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a series of 4 assembly assays was then calculated. Stoeks of these dilutions were then used for 
all subsequent assays and direct aliquots from each were termed as ‘neat’ for subsequent 
experiments. The variation from assay to assay in the dilution factor required for most of the 
supernatants was found to be relatively small with the exeeption of LFA-1287C294c- This result 
suggests that the introduetion of cysteine as opposed to alanine substitutions at positions K287C 
and K294C has a dramatic effect on the binding of the mAbs used in these assays. The locking 
of the IDAS in a ‘elosed’ position using the same K287C substitution, and a substitution at 
position L289C, does not appear to affect the way in which the various mAbs bind. Also, single 
cysteine substitutions at these positions do not show large variations in binding. Although 
Shimaoka et al. (2001) have show that locking the I domain in the ‘closed’ conformation does 
shift the position of the a7 helix, this shift is evidently not as dramatic as locking the protein in 
the ‘open’ form. Comparison of the results of the Western blotting experiments with the 
assembly assay results shown here suggests that the supernatants contain, in addition to free 
mFc, varying amounts of misfolded and/or homodimeric product.
Capture mAh Biotinylated Reveal mAb
KIM185 6.5E 6m
6.5E DA36 bio
Ab38 6.5E bio
6.5E KIM185 6m
DA36 KIM185 6m
KIM185 DA36 bio
T able 4.2 C om binations o f mAbs used in the  LFA-1 assem bly assay. This table lists the mAbs and 
their biotinylated partners that were used in a series o f assembly ELISAs designed to 
quantify the amount o f eorrectly folded heterodimer present in the LFA-1 mutant 
supernatants.
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6 .5 2 /  B iotin ylated  K IM 185 A s s e m b l y  A s s a y
Dilution
D A 3 6  I B iotin ylated  K IM 18 5  A s s e m b l y  A s s a y
2.00 -I
E
I
(A
<
0.75 -
0.50 -
0.25 -
0.00
1/32 1/16 1/8 1/4 1/2 Neat
2.0 -
E= 1.5
(A
§ . 0
0.5 -
0.0
1/32 1/16 1/8 1/4 1/2
Dilution
L299a ^2 ^ 0  
®L287c294c P2FC 
Lsoea p2^c
Ct L287c P2FC
(X LvvtP 2^ 0  
1-2953 P2 FC 
(-28902940 ^2^^ 
aLj;,53 PzFc
aL287phe pjFc
Ct L292a P2 FC
®L295a306a Pz^C
Figure 4 .2  Assembly Assay Titration curves for the various sLFA-1 mutants in two 
representative assays. Supernatants were titrated from neat with doubling dilutions 
onto plates coated with 5jug/ml 6.5E or DA36. Bound biotinylated KIM 185 was 
revealed with addition o f Streptavidin-HRP and the degree o f binding was assessed as 
absorbance at 630nm using TMB substrate. Each data point represents the mean o f  two 
values (error bars represent individual values). The data presented here are 
representative o f that obtained in at least three other independently performed 
experiments.
4.4 ICAM-1, -2 & -3 Ligand Binding
In order to determine the effect each o f  the mutations had on the function o f  LFA-1, a series o f  
assays were developed in which the binding o f various ICAM-hFc ligands to captured sLFA- 
ImFc was quantitated by detecting the hFc portion o f  the ligand molecule with an anti-hFc-HRP 
polyclonal Ab. The concentrations o f lCAM -1, -2, -3 used in the assays were determined by 
titrating the ligands from 30pg/ml in the presence o f  sLFA-LgsAmFc and selecting a 
concentration within the linear section o f the graph (Figure 4.3). A  construct (sLFA-l^gsAmFc) 
with high affinity for ligand compared to wild-type (as determined by preliminary ligand binding 
assays) was chosen to determine the concentrations o f  ligands to be used in the binding studies 
so that at no point would saturation o f  ligand in the case o f  some o f  the active constructs become 
an issue.
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Figure 4.3 Titration of ICAM-1 hFc, ICAM-2hFc and ICAM-3hFc. Titrations o f  ICAM-1 hFc, 
ICAM-2hFc and ICAM-3hFc using tripling dilutions from 30)Lig/ml (start concentration) 
were ineubated with mFc-eaptured sLFA-lzg^AmFe for 3hrs. Bound ligand was revealed 
with an anti-hFc-HRP Ab. Each data point represents mean -F/-SD (n=3) and these 
graphs are representative o f 2 or more independently conducted assays.
Figure 4.4 shows the binding curves o f the sLFA-lm Fc constructs to ICAM-1 hFc, ICAM-2hFc 
and ICAM-3hFc. Where ligand binding was demonstrated, this appeared to be dose-dependent. 
Moreover, the presence o f cation was required for binding as addition o f  EDTA com pletely  
abolished binding. It must however be noted that sigmoidal curves were not achieved in most 
cases and hence only limited analysis o f  the data could be carried out. The data does however 
highlight the increase in ligand affinity o f  several o f the mutants compared to wild type. The 
introduction o f  the double cysteine substitution at residues K287 and K294 and single alanine 
substitutions at positions F295 and 1235 showed the greatest increase in ligand binding over wild  
type. The binding o f  sLFA-lm Fc, containing either the single substitution o f  K294C or the 
novel alanine substitution at position 292, to ICAM-1 was also increased relative to wild type. 
The pairing o f  the K294C substitution with L289C, which is equivalent to the double mutation 
introduced by Shimaoka et a l  (2001) to generate the ‘closed’ conformation o f  the I domain, 
showed similar levels o f  ICAM-1 binding to sLFA-lmFcwi-
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Figure 4.4 Binding of sLFA-lmFc constructs to ICAM-1, -2, 3hFc. mFc samples were captured 
on anti mFc-coated plates and bound ligand was revealed by anti-hFc-HRP Ab binding. 
All assays were carried out in TBS in the presence o f ImM Mn^^. ICAM-1 hFc, ICAM- 
2hFc, lCAM-3hFc was used at 200ng/ml, 500ng/ml and 500ng/ml, respectively. The 
initial concentration o f each construct used as the starting point for each titration was 
determined from the assembly assay as in Figure 4.3. Each data point represents the 
mean o f two values (error bars represent individual values). Data presented here are 
representative o f that obtained in at least six other independently perform ed 
experiments.
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The substitution of alanine residues rather than cysteine residues at positions K287 and K294 
resulted in only a slight increase in ligand binding over wild-type and was comparable to that 
seen for the 1306A substitution. This result suggests that the chemical nature of the substitution 
and possibly the formation of a disulphide bond has an effect on the activation state of the 
integrin. The introduction of an alanine substitution at residue F299, and a double substitution at 
positions L295 and 1306 within the IDAS completely destroyed the ability of the integrin to bind 
ligand. Interestingly, the sLFA-l299AmFc construct was one of the more highly expressed 
constructs and appeared to heterodimerize efficiently, despite having lost ligand-binding 
capability.
However, the most dramatic effects on ligand binding affinity were seen with ICAM-2hFc and 
ICAM-3hFc. Whereas sLFA-lmFcwr bond both ligands only at very low levels in the presence 
of ImM Mn^ ,^ five of the constructs (those containing mutations at positions 287C294C, 295A, 
292A, 294C and 235A) demonstrated relatively high levels of binding to ICAM-2 and -3 with 
sLFA-lmFc287C294c again appearing to show the greatest increase over wild-type. In agreement 
with results obtained with ICAM-1, both sLFA-1295A306AmFc and sLFA-l299AmFc showed no 
binding to ICAM-2 or ICAM-3, suggesting that the introduction of these mutations alters the 
ability of aLP2  to bind ligand in a fundamental way.
4.5 Activating mAbs
Huth et al. (2001) have previously shown that loss of ligand binding in cases where residues 
within the IDAS were mutated could be rescued in the presence of an activating mAb. As both 
KIM 127 and KIM 185 have been extensively shown to be activators of LFA-l/ICAM cell 
binding events (Andrew et aL, 1993, Porter and Hogg, 1997; May et aL, 2000; Lu et aL, 2001), 
it was of interest to determine if these mAbs were capable of enhancing the binding of mutant 
forms of sLFA-lmFc to ICAM ligands. MEM148, another activating mAb, which is thought to
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activate ligand binding through a different mechanism from KIM 127 and KIM 185 (Drbal, 
2001), was also used in the study. Data generated during the assembly assay development 
showed that all three mAbs, including MEM 148 which was not used in final assembly assays 
due to limited supplies, recognised all of the constructs and Figure 4.5 illustrates the percentage 
increase in binding in the presence of these mAbs over control. Although the baseline binding 
for each construct was different, in order to highlight the effects each of the activating mAbs had 
on the constructs, results are plotted as a percentage of increased binding relative to that 
demonstrated in the absence of activating mAbs for each individual construct.
sLFA-1\vtIîiFc binding to ICAM-1 hFc was enhanced by -40% in the presence of all 3 mAbs and 
all mAbs enhanced the percentage binding to ICAM-2 and ICAM-3 even further, with MEM 148 
increasing this binding by -100% and -300% with ICAM-2hFc and ICAM-3hFc, respectively. 
Enhanced binding was also seen for sEFA-DstaHiFc, sLFA-lsoeAmFc, sLFA-1289C294cmFc and 
sLFA-1287A294AmFc, all of which gave similar titration curves to sLFA-lwrmFc with cation. This 
enhanced binding did not, however, reach the level of binding seen for constructs such as sLFA- 
l 287C294cmFc, aud sLFA-l295AinFc in the presence of cation alone.
Interestingly, most constructs that showed increased binding over sLFA-lwrHiFc in the presence 
of cation alone (see Figure 4.5) could not be further activated to any appreciable degree on 
addition of the mAbs. The exception to this was sLFA-l235AmFc, which showed increased 
binding to all 3 ligands in the presence of the activating mAbs, although KIM 185 was unable to 
further activate LFA-1235AmFc binding to ICAM-3. In this case the binding of LFA-l235AinFc 
reached similar levels to that seen for sLFA-l287C294cmFc in the presence of cation alone. The 
addition of activating mAbs was unable to restore ligand binding to sLFA-l299AmFc, once again 
indicating the requirement for a phenylalanine at this position to support ligand binding. The 
lack of binding with sLFA-l295A306AinFc also suggests that substitution at both these residues has 
a major negative effect on ligand binding.
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Figure 4.5 Binding of ICAM-1 hPc, lCAM-2hFc and ICAM-3hFc to sLFA-1 constructs in the 
presence of activating mAbs. Captured sLFA-lm Fc constructs were incubated for 3hrs 
with 200ng/ml ICAM-1 hFc, 500ng/ml ICAM-2hFe ng/ml or 500ng/ml ICAM -3hFc +/- 
activating mAbs K1M127, K1M185, MEM 148 or M 0PC21 control, all at 20p.g/ml.
Assays were performed in the presence o f ImM Mn . Bound ICAM-hFc was revealed 
with an anti-hFc-HRP Ah. % binding for each construct was calculated relative to the 
readout in the absence o f activating mAbs. Each data point represents mean +ASD 
(n=4). These graphs are representative o f 2 or more independently conducted assays.
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4.6 Blocking of Ligand Binding with mAbs and Lovastatin
To confirm that the enhanced binding demonstrated by some of the mutants was LFA-1- 
dependent, the effects of known LFA-1/ ICAM blocking mAbs and low molecular weight 
antagonists was investigated. Figure 4.6 (A-E) shows the binding profile of some of the 
constructs in the presence of DA36 (aL mAh), 6.5E (P2 mAh) and Lovastatin (a fungal 
metabolite previously shown to inhibit ICAM-1 binding to cell associated and soluble-expressed 
LFA-1 (Kallen et aL, 1999)). DA36 blocks the binding of all of the sLFA-lmFc constructs to all 
three ICAM ligands. Whether this inhibition is through direct binding around the MIDAS site or 
through allosteric influences is unknown. 6.5E mAb also completely blocks most sLFA-lmFc 
construct / ligand interactions with the exception of the interaction of sLFA-1295aHiFc with 
ICAM-1 and sLFA-l287C294cmFc with all three ligands. The possible reasons for this reduced 
inhibition will be discussed in Section 4.9. Lovastatin has previously been shown to bind in the 
IDAS cleft (Kallen et aL, 1999) and has been demonstrated by Shimaoka et al. (2001) to bind to 
the ‘closed’ form of the I domain. Although Lovastatin had a slight inhibitory effect on sLFA- 
1292aHiFc, and reduced binding of sLFA-lwrmFc to ICAM-1 by -80%, no blocking of ICAM-1 
binding to the sLFA-lmFc constructs containing substitutions at positions 295A, 287C294C or 
294C was observed. Inhibition of sLFA-l292AinFc, sLFA-l295AinFc and sLFA-l294cmFc binding 
to ICAM-2 and ICAM-3 with Lovastatin was greater than that seen with ICAM-1.
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Figure 4. 6 Binding of ICAM-1 hFc, ICAM-2hFc and ICAM-3hFc to sLFA-lmFc constructs in 
the presence of blocking agents. Captured sLFA-lm Fc constructs were incubated for 
3hrs with 200ng/ml ICAM-1 hFc, 500ng/ml lCAM-2hFe, 500ng/ml lCAM -3hFc with or 
without the following; mAbs M 0PC21 (control) DA36 or 6.5E at 20pg/ml or 50pM 
Lovastatin. Bound ICAM-hFc was revealed with an anti-hFc-HRP Ah. Each data point 
represents mean +/-SD (n=3) and these graphs are representative o f  2 or more 
independently conducted assays.
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4.7 6.5E Blocking in the Presence of Activating Abs
Because of the reduced capacity of mAh 6.5E to inhibit the ICAM binding of some of the 
mutated soluble constructs, it was of interest to see if, when further activated by activating 
mAbs, sLFA-lwrmFc would behave in a similar manner. The data in Figure 4.7 shows that both 
KIM 127 and MEM 148 activation did slightly reduce the inhibitory effect of mAb 6.5E on the 
sLFA-lwrmFc /ICAM-1 hFc interaction but still not to the same extent as that observed by the 
introduction of the 287C294C mutation. Furthermore, when the same activating mAbs were 
added in the presence of 6.5E to other constructs, the ability of 6.5E to inhibit was also reduced 
to some extent even in circumstances where the activating mAh does not further enhance the 
binding of LFA-1 to the ICAM-1. This was most evident in the case of the sLFA-1287C294cmFc 
construct where, on addition of MEM 148, the blocking capacity of 6.5E was almost completely 
removed.
This result suggests that while sLFA-1287C294cmFc appears to achieve maximal binding without 
the aid of activating mAbs, binding of the mAh still occurs. Indeed this may act to further 
stabilize the active conformation and, in doing so, reduce the ability of 6.5E to block, 
presumably through an allosteric mechanism. The inability of 6.5E to block binding when 
MEM 148 is bound is unlikely to be due to steric hindrance as blocking occurs in all the other 
constructs. This will be discussed further in Section 4.9. In all cases, inhibition with the aL 
mAh DA36 was greater than 95%.
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Figure 4.7 6.5E and DA36 blocking of the sLFA-lmFc/ICAM-lhFc interaction in the presence
of activating mAbs. Captured sLFA-lm Fc constructs were incubated for 3hrs with 
200ng/ml ICAM-1 hFc +/- activating Abs, KIM 127, KIM 185 or MEM 148 and +/- 
blocking Abs, DA36 or 6.5E or M 0PC21 (control). All mAbs used at 20|ig/m l. Bound 
ICAM -1 hFc was revealed with an anti-hFc-HRP. Ab. % binding for each construct was 
calculated relative to the readout in the absence o f both activating and blocking mAbs. 
Each data point represents mean -F/-SD (n=3) and this graph is representative o f  2 or 
more independently conducted assays.
4.8 Cation Requirements
4.8.1. and Mn^^
Analysis of the increased affinity of some of the constructs for ICAM-1 hFc over wild-type seen 
in previous experiments suggests that the introduction of selected amino acid substitutions 
within the IDAS eonstitutively activates the integrin. This activation appeared to be maximal for 
sLFA-l287C294cmFc, sLFA-l294cmFc, sLFA-l295AmFc, since addition of activating Abs did not
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appear to further increase the amount of ligand bound. It was therefore of interest to determine if 
the concentration of cations required by the mutants to give maximal binding was similar to wild 
type. Although Mn^  ^is routinely used in this laboratory at ImM, the possibility that varying the 
Mn^  ^concentration could further increase binding affinity was investigated. Figure 4.8 shows 
Mn^  ^titration curves for five of the constructs compared to sLFA-lwrmFc.
Titrations over a wide range of cation concentrations were initially carried out (see Figure 4.8) to 
determine the optimal range for further experiments. In these initial titrations most of the 
constructs demonstrated an optimal binding at a concentration of approximately 0.5mM for Mn^  ^
and above these concentrations, no further increase in ligand binding was detected. 
Additionally, varying the Mn^  ^concentration had no effect on inducing binding of ICAM-1 hFc 
to sLFA-l299AmFc. Further titrations (Figure 4.9) over the optimal ranges indicated that the 
cation requirements for all the constructs were very similar. These results suggest that activation 
of the integrin by the introduction of mutations, or restraining the a l  helix in a downward 
position, has no effect on cation requirements when Mn^  ^was used.
Similar titration curves were carried out in the presence of Mg^  ^ (Figure 4.10 A&B). Initial 
titrations showed that maximal binding of all soluble LFA-1 mFc forms occurred around ImM 
Mg^ "^ . Further titrations over the optimal range also showed that, similar to Mn^  ^requirements, 
the requirement for Mg^ "^  was not affected by introduction of mutations into the IDAS.
4.8.2. Effect of on the binding of LFA-1 to ICAM-1
Ca^  ^has been shown in several studies to inhibit binding of LFA-1 to its ligands (Marlin and 
Springer, 1987; Dransfield et a l, 1992). In order to determine if Ca^  ^had a similar effect on 
sLFA-lmFc, a series of checkerboard experiments were conducted where Ca^ "^  and Mn^^ were 
titrated concomitantly. Results from these experiments (Figure 4.11) suggest that Ca^  ^ inhibits
114
Chapter 4
in a dose-dependent manner with almost complete blocking at lOmM. In all cases, as the Mn^  ^
concentration was increased, the amount of Ca^  ^required to inhibit binding also increased. This 
suggests that the two cations compete for binding sites on LFA-1 and these sites are not affected 
by the introduction of mutations within the IDAS.
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Figure 4.8 Wide Range Titrations of Mn^  ^ in the sLFA-lmFc/ICAM-lhFc Assay. These 
graphs represent the initial Mn^^ titrations carried out to determine the range over which 
any variation in cation concentration from construct to construct could be detected. 
Captured integrin was depleted o f divalent cation by washing (x2) in 20mM EDTA/TBS 
followed by 4 washes in TBS. 50pl o f 400ng/ml ICA M -lhFc in TB S/0.1% BSA, pH7.5 
was added to each well along with 50pl o f twice the required final concentration o f 
Mn^^ in TBS/0.1% BSA, pH7.5. The results are expressed in terms o f  percentage 
binding, with 100% binding defined as the maximal signal seen with optimal 
concentration o f Mn^^. Each data point represents Mean +!- SD (n=3) and data 
presented here are representative o f 1 more independently conducted experiment.
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Titrations of Mn '^ (^0- 0.5mM) in sLFA-1mFc/ICAM-1hFc Assay
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Figure 4.9 Titrations of Mn  ^ (0-0.5mM) in the sLFA-lmFc/lCAM-lhFc Assay. Captured 
integrin was depleted o f divalent eation by washing (x2) in 20mM EDTA/TBS followed 
by 4 washes in TBS. 50pl o f 400ng/ml ICA M -lhFc in TBS/0.1% BSA, pH7.5 was 
added to eaeh well along with 50pl o f twiee the required final concentration o f Mn^^ in 
TBS/0.1% BSA, pH7.5. The results are expressed in terms o f percentage binding, with 
100% binding defined as the maximal signal seen with optimal concentration o f Mn^^. 
Each data point represents Mean +/- SD (n=3) and data presented here are representative 
o f 2 or more independently conducted experiments.
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Wide Range Titration of in sLFA-1/ICAM-1hFc Assay
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Figure 4.10 Titrations of in the sLFA-lmFc/ICAM-lhFc Assay. Figure 4.10(A) represents 
the initial titrations carried out to determine the range over which any variation in 
cation concentration from construct to construct could be detected. Figure 4.10(B) 
represents titrations between 0-1 mM Mg^^. Captured integrin was depleted o f divalent 
eation by washing (x2) in 20mM EDTA/TBS followed by 4 washes in TBS. 50pl o f 
400ng/ml ICAM -lhFc in TBS/0.1% BSA, pH7.5 was added to each well along with 
50pl o f twice the required concentration o f Mg^^ in TBS/0.1% BSA, pH7.5. The results 
are expressed in terms o f percentage binding, with 100% binding defined as the 
maximal signal seen with optimal concentration o f Mg^". Each data point represents 
Mean +/-SD (n=3). Data presented in A are representative o f  1 experiment and B are 
representative o f 2 or more independently conducted experiments
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Figure 4.11 Inhibitory effect of on Mn^-induced binding of LFA-1 to ICAM-1. Captured 
integrin was depleted o f divalent eation by washing (x2) in 20mM EDTA/TBS followed 
by 4 washes in TBS. 50pl o f 400ng/ml ICAM -lhFc in TBS/0.1% BSA, pH7.5 was 
added to eaeh well along with 50pl o f 2X required concentrations o f Ca^^ and Mn^^ in 
TBS/0.1% BSA, pH7.5. The results are expressed in terms o f percentage binding, with 
100% binding defined as the maximal signal seen with optimal concentration o f  M n^\ 
Eaeh data point represents mean +/- SD (n=3) and data presented here are representative 
o f 2 or more independently conducted experiments
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4.9 Discussion
This chapter describes the generation of a series of soluble forms of LFA-1 containing mutations 
within the IDAS of the aL I domain and the effects these mutations have on the activation state 
of LFA-1 compared to wild type. A soluble active derivative of the integrin a4(3lhFc generated 
by fusing the extracellular regions of the a4 and pi subunits to separate Fc domains of the 
human immunoglobulin yl has previously been reported (Stephens et al, 2000). Analysis of this 
construct showed that co-expression of these chimaeric molecules resulted in dimérisation of the 
a  and (3 subunits, presumably brought about by the CH3 domains of the immunoglobulin and 
maintained by formation of disulphide bridges in the hinge region (Stephens et al., 2000). A 
similar method using mouse immunoglobulin Fc (yl isotype) domains was utilised in this study 
to generate a soluble form of LFA-1. Mouse Fc regions rather than human were used as purified 
ICAM-hFc’s were already available and allowed for development of ELISA-based ligand 
binding assays using anti-mFc capture and anti-hFc reveal. Non-reduced Western blotting 
analysis of the sLFA-lmFc constructs, in addition to assembly assay results, also confirmed 
heterodimer formation of the aL and (32 subunits using mFc tails. However, expression levels of 
many hFc/mFc-tagged soluble integrins have been shown to vary greatly from integrin to 
integrin, with expression levels of integrins with hFc tails being generally higher (personal 
communication, V. Perkins). These expression levels also compare unfavourably to levels of 
soluble LFA-1 expression in CHO-Kl cells of 1.0|xg/ml reported by Tominaga et al. (1998). In 
this instance, stop codons were introduced directly before the beginning of the transmembrane 
domain of both the aL and ^2 subunit DNA sequences and no tagging system was employed. 
That Tominaga's group reported functionally active integrin suggests that dimérisation of the a  
and p subunits occurs without the need for interacting tails. However, efforts within this 
laboratory to generate active LFA-1 without tagging was unsuccessful.
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Production of a soluble form of LFA-1 using the mFc tagging system also generated a 
functionally active form of the integrin. While sLFA-lwrmFc bound to ICAM-lhFc in the 
presence of Mn^  ^ in a concentration-dependent manner only minimal binding was seen when 
soluble ICAM-2hFc and ICAM-3hFc were used as ligands in the presence of Mn^ "^ . In the case 
of all three ligands further binding could be stimulated on addition of stimulating mAbs (See 
Figure 4.5).
Introduction of a range of mutations in and around the IDAS had varied effects on expression 
and ligand binding of sLFA-1 compared to wild type. Substitutions at residues L295A, F292A 
and K287C/K294C increased the expression of sLFA-1 over sLFA-lwjmFc as measured by 
mIgG ELISA and Western blotting analysis. Whether these substitutions increase transcription 
or translation or stabilise the protein allowing for the increased potential for heterodimer 
formation is unknown. Interestingly, the double substitution at L295A/I306A, which appeared 
to be highly expressed as measured by mIgG ELISA, was shown to consist predominantly of P2 
homodimers by Western blotting analysis. It has previously been shown (unpublished results) 
that soluble p2hFc can be expressed independently of the a  subunit, and although the number of 
p2 mAbs that do not require the presence of the a-subunit to bind is limited, binding to both 
KIM 127 and KIM 185 has been shown. The introduction of the double substitution may 
therefore have lead to a misfolding of the aL subunit rendering it unable to pair with the P2 
subunit.
Mutational analysis of the IDAS within the context of the soluble integrin confirmed that this 
region has a major role to play in controlling the affinity of integrin for ligand. This was most 
evident in binding experiments with ICAM-2 and ICAM-3 where sLFA-lwrmFc was unable to 
bind ligand above background level in the presence of Mn^  ^without the addition of activating 
mAbs, whereas introduction of alanine substitutions at positions L292, L295, 1235, 1306, a 
cysteine substitution at residue K294, and a double cysteine substitution at residues K287 and 
K294, enabled the integrin to bind ligand eonstitutively. This higher affinity of wild type LFA-1
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for ICAM-1 over ICAM-2 and -3 has previously been reported in the literature for both cell 
surface expressed LFA-1 and isolated I domain with the measured Kd for ICAM-1 (173nM) 
shown to be ~3 times and ~20 times less than that for ICAM-2 and ICAM-3, respectively 
(Shimaoka et al., 2001; Labadia et al., 1998; de Fougerolles et a l, 1994; Woska et a l, 1998). 
Several attempts to measure the Kd of sLFA-lwrmFc for the 3 ligands, by Biacore, were made 
during the course of this study but were unsuccessful due to the low concentrations of 
heterodimer in cell culture supernatants.
Shimaoka et al. (2001) have previously shown that the introduction of the double cysteine 
mutation at positions 287C and 294C promoted the formation of a cysteine bond that appeared to 
‘lock’ the a7 helix in a downward position that resembled the ‘open’ conformation seen in 
crystal structures of the aM and a l  I domains when complexed with ligand. This group also 
showed that soluble I domain containing this double mutation had a -9000 fold increase in 
affinity over wild type LFA-1 on binding to ICAM-1. Although the increase in ICAM-1 binding 
with sLFA-l287C294cmFc relative to sLFA-lwrmFc seen in our studies appears to be much lower 
than that reported by Shimaoka et al., the increased binding is still significant and suggests that 
other domains within the extracellular region of the integrin may impose constraints on the I 
domain and thus influence its ability to bind ligand. The increases in ICAM-1 binding appear to 
be more similar to that seen by Huth et a l (2000) on introduction of SLFA-I235A and SLFA-I306A 
mutations into an LFA-1 COS expression system.
Xiong et al (2000) have previously shown that mutation in the aM I domain at 1316 (equivalent
to 1306 in aL) to glycine increased the affinity of recombinant soluble aM  I domain for its
ligands and was sufficient to favour the ‘open’ conformation. The side chain of 1306 appears to
pack into a hydrophobic pocket between the C-terminal a-helix and the opposing P-sheet in the
‘closed’ conformation, but due to the downward movement of this helix in the ‘open’
conformation, this residue cannot pack against the side of the domain in the ‘open’ conformation
and is not visualized in the crystal structure of aM in the ‘open’ conformation (Lee et a l, 1995).
121
Chapter 4
Consistent with observations made from the aM  I domain, alanine substitution at 1306 of aL in 
this study also increased adhesion to ICAM-1. While this suggests that 1306 has a role to play in 
restraining the aL I domain in an inactive conformation, the ability of activating mAbs to further 
increase ligand binding also suggests that altering the chemical nature of the amino acid at 
position 306 is not sufficient to completely push the equilibrium in favour of the ‘open’, active 
conformation.
Amaout’s group (Li et al, 1998) also mutated F302 at the top of the p6-a7 loop in the aM I 
domain which was shown to be buried in the ‘closed’ conformation and exposed in the ‘open’ 
conformation of the aM I domain crystal structures. This residue is equivalent to F292 in the 
aL I domain and mutation of F302 to a tryptophan appeared to stabilize the ‘open’ conformation 
and increase ligand binding. In our study, sLFA-l292AmFc also showed increased ligand binding 
compared with sLFA-lwrmFc. Interestingly, binding of sLFA-l292AmFc could be further 
enhanced on addition of activating mAbs. This result suggests that although mutating F292 to 
alanine does not ‘lock’ the I domain in an active conformation, an alanine at this position 
preferentially shifts the equilibrium towards the active conformation and may represent an 
intermediate conformation between inactive, ‘closed’ and active, ‘open’. Shimaoka et a l (2003) 
have since shown that in the low affinity, ‘closed’ conformation, F292 in the aL I domain is 
buried in a hydrophobic pocket and its removal from this pocket appears to be a key factor in 
enabling rearrangement at the MIDAS to allow ligand binding. Therefore, by mutating this 
residue to alanine, the interactions that normally hold it in the hydrophobic pocket are 
presumably lost and hence no longer hold the I domain in the ‘closed’ conformation. We 
hypothesise that an alanine substitution at residue L295, further down on the a l  helix, behaves 
in a similar way by reducing the number of interactions with sides chains of other residues that 
would hold it in the inactive, ‘closed’ state. However, unlike the case with sLFA-l292AmFc, 
activating mAbs cannot further activate sLFA-l295AmFc.
122
Chapter 4
Interestingly an alanine substitution at position F299 completely abrogated LFA-1 ligand 
binding even though expression levels of sLFA-l299AinFc were double that seen for sLFA- 
IwrinFc and the former protein appeared to fold and dimerise efficiently, as evidenced by the 
assembly assays. The complete lack of ligand binding with this protein, even in the presence of 
activating mAbs, suggests that the presence of a phenylalanine at this position on the a7 helix 
has a role to play in forming hydrophobic interactions with other residues both inside and 
outside the IDAS. There are no previous reports of substitution at the 299 position.
Binding of all mutant forms of sLFA-lmFc to ICAM-1, -2, -3 was fully blocked by DA36. 
However, the inability of 6.5E to completely block the interaction of sLFA-l295AmFc with 
ICAM-1 and sLFA-l287c294cinFc with all three ligands suggests this mAh favours the ‘closed’ 
conformation of the I domain. The epitope of 6.5E has been reported to be located at the top of 
the P-subunit I-like domain (Huang et al, 2000) and so its ability to block the LFA-1/ICAM 
interaction is probably through an allosteric mechanism because of the distance between the 
6.5E epitope and the ligand binding site epitope. The fact that 6.5E binding was shown by 
FACS analysis not to be affected by introduction of the 287C294C mutation (Lu et al., 2001) 
suggests that the shift downwards of the a l  helix hinders the ability of 6.5E to effect allosteric 
inhibition. When 6.5E is added in the presence of activating mAbs its capacity to block ICAM-1 
binding is further reduced and is almost totally abolished in the case of sLFA-1287C294cmFc. The 
reduced capacity of 6.5E to block ligand interactions is unlikely to be due to steric hindrance 
because of the distance between the epitopes. It is more likely that activating mAbs bind to a 
proportion of the sLFA-lmFc molecules and stabilizes them in the active state which affects 
allosteric inhibition by 6.5E. With sLFA-1287C294cmFc, the binding of the activating mAbs must 
further stabilize the active conformation reducing even further the capacity of 6.5E to block 
through allosteric means.
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Results shown here also demonstrated that certain mutant forms of LFA-1 (sLFA-l287C294cmFc, 
sLFA-l295AmFc and sLFA-l294cHiFc) cannot be further activated by activating mAbs, which 
supports and extends previous work using cysteine substitutions that allow the introduction of 
disulphide bonds and thus lock the I domain in a fully activated form (Shimaoka et a l, 2000). It 
is unlikely, however, that single mutations allow the formation of physical restraints similar to 
the disulphide bond. Instead, removal of the bulky groups that link the P6 and a l  helix may 
reduce the energy barrier sufficiently for the a l  helix to shift downward and a take up a position 
similar to that seen in the locked ‘open’ conformation of Shimaoka’s 287C294C I domain. This 
has also been suggested by Huth et al. (2001) who investigated the effects of a wide range of 
mutations within the IDAS. They proposed that large hydrophobic amino acids within the IDAS 
such as 1306,1235 and 1255 sit in a pocket creating an energy barrier to conformational change 
in the I domain which stabilizes the ‘closed’ conformation. On the other hand, hydrophilic 
amino acids on the surface of the IDAS such as K232, K287, Q303, K304 and K305 appear to 
stabilize an active state by interacting with other amino acids in LFA-1.
Interestingly, although Shimaoka et al. (2001) claim that it is the introduction of the disulphide 
bond rather than the mutations themselves that generates a eonstitutively active form of the I 
domain, the introduction of a single cysteine substitution at position K294 also appears to 
eonstitutively activate LFA-1 in our system. This sLFA-l294cmFc protein behaves in a similar 
manner to sLFA-1287C294cmFc and, indeed, cannot be further activated by mAbs. Mutation of 
K294 to alanine had previously been shown to behave in a similar manner to wild type (Huth et 
al., 2000) suggesting that the chemical nature of the substitution affects the overall conformation 
of the IDAS. Shimaoka et al. (2001) provide no data on the binding capacity of the 294C mutant 
within the context of an isolated I domain but expression of full length LFA-1 in a T293 cell 
system showed it to be eonstitutively active although wild type LFA-1 behaved in a similar 
manner.
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In contrast, mutation of the K287 residue to cysteine did not appear to alter ligand binding over 
that seen for wild-type but was inducible by activating Abs. Huth et al. (2000) showed that 
whilst a K287A mutation reduced binding below wild type, increased binding was achieved on 
addition of an activating mAb. Interestingly, in the present study introduction of the K287F 
mutation had a detrimental effect on the LFA-1/ligand interaction which could not be rescued by 
activating mAbs (data not shown). Comparison of the a  subunits of the leucocyte integrin 
family show that this position in all the a  subunits, except aL, contains a conserved 
phenylalanine. Results suggest that a phenylalanine at this position in other members of the p2 
family I domains may explain their reduced affinity for ICAM ligands compared to LFA-1.
The determination of the overall conformation of the sLFA-lFc constructs is beyond the scope 
of this study. However, because there are no restraining cytoplasmic tails, we hypothesise that 
the molecule is quite flexible and could oscillate from the ‘bent, inactive’ conformation to the 
‘upright, active’ conformation, with a proportion of the molecules at any one time primed for 
ligand binding. This hypothesis is similar to that suggested by Drbal et al. (2001) from analysis 
of their soluble integrins. If this is the case, it could explain the ability of KIM 127, KIM 185 and 
MEM 148 to further activate sLFA-lwrHiFc and several of the mutated forms of sLFA-lmFc 
since one could postulate that such mAbs bind to integrin flexed in the active conformation and 
stabilize it. KIM 127 and other activating mAbs which bind in the P2 stalk region are thought to 
work by acting as a wedge to break the a  and p domain-domain contacts when in the ‘upright 
active’ conformation (Huang et al., 2000). Such a hypothesis would also argue that mutants that 
cannot be further activated in the presence of mAbs were already in the optimum conformation 
for ligand binding. In these cases, the preferential positioning of the a l  helix in the downward 
position may alter the position of the other extracellular domains and hold the construct in the 
‘upright active’ form. The epitopes for the activating mAbs would therefore be available for 
binding but not required to stabilize the conformation.
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Characterisation of Lovastatin / aL I domain interaction by Kallen et al. (1999) showed that the 
main contacts between ligand and protein are formed by the side chains of the residues Leu 132, 
Phel53, Ile235, Tyr257, Lys287, Leu298, Glu301, Leu302 and Lys305. Comparison of the 
unliganded (Qu and Leahy, 1995) and Lovastatin-bound aL I-domain crystal structure showed 
that only minor differences, especially in the MIDAS, exist between both structures (Kallen et 
al., 1999). This suggested that Lovastatin functions by stabilizing the inactive conformation, 
and results from the present study support this conclusion. Although Lovastatin inhibited the 
ICAM-1 /LFA-1 wrmFc interaction by -75%, the inhibitory capacity of this compound on ICAM- 
1 binding to sLFA-l287C294cmFc, sLFA-l295AmFc and sLFA-l294cmFc was sharply reduced, 
indicating that the I domains of these mutated forms of sLFA-1 are predominantly in the ‘open’, 
active conformation.
It is well established that integrins require divalent cations to support ligand binding (Marlin and 
Springer, 1986; Dransfield and Hogg, 1989; Dransfield et al., 1990, 1992) and recent 
crystallographic studies of the I domains with ligand have confirmed that cation binding in the 
MIDAS is essential for ligand binding. Previous analysis of a soluble a4pi construct have 
shown that both Mn^  ^ and Mg^  ^ support VC AM binding, with ImM Mn^ "^  and >lGmM Mg^ "^  
required to give maximal binding (Stephens et al., 2000). Data presented here suggests that 
0.5mM Mn^  ^ and ImM Mg^ "^  are required for optimal binding of sLFA-lmFc constructs. 
Introduction of mutations within the IDAS site do not appear to alter this requirement. Similar 
results were reported by Shimaoka et al. (2001) when comparing the cation requirement of cell 
expressed LFA-1 wt and LFA-1287C294c- These findings are not surprising as the IDAS is distal to 
the MIDAS and no cation binding site that could be affected by the introduction of selected 
mutations has been identified in the IDAS region.
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Several studies have shown that, whilst the divalent cations, Mn^  ^ are required for ligand 
binding, Ca^  ^appears to inhibit LFA-1/ligands interactions (Dransfield et al., 1992; Jackson et 
al., 1994) and that subtle changes in the ratio between Mn^  ^/Mg^^ and Ca^  ^may actually be a 
controlling factor in the activation of LFA-1, and integrins in general (Labadia et al., 1998; 
Rothlein and Springer, 1986; Stewart et a i, 1996). In the present study, Ca^  ^was shown to 
inhibit Mn^^-dependent sLFA-1/ICAM-1 binding in a concentration dependent manner 
suggesting that both cations compete for binding sites on the LFA-1 molecule. The results also 
show that Ca^ "^  is not capable of supporting ligand binding even at high (mM) concentrations. 
Similar findings of cation competition were also reported by Labadia et al. (1998). Using 
surface plasmon resonance to measure ligand binding they showed that titration of Ca^ "^  into the 
millimolar concentration range, in the presence of Mg^\ resulted in a dose dependent decrease in 
ICAM-1 binding. Measurement of the binding constants of Mg^  ^and Ca^  ^ (K^^cam (133nM) 
and K^ i^cAM (1  IfiM) respectively) suggest that, at high concentrations, Ca^  ^could competitively 
displace Mg^ "^ . Interestingly, in vivo cation concentration measurements have shown that levels 
of Mg^  ^ increase significantly, with a similar corresponding decrease in the concentration of 
Ca^ "^ , during injury and trauma and this increase in Mg^  ^ correlates with increased integrin- 
dependent migration of inflammatory cells to the site of injury (Grzesiak and Pierschbacher, 
1995).
Overall, this chapter has demonstrated that the introduction of select mutations within the IDAS 
can have a major effect on the ability of LFA-1 to bind integrin in a cell free system. While 
several of the mutations appeared to shift the equilibrium in favour of the ‘open’ conformation, 
an alanine substitution at position F299, which although expressed well, had a deleterious effect 
on ligand binding. The introduction of these mutations and their ability to alter the activation 
state of LFA-1 also appears to have no effect on the cation requirement of the integrin. In light 
of these results it is of interest to determine if the introduction of similar mutations, especially 
the novel single mutations at positions F292 and K294, into a cell surface expressed form of
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LFA-1 would behave in a similar manner compared to wild type or whether other factors such as 
cytoplasmic restraints would over ride their effects.
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Chapter 5
Effect of I Domain Mutations on Activation and 
Binding Properties of LFA-1 in the K562 Cell
System
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Chapter 5 Effect of I Domain Mutations on Activation 
and Binding Properties of LFA-1 in the K562 Cell System
5.1 Introduction
Data in chapter 3 showed that introduction of certain mutations within the I domain of soluble 
forms of LFA-1 lead to an increase in the affinity for its ligands ICAM-1, -2 and -3. Since this 
system is dependent only on affinity changes arising from conformational changes induced by 
the mutations, it was of interest to see if such mutations would have the same effect in a cell 
system. It is known that cell adhesion can have a large avidity component and it is not clear 
what the effects would be of increasing affinity without necessarily changing the avidity of the 
interaction.
Previously, this laboratory has generated a K562 cell line expressing full length wild-type LFA-1 
(KL4 cell line) and showed it to be functionally active and able to bind the appropriate ligands 
(Ortlepp, 1997). Other laboratories have also successfully transfected K562 cells with LFA-1 
(Bleijs et al., 2000; Lub et al, 1997) as well as other members of the integrin family including 
VLA-4 (Masumoto et al., 1993) and VLA- 6  (Delwel et ah, 1996). The K562 cell line is a non­
adherent human erythroleukaemic cell line originally established by Lozzio and Lozzio (1981) 
from the pleural effusion of a patient with chronic myelogenous leukaemia. As this cell line also 
shows no significant expression of p2 integrins (Hickstein et al., 1993) (See Table 5.1) it makes 
it an ideal cell line in which to study the activation and binding properties of various transfected 
mutated forms of LFA-1 without interference from other members of the (32 family. The 
presence of endogenous a5pi also makes it possible to investigate the extent of crosstalk 
between a5(3l and LFA-1 within such newly generated cell lines.
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Using KL4 cells as our wild type control, the K562 parental cell line was stably transfected with 
double gene vectors containing full length LFA-1 carrying a range of mutations that had 
previously been introduced into the soluble-Fc system. This chapter will outline the generation 
and selection of these cell lines and describe the results obtained from ligand binding studies in 
the presence and absence of activating and blocking agents.
5.2 Characterisation of K562 Cells
Prior to transfection of K562 cells with the various mutant forms of LFA-1, the cell line was 
evaluated for expression of a  and (3 integrin chains on the cell surface by flow cytometry using 
several Abs to the same antigen. Results are shown in Table 5.1.
5.3 Expression of mutant forms of LFA-1 in the K562 cell line
K562 cells were stably transfected using electroporation with double gene vectors encoding (32 
and one of the 5 mutations listed in Table 5.2. Individual vectors were DNA sequenced with 
primers to the I domain region just prior to transfection to verify the presence of the mutation(s). 
Following positive selection using the G418 selection method, clonal selection was carried out 
by several rounds of flow cytometry analysis using antibodies to both the a  and (3 chains (HIl 11 
and CTBlOl) and 6.5E which requires the ap heterodimer to be correctly folded for detection. 
Expression of the antibody epitopes is similar for all cell lines except for the K562287C294c cell 
line, which has much lower expression of the HIl 11 epitope but has similar CTBlOl and 6.5E 
expression (Fig 5.1). The fact that the single mutation, 294C incorporated into the K562 cell 
line behaves in a similar manner to the KL4 cell line suggests that either the 287C mutation, or
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the combination of both mutations in close proximity to each other, distorts the HIl 11 epitope 
and leads to reduced antibody binding.
Ab Name Antigen Host Species Isotype K562 n=l K562 n=2
No Ab ND 2.55
M0PC21 Control mouse IgGl 0.1 3.77
BHA2.1 ha2Pl mouse IgGl 3.25 6.13
Y9A2 ha93l mouse IgGl ND 7.39
TS2/7 h a l mouse IgGl 7.17 8.14
C3II.1 h «3 mouse IgGl 3.91 4.11
Max68P h «4 mouse IgGl 5.75 5.07
TS2/16 h p l mouse IgGl 173 103.74
LM609 h avb3 mouse IgGl 3.73 9.65
AB1926 hp5 rabbit polyclonal 3.17 2.59
E7P6 h avP6 mouse IgGl 4.38 5.34
sevenES h allbpS mouse IgGl 7.72 11.6
AMF-7 h aV mouse IgGl 4.55 3.15
BP6 hp7 mouse IgGl 3.7 3.12
LF61 h a E mouse IgGl 5.01 5.27
DA36 aL(I Domain) mouse IgGl 3.97 3.4
R7.1 h aL mouse IgGl 7.78 7
KIM247 h oM mouse IgGl 8.4 9.54
KIM249 h oM mouse IgGl 11.02 17.98
KIM 185 hp2 mouse IgGl 8.3 4.7
KIM202 hp2 mouse IgGl 4.08 3.66
KIM215 hp2 mouse IgGl 4.01 3.76
6.5E h o L 32 mouse IgGl 10.2 9.7
KIM 75 h aM 32 mouse IgGl 8.46 10.6
aD h aD mouse IgGl 3.96 2.88
15.2 ICAM-1 mouse IgGl 256.31 109.96
MCA 1140 ICAM-2 mouse IgGl 114.4 38.91
MCA 1485 ICAM-3 mouse IgGl 3.79 ND
Cal3.10 ICAM-3 mouse IgGl 8.12 8.7
Ig ll VCAM mouse IgGl 4.67 4.34
UPC 10 gG2a Control mouse IgG2a 6.84 5.44
CBR-IC/2 ICAM-2 mouse IgG2a 46.13 ND
M EM lll ICAM-1 mouse IgG2a 122.59 64.61
HA5 o5 31 mouse 133.61 55.1
P1D6 a5 mouse IgG3 127.94 97.21
sc6597 a6 goat polyclonal 6.09 5.9
sc6638 38 goat polyclonal 4.17 4.22
sc6628 34 goat polyclonal 4.62 5.02
Ab3.9 oX mouse IgGl 2.46
Table 5.1 FACS analysis of parental K562 cells. Results are shown as mean fluorescence
intensity in arbitrary units and are from two determinations carried out on separate days. 
Antibodies that showed high levels of binding are highlighted in red.
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Residue Change Effect on activity in 
Soluble system
287 and 294 287K^287C,
294R^294C >WT
235 235W235A >WT
306 306W306A >WT
294 294K-A294C >WT
292 292F^292A >WT
Table 5.2 List of mutations introduced into LFA-1 and expressed in K562 cells.
K 5 6 2 K L 4
10“ 10' 10^  10 
FL2-H FL2-H
2 3 5 a
m J \ . .10"  1 0 '  10 "^  10 '^ 10
FL2-H
FL2-H
2 8 7 c 2 9 4 c
2 9 2 a
Figure 5.1 FACS analysis of final stable cell lines chosen for each introduced mutation. Cells 
were stained with H i l l  (aL)(Green), CTBlOl (|32) (Blue), 6.5E( ocLp2) (Pink) or the 
isotype eontrol M 0PC21 (Puiple). The above profiles are representative o f 6 or more 
independently performed experiments.
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5.4 Binding of LFA-1 Expressing K562 Cells to ICAMs
Chapter 4 showed that the affinity of the soluble-expressed LFA-1 could be dramatically 
increased when select mutations were introduced into the IDAS of the I domain and it was 
therefore of interest to see if expression of these mutated forms of LFA-1 on the cell surface 
would also induce binding in the absence of stimulus. To study the binding of the various LFA- 
1-expressing K562 cell lines to ICAM ligands, cells were incubated on plates coated with anti- 
hFc-captured ICAM-lhFc, ICAM-2hFc, or ICAM-3hFc in the presence of cations, activating 
mAbs, blocking mAbs or other stimulating agents with the degree of cell binding being 
measured using a simple cell stain.
Figure 5.2 shows binding of transfected K562 cell lines to immobilized ICAM-lhFc. As 
expected, the untransfected K562 cell line is unable to support ligand binding even in the 
presence of activating mAbs. The KL4 cell line, which expresses LFA-1 wt on the cell surface, 
is also unable to support ICAM-lhFc binding when the assay is carried out in complete media 
which contains both Mg^ "^  and Ca^  ^at concentrations of ~lmM and ~1.8mM respectively. The 
level of binding is increased when KL4 cells are incubated in media containing ImM Mn^  ^but it 
is only on the addition of activating mAbs KIM 127 and KIM 185 that maximal binding is 
achieved with cells expressing wild type LFA-1.
In contrast to results with KL4 cells, all the mutated forms show a significant increase in binding 
to ICAM-1 in the presence of media alone and this binding is similar to, or greater than, the 
binding of KL4 cells in the presence of Mn^  ^ (Figure 5.2). The K562287C294c cell line shows 
approximately a 10-fold increase in binding above KL4, with the other mutated forms showing 
an increase of between 2- and 5- fold. The binding of all the mutant forms was further enhanced 
when cells were incubated with ImM Mn^  ^and again there is a significant 3-5-fold increase in 
binding over KL4 cells. Although there is some variation in levels of binding, addition of
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KIM 127 and KIM 185, incubated with media alone or in the presence of Mn^ ,^ led to a similar 
level of binding with all cell lines.
Binding of the KL4 cell line to ICAM-2hFc and ICAM-3hFc, like ICAM-lhFc, also required the 
presence of activating mAbs to achieve optimal binding, with only low level binding in the 
presence of Mn^  ^ and only background binding in media alone. Constitutive binding of 
K562287C294C and K56223sa to ICAM-2 and ICAM-3 in media alone was again observed and this 
binding was further increased by addition of Mn^ .^ Although the binding of the K562306a, 
K562294C and K562292A cell lines to ICAM-2 and ICAM-3 is significantly reduced compared to 
ICAM-1 in media alone, the level of binding was still approximately 2-fold higher than that seen 
for wild type and addition of ImM Mn^  ^restored binding levels of K562294c and K562292A to 
those seen for the K562287C294C and K562235Acell lines. Interestingly, whilst the binding of the 
K562306A cell line to ICAM-1 in the presence of Mn^  ^was comparable to the other mutant cell 
lines, comparison of levels of binding of this cell line with ICAM-2 and ICAM-3 showed ~50% 
reduced binding. Again, addition of KIM 127 increases binding of all cell lines to ICAM-2 and 
ICAM-3 to similar levels.
These results suggest that introduction of mutations within the IDAS can activate LFA-1 
although results shown here indicate that they are not capable of rendering the LFA-1 fully 
active as judged by the ability of mAbs and Mn^  ^to further enhance binding. These results are 
in contrast to those seen with soluble forms of the integrin containing the 278C294C, 295A and 
294C mutations. In the soluble system, introduction of these mutations fully activate the soluble 
integrin in the presence of Mn^ "^  and addition of activating mAbs could not increase binding 
further.
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Figure 5.2 Binding of K562 Cell-Lines to ICAM-lhFc, ICAM-2hFc and ICAM-3hFc. SxloVml o f 
cells were washed and diluted in DMEM (media) alone or containing M 0PC21 (control 
mAh), ImM Mn^^ 20pg/ml KIM127, 20pg/ml K1M185, ImM  Mn^^ + 20pg/ml KIM 127 or 
DMEM containing ImM Mn^^ + 20pg/ml KIM185. The degree o f binding was assessed at 
570nm using the Rose Bengal Assay. Each data point represents Mean +/- SD (n=3) and the 
data presented here are representative o f that obtained in three other independently 
performed experiments. Statistical analysis was performed to compare KL4 binding with the 
other lCAM-1 binding K562 cell lines under the same conditions. * indicates significance
p<0.01.
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5.4.1 Binding of LFA-1 Expressing K562 Cells to ICAMs with blocking mAbs
To confirm that the enhanced binding of the mutants was LFA-1 dependent, the effects of known 
LFA-1 blocking mAbs were investigated. Figure 5.3 shows the binding profile of the cell lines 
in the presence of DA36 (aL mAh) and 6.5E ((32 mAh). As predicted DA36 blocked binding of 
all the LFA-1 expressing cell lines to all three ICAM ligands even when fully activated in the 
presence of KIM 127. However, whilst 6.5E was also capable of significantly blocking the 
ICAM-1, -2, -3 interactions of KL4, K562292A and K562306a cell lines in the presence of Mn^\ it 
was not as effective as DA36 in inhibiting ligand binding of the K562287C294c and K5 62294c cell 
lines. Also, in the presence of KIM 127, the ability of 6.5E to block binding to all three ligands 
was reduced in all the mutant cell lines. This result is similar to the result seen for the soluble 
mutant constructs when 6.5E was added in the presence of KIM 127 (see Figure 4.7).
5.4.2 Effect of PMA and Cytochalasin D on Ligand binding of K562 Cells
To gain an insight into the role the cytoskeleton might play in restraining the integrin in an 
inactive state, the effect of cytochalasin D was investigated. Several researchers have reported 
that addition of cytoskeletal-disrupting agents such as cytochalasin D have an enhancing effect 
on ligand binding (Van Kyook et ah, 1999, Leitinger et ah, 2000). This is thought to be due to 
the untethering of the cytoplasmic domains from cytoskeletal restraints, allowing lateral 
movement of integrins into clusters which increases the avidity of the integrin for ligand. Figure 
5.4, however, shows that cytochalasin D has only a very slight positive effect on binding of all 
K562 cell lines to ICAM-lhFc. This result suggests that the majority of the integrin-mediated 
ICAM-binding of the K562 cells does not require an intact cytoskeleton. Phorbol esters such as 
PMA are known activators of the PKC pathway and have been shown to be a major regulator of 
‘inside out’ signalling-induced integrin-mediated interactions which result in clustering of 
integrins on the cell surface (Stewart et aL, 1996; Lub et aL, 1997(a); Chapter 1 Section 5.1).
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Figure 5.3 Binding of K562 Cell Lines to lCAM-1, -2, -3 in the presence of DA36 and 6.5E 
mAbs. 5x10' /ml o f cells were washed and diluted in DMEM containing ImM  Mn^^ 
(control) with or without 20pg/ml KIM 127 or M 0PC21 (control Mab) to which was 
added 20pg/ml DA36 or 20pg/ml 6.5E. The degree o f binding was assessed at 570nm 
using the Rose Bengal Assay and 100% represents the binding o f the individual cell 
lines under control conditions in the presence o f M 0PC21. Each data point represents 
Mean +/- SD (n=3) and the data presented here are representative of that obtained in 
three other independently performed experiments.
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Binding K562 Cell-Lines to ICAM-1 hFc in the Presence of 
Cytochalasin D and PMA
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Figure 5.4 Binding of K562 Cell Lines to ICAM-lhFc in the presence of Cytochalasin D and 
PMA. Cells were washed and diluted in DMEM (control) in the presence or absence of 
ImM Mn^^ with or without 5pg/ml Cytochalasin D (final) or lOOng/ml PMA (final). 
The degree o f binding was assessed at 570nm using the Rose Bengal Assay. 100% 
represents the binding o f the individual cell lines under control conditions both in the 
presence or absence o f Mn "^ .^ Each data point represents mean +/- SD (n=3) and the 
data presented here are representative o f that obtained in three other independently 
performed experiments.
In this study addition of PMA to most cell lines had a very slight positive effect on ligand 
binding relative to the control. However these effects were not statistically significant, which 
suggests that either upregulation of PKC in the K562 system has little effect on LFA-1 activation 
or that the integrins are already in a clustered state on the cell surface. The inability of PMA to 
activate K562 transfected cells has previously been noted by Ortlepp et al. (1997).
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5.5 Integrin Crosstalk
Evidence is now emerging suggesting that integrin ‘outside-in’ signalling can alter the activity of 
neighbouring integrins in a process termed ‘crosstalk’ (Blystone et a/., 1994; Leitinger and 
Hogg, 2000). Several researchers have shown both up- and down-regulation of LFA-1- 
dependent ligand binding when other integrins are activated on the same cell surface (Van 
Kooyk et al, 1993(b); Porter and Hogg, 1997; May et a l, 2000; Chan et al, 2000).
As mutant forms of LFA-1 expressed in K562 cells appear to be partially activated it was of 
interest to see if these forms of LFA-1 (or indeed mAb-activated LFA-1) have an effect on the 
binding of other integrins expressed on K562 cells. Table 5.1 confirmed previously published 
data (Ortlepp, 1997) that the parental K562 cell line predominantly expresses only one integrin, 
a5(3l, on its cell surface. FACS analysis of aSpi expression on all the LFA-1 expressing cell 
lines was also carried out and showed that all the transfected cell lines expressed similar levels 
of aSpi (See Figure 5.5). Interestingly, the parental K562 cell line has slightly higher 
expression levels of a5pi compared with the other cell lines. Whether the transfection process 
caused this reduced expression level in transfected cells is unknown.
Initial analysis of the binding of K562 cells to fibronectin-coated plates showed that binding 
took place in the presence of media alone but that this could be enhanced by the addition of 
ImM Mn^  ^ (Figure 5.6). Cells expressing various IDAS mutations bound to fibronectin in a 
similar manner to the parental cell line (Figure 5.6). There was slight variation in the binding 
levels of the transfected cells with the K56223sa cell line showing a consistent trend towards 
increased binding, however, this did not reach statistical significance.
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Figure 5.5 FACS analysis of K562 cells for oc5pi expression. Cells were stained with SAM-1-PE 
(a5)(ureen) or MAB 1382E-PE (a4 ) (Puiple). The binding o f the a4  mAb was used as 
an isotype eontrol as K562 eell line does not express a 4 p l .  The above profiles are 
representative o f  3 or more independently performed experiments.
Further characterisation of the binding of K562 cells to fibronectin showed that this interaction 
could be blocked by the a5 mAb, SAM-1 (Figure 5.7). The inability of Max6 8 P to affect the 
binding of any of the cell lines to fibronectin supports previous findings that a4pi is not 
expressed on the K562 cell line (Figure 5.7). The cells could also be further stimulated to bind 
ligand in the presence of the pi activating mAb TS2/16. In these experiments, the variations in 
levels of binding were not statistically significant when compared to the parental K562 cell line. 
As this cell line does not express LFA-1, it suggests that the activation state of LFA-1 does not 
affect the binding of aSpi to fibronectin.
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5.5.1 Binding of K562 cells to Fibronectin in the presence of LFA-1 mAbs
Addition of LFA-1 blocking mAbs 6.5E and DA36 had no effect on the capacity of the K562 
cell lines to bind fibronectin (Figure 5.8). This was an expected result since the original K562 
cell line, which does not express LFA-1, binds in a similar manner to the LFA-1-transfected cell 
lines. Interestingly, however, maximal activation of the LFA-1-transfected K562 cell lines 
achieved by the addition of KIM 127 appeared to increase the binding of all cell lines to 
fibronectin (Figure 5.9). The ability of the mAb SAM-1 to completely block this interaction 
(Figure 5.10) suggests that in the presence of KIM 127 this increased binding is a5p i dependent 
and not through some other fibronectin receptor that may be present on the cell surface. This 
data suggests that LFA-1 may be able to crosstalk to a5pl under defined conditions. No such 
activation was noted for the parental K562 cell line. Data previously shown in Figure 5.2 
demonstrated that binding of the LFA-1-expressing K562 cell lines to ICAM in the presence of 
KIM 127 was similar and maximal for all cell lines. This data suggests that, whilst mutations 
within the IDAS site can increase affinity of LFA-1 for ICAM ligands, this level of activation 
alone is not sufficient to support crosstalk with a5pl. Effective crosstalk only appears to take 
place on addition of KIM 127 which maximally activates all the cell lines.
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Figure 5.6 Binding of K562 Cell Lines to Fibronectin. 5x10^ /ml o f cells were washed and 
diluted in DMEM (media) in the presence or absence o f ImM Mn^^. The degree o f  cell 
binding to fibronectin coated plates was assessed at 570nm using the Rose Bengal 
Assay. The data presented here are the mean from 5 independently performed 
experiments (n=3 for each assay) +/- SD.
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Figure 5.7 Binding of K562 Cell Lines to Fibronectin in the presence of tx5pi Blocking and 
Activating mAbs. In each experiment, 100% represents the binding o f the individual 
cell lines in the presence o f the control mAh M0PC21 either in the presence o f  media 
(DMEM) or Mn^^. All mAbs were used at 20pg/ml. Each data point represents Mean +/- 
SD (n=3) and the data presented here are representative o f  that obtained in three other 
independently performed experiments.
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Figure 5.8 Binding of K562 mutant cell lines to Fibronectin in the presence of LFA-1 Blocking 
mAbs. 5x10^ /ml o f cells were washed and diluted in DMEM (media) in the presence o f 
ImM  Mn^^. In each experiment 100% represents the binding o f the individual cell lines 
in the presence o f the control mAb MOPC21. All mAbs were used at 20pg/ml. Each 
data point represents mean +/- SD (n=3) and the data presented here are representative 
o f that obtained in two other independently performed experiments.
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Figure 5.9 Binding of the K562 cell lines to Fibronectin in the presence of KIM127. 5x10^ /ml 
o f cells were washed and diluted in DMEM media with or without ImM Mn^^ or 
20pg/ml KIM 127. In this experiment, 100% represents the binding o f  the individual cell 
lines either in the presence o f media with or without Mn^^ and without the presence o f 
KIM 127. Eaeh data point represents mean +/- SD (n=4) and is representative o f  2 other 
independently performed experiments. Statistical analysis was performed to compare 
binding in the absence and presence o f KIM 127. * indicates significance p<0.01.
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Figure 5.10 Blocking of K562 cells binding to Fibronectin in the presence of Mn2 and KIM 127.
5x10^ /ml o f cells were washed and diluted in DMEM containing ImM  Mn^^ and 20pg/ml 
KIM 127 (control) to which was added 20|ig/ml 6.5E, 20pg/ml DA36 or 20ug/ml MOPC21. 
100% binding represents the binding o f  the individual cell lines under control conditions. 
The degree o f binding was assessed at 570nm using the Rose Bengal Assay. Eaeh data point 
represents mean +/- SD (n=3) and is representative o f 1 other independently perform ed 
experiment.
5.5.2 Binding of cell expressed LFA-1 to ICAM-1 in the presence of a5pl Abs
Following on from the experiments investigating the effects of LFA-1 activation on the binding 
of a5(3l to fibronectin, it was of interest to see if addition of a5(3l blocking and activating mAbs 
had an affect on the activation of LFA-1 wi and the various mutant forms of LFA-1  expressed in 
K562 cells. Results from binding assays in the presence of the a5 blocking mAb, SAM-1, 
showed that it had a slight stimulatory effect on the binding of LFA-1 to ICAM-1, although this 
increase was not statistically significant (Figure 5.11). It is unlikely that any increase in binding 
could be attributed to the activation state of LFA-1, since the KL4 cell line behaved in a similar 
manner to K562287C294C, the most active mutant with respect to LFA-1 activity. Addition of the 
activating pi mAh, TS2/16, also showed a slight increase in K562 ICAM-1 binding, similar to 
that seen in the presence of SAM-1. On the other hand mAh Max6 8 P, a blocking a4 mAb has a 
slight inhibitory effect on LFA-1 ligand interaction but this again was- not statistically 
significant.
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Figure 5.11 Binding of K562 Cell lines to ICAM-lhFc in the presence of o5pi mAbs. Cells were 
washed and diluted in DMEM containing ImM  Mn^^ (control) to which was added 
20pg/ml SAM-1, 20|ig/ml TS2/16, 20pg/ml Max68P or 20ug/ml MOPC21. 100% 
binding represents the binding o f the individual cell lines under control conditions. The 
degree o f binding was assessed at 570nm using the Rose Bengal Assay. Each data point 
represents mean +/- SD (n=3) and the data presented here are representative o f that 
obtained in three other independently performed experiments.
5.6 Discussion
In Chapter 4, alanine or cysteine substitutions of residues K287 and K294, K294, 1306, L292, 
F295 and 1235 in the I Domain of aL were all shown to have a significant effect on the 
activation state of the soluble integrin when compared to sLFA-lwimFc. Generation of a 
soluble form of LFA-1 allowed for the study of the interaction of the integrin containing such 
mutations in the context of other domains but without the constraints of the cytoskeleton. A 
limited characterisation of some of these mutations has previously been investigated by other 
researchers in a variety of cell systems including T293 cells, COS cells, JB2.7 cells and K562
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cells (Ma et al., 2002; Huth et al, 2000, Lupher et al, 2001). The data presented here extends the 
characterisation of the known mutants and ineludes a new mutation at position F292. The K562 
cell line was chosen because a K562 cell line expressing LFA-1 wr (KL4) had previously been 
generated and characterised in this laboratory (Ortlepp et aL, 1995). It was also selected beeause 
the KL4 eell line cell line requires the presence of Mn^  ^or activating mAbs to stimulate binding 
to ICAM-1. Therefore, it was expected that the effects of the introduction of mutations that 
might increase the activity of LFA-1 would be easily detected.
Data generated in this study on the KL4 cell line showed that it was unable to bind the ICAM 
ligands in media alone and only low levels of binding were seen in the presence of ImM Mn^ .^ 
This data confirms previously reported results showing that transfected LFA-1 wr expressed on 
the eell surface of K562 cells is in a low activation state as judged by its low binding to ICAM-1 
and low level binding of antibodies reported to recognise activation epitopes (Mab24 and 
MEM 148) (Ortlepp 1997; Lub et aL, 1997(a); Lu et al., 2001(c)). In contrast, expression of cell 
surface-expressed LFA-1 containing the various amino acid substitutions listed in Table 5.1 
upregulated binding to eoated-ICAM-1 hFc in the presence of media, and this could be further 
activated in the presence of Mn^ .^ These results suggest that structural changes in the IDAS site 
can affect the adhesive function of the integrin when expressed both in the soluble form and as a 
whole integrin expressed on the cell surface. However, because all of the mutant eell lines could 
be further activated to bind in the presence of the activating mAbs KIM 185 and KIM 127 (Figure 
5.2), one can conclude that the high affinity state induced by addition of Mn^  ^is not sufficient to 
get maximal ligand binding, and that the cytoplasmic tails tethering the integrin to the cell 
membrane may also have a controlling effect on the activation state of the integrin even when 
the I domain is locked ‘open’ as in the case of K562287C294c- As hypothesized in Chapter 4, the 
activating mAbs may act to stabilize the integrin in the active upright form, which is competent 
to bind ligand thus increasing the ligand binding readout over that seen in the presence of Mn^  ^
alone.
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In contrast to the ability of all the mutated forms of LFA-1 used in this study to be further 
activated in the presence of KIM 185 and KIM 127, Lu et al. (2001(c)) claim that LFA-12S7C294C 
expressed in their K562 eell system is fully activated in the presence of media alone and that 
activating mAbs or Mn^  ^cannot further increase this binding. Their result suggests that Mn^  ^
and Mg^  ^are interchangeable in the MIDAS once the I domain is in the right conformation for 
ligand binding as suggested by the introduction of the 287C294C mutation. This is further 
supported by their results from cation studies using the isolated I domain containing the 
287C294C mutation since they showed that the level of ICAM-1 binding was comparable in the 
presence of Mn^  ^ or Mg^  ^ (Lu et aL, 2001(d)). In a subsequent paper, they suggest that the 
cation binding site in the I-like domain of the (32-subunit preferentially binds Mn^ ,^ and it is the 
binding of Mn^  ^to this site that induces conformational change within the I-like domain which 
in turn alters the position of the a7 helix of the I domain, pulling it downward making the I 
domain competent to bind ligand (Shimaoka et aL, 2001).
Interestingly, although they showed that LFA-1 wr demonstrated only low level binding when 
assayed in eell culture media, it could be fully activated in the presence of Mn^  ^and addition of 
the activating mAh CBR LFA-1/2 did not further increase the level of binding. In our studies, 
addition of Mn^  ^was not sufficient to fully activate wild type LFA-1 expressed on K562 cells 
since activating mAbs such as KIM 127 and KIM 185 were needed to fully activate the integrin. 
The opposing results could be explained by the fact that different activation mAbs were used. 
Our results confirm data published by Ortlepp et aL (1995) where KIM 127 and KIM 185 were 
required to demonstrate maximal binding in the presence of Mn^ .^
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Also similar to the data presented here on the constitutive binding of K562 235A and the increased 
binding in the presence of PMA (Figures 5.2 and Figure 5.4), Lupher et al. (2001) reported that 
ligand binding by LFA-1 containing the I235A mutation in lymphoid cells (JB2.7 cells) was 
inducible and showed increased binding at lower PMA concentrations relative to wild type. 
However, while K56223sa in our study was shown to bind ligand in the presence of media alone, 
in their expression system this mutation was unable to support ligand binding under similar 
conditions. The authors suggest that negative regulation by cytoplasmic interactions, as well as 
IDAS regulation, control the binding ability of the integrin and that the 1235A mutation does not 
spontaneously induce the activated state of LFA-1. Rather, the mutation may either stabilize the 
activated state once it forms or destabilize the inactive state and thereby lower the threshold 
necessary for activation. Both the 294C and 1306 mutations have also been previously expressed 
on the cell surface and shown to be constitutively active. However, in the case of the 294C 
mutation, a transient T293 system was used which is known to have a high basal level of wild 
type LFA-1 expression (Lu et al., 2001). In the COS-7 cell system used to express the 1306 
mutant, integrins are also known to become partially activated without stimulation (Lupher et 
a l, 2001).
As with the LFA-1 constructs expressed in a soluble form, DA36 was capable of blocking all 
ligand interactions of the LFA-1 expressing K562 cell lines even in the presence of activating 
mAbs. Its ability to completely block binding to all ligands evaluated suggests that the binding 
of DA36 can, in some way, directly disrupt the interaction of the MIDAS binding site with 
ligand. While mAh 6.5E blocked the ICAM-1 interaction (80-90%) with KL4, K5623Q6a and 
K562292A cell lines when assayed in the presence of Mn^ "^ , the blocking capacity of 6.5E was 
only -60-70% with the cell lines K562294C, K562287C294c and K56223sa. In all eases, the addition 
of the activating mAh KIM 127 reduced the ability of 6.5E to block by a further 10-20%. 
Interestingly, whilst in the soluble system the introduction of the 287C294C mutation appeared 
to have the greatest influence on the ability of 6.5E to inhibit, in the cell system K562294c,
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K562287C294C and K562292A all appear to have a similar effect on the ability of 6.5E to inhibit 
ICAM-1 binding. The profile discussed here with respect to ICAM-1 was also true for all cell 
lines when ICAM-2 and ICAM-3 were employed apart from the K56223sa cell line in the 
presence of ICAM-3. This cell line behaved in a similar manner to K562294c cells with the 
ability of 6.5E to block being reduced to approximately 50%. Why this is the case when more or 
less maximal blocking is achieved with both ICAM-1 and ICAM-2 is unknown.
Addition of cytochalasin D, a chemical agent known to disrupt aetin polymerisation, also had no 
effect on the ability of cell-expressed LFA-1 to bind ligand. The inability of cytochalasin D to 
alter ligand binding suggests that outside-in signalling subsequent to addition of Mn^  ^ or 
activating mAbs does not require an intact cytoskeleton.
The ability of LFA-1 to regulate other integrins expressed on the same cell surface has been 
reported by several researchers (Van Kooyk et ah, 1993; Porter and Hogg, 1997; Leitinger et al, 
2002). Although K562 cells endogenously express a5(31, there are no reports to date on the 
ability of transfected integrins to influence the activation or ligand binding function of this 
integrin. It was, therefore, of interest to note that addition of the mAh KIM 127 to K562 cells 
expressing LFA-1 caused increased a5(3l-dependent binding to fibronectin. However, in the 
absence of KIM 127 none of the activated forms of LFA-1 alone were capable of significantly 
modulating ot5pi-mediated fibronectin binding in K562 cells.
On addition of KIM 127, all of the LFA-1 transfected cell lines appear to achieve a similar level 
of activation as demonstrated by similar levels of binding to ICAM-1 (Figure 5.2). In all cases 
KIM 127 seems to promote a higher level of activation than that generated by the I domain 
mutations alone. The ability of KIM 127 to influence the binding of a5pi to fibronectin suggests 
that LFA-1 when expressed on K562 cells must be in a highly activated state to cross talk. 
These results are consistent with those reported by Leitinger et al. (2000). In their study an 
activated form of LFA-1, generated by deleting the I domain and shown by reporter mAb
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binding analysis to resemble activated LFA-1, enhanced binding of both «4(31 and a5(3l to 
VCAM-1 and fibronectin respectively when expressed in the JB2.7 eell line. This binding could 
also be further enhanced by the addition of activating (32 mAbs. The inability of our mutant eell 
lines to enhance oc5(3l without the presence of KIM 127 suggests either that their activation state 
is not sufficient to support crosstalk or that the signalling mechanisms within K562 cells are not 
as finely tuned as in the JB2.7 cell system.
While LFA-1 appears to have an effect on aSpl ligand binding in our K562 cell system, we 
found no evidence to suggest that aSpi had any effect on the activation or ligand binding 
capacity of LFA-1. While several researchers have shown cross talk leading to LFA-1 activation 
(Rose et al, 2001; Chan et al.', 2000; May et al, 2000), these investigations have primarily 
focused on the ability of VLA-4 to affect the activation of LFA-1. It would appear therefore that 
there is another level of complexity allowing for cross talk between some, but not all, 
neighbouring integrins.
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Chapter 6 Effect of I Domain Mutations on Activation 
and Binding Properties of LFA-1 in the JB2.7 
Cell System
6.1 Introduction
Although the K562 cell-line is well established for studying the effects of transfected integrins 
(Andrew et a l, 1993; Ortlepp et a l, 1995; Stephens et a l, 1995; Yalamanchili et a l, 2000; 
Shimaoka et al, 2001; Bleijs et a l, 2000; Lub et al 1997), published work from Lub et a l 
(1997) has shown that the K562 cell line lacks some of the signalling elements that are known to 
be required to fully regulate p2 integrin adhesion. While endogenous «5^1 was capable of 
binding ligand in response to PMA stimulation, p2 integrins expressed in K562 eells were 
unresponsive even at high concentrations of the phorbol ester. The PKC pathway, which is 
upregulated by PMA treatment, appears to be involved in the activation of LFA-1 in some cell 
types (Hibbs et al, 1991) and may therefore also have a role to play in LFA-1 ‘crosstalk’. If this 
is the case, the crosstalk described in the previous chapter may not truly represent the process of 
crosstalk in the majority of cell types. In order to support the K562 cell data, full length LFA-1 
containing the aL mutations listed in Table 5.1 were also expressed in the JB2.7 cell line, and 
the effects of LFA-1 activation on the regulation of other integrins expressed by the cell line 
were investigated.
The JB2.7 cell line is deficient in the endogenous aL subunit. Originally established to evaluate 
the extent of interdependence of the a  and P subunits for cell surface expression and function, 
the cell line was generated by treatment of the Jurkat cell line with EMS (ethylmethane 
sulphonate) followed by selection of clones negative for aL and p2 expression (Weber et a l, 
1997). Characterisation of the JB2.7 cell line by Weber et a l revealed the absence of aL  mRNA 
expression and further biosynthetic studies revealed that the P2  subunit was synthesised and
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detectable by immunopereipitation but was not detected by anti-P2  antibodies on the cell 
surface. Subsequent transfection of this cell line with aL cDNA restored surface expression of 
LFA-1 and confirmed the requirement of both subunits for presentation on the cell surface. 
Transfection of aL also reconstituted ligand binding functions of LFA-1 upon stimulation with 
phorbol esters, suggesting that the chemical mutagenesis methods used to generate the mutant 
eell line had not affected this eellular signal transduction pathway.
The JB2.7 eell line (which will be referred to as the J B 2 .7 org cell line through out the remainder 
of the thesis) has been used by several researchers to analyse LFA-1-dependent function since it 
allows for interactions to take place in a Tymphocyte-like’ background (Lupher et aL, 2001; 
Leitinger and Hogg, 2000; Ostermann et al., 2002). More recently Leitinger and Hogg (2000) 
have reported the ability of LFA-1 to ‘crosstalk’ to both aSpi and a4pi in this cell line. They 
demonstrated this by using a JB2.7 cell line expressing LFA-1 that lacks an I domain 
(JB2.7AiDomain). Although this form of LFA-1 was unable to support ICAM-1 binding, binding 
studies with activation reporter mAbs such as mAb24 and NKLl-16 showed that it expressed 
epitopes generally associated with the active form of the integrin, suggesting that LFA-1 Aioomain 
had characteristics of a constitutively active integrin. Furthermore, the JB2.7AiDomain cell line 
demonstrated higher levels of binding to the aSpi and a4pi ligands, fibronectin and VCAM-1, 
relative to a JB2.7 cell line expressing LFA-1 w r  ( J B 2 .7 lfa-iw t)  suggesting that the activation 
state of LFA-1 had an effect on the ability of other integrins expressed on the same cell surface 
to bind their respective ligands. Addition of LFA-1 activating mAbs were shown to further 
increase this ‘crosstalk’. Their results are similar to the results shown in the previous chapter 
where KIM 127 appeared to activate LFA-1-expressing K562 eells which in turn upregulated 
aSpi binding to fibronectin. In order to determine if activation of LFA-1 through introduction 
of mutations within the IDAS altered the function of other endogenous integrins expressed on 
JB2.7 cells, the JB2.7 cell line was transfected with the genes encoding mutant forms of aL and
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the binding of the transfected cell lines to fibronectin, VCAM-1 and the ICAMs were compared 
with that of the JB2.7AiDomain and the J B 2 .7 lfa-iw t  cell lines (both used in the Leitinger study).
6.2 Expression and Characterisation of Mutated Forms of LFA-1 in 
the JB2.7 Cell Line
JB2.7 eells were stably transfected using electroporation with single gene pEE6  vectors 
encoding mutated forms of full-length aL (See Section 3.5), Following positive selection using 
the G418 selection method, clones for use in experiments were selected after several rounds of 
flow cytometric analysis using mAbs to both the aL and p2 subunits. Clones were selected on 
the basis of the similarity of their aLp2, a5pi and a4pl expression profiles compared with the 
J B 2 .7 lfa-iw t  cell line. It was felt that similar integrin expression profiles on all eell lines were 
required so that direct comparisons of the effects of the introduced mutations within the IDAS 
could be evaluated. Both the J B 2 .7 lfa-iw t  and JB2.7AiDomain cell lines had previously been 
selected for similar expression (Leitinger and Hogg, 2000).
The analysis of aLp2, a5pi and a4pi expression on the various JB2.7 cell lines is shown in 
Figure 6 .1 where the MFI values have been tabulated in order to more easily make comparisons 
across all the eell lines. Since the same parental eell line was used for transfection of the various 
LFA-1 mutants, the similar expression profiles of a5^1 and a4^1 on all cell lines were as 
predicted. Also, as expected, both H Hl l  and Ab38 mAbs which bind to epitopes on the I 
domain did not bind to either the J B 2 .7 org or JB2.7AiDomain cell lines. All other transfected cell 
lines had a similar profile for Ab38 and H I l l l  binding apart from the binding of H H l l  to the 
JB2 .7287C294C ccll linc. The reduction in binding of this mAh to LFA-1 containing the 287C294C 
mutation was also noted with the K562 eell line expressing the same mutation (Figure 5.1 in this 
thesis; Ma et a l, 2002).
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Figure 6.1 FACS analysis of surface expressed integrins on JB2.7 cell lines. Expression profiles 
are tabulated and expressed as geometric Mean Fluorescence Intensity (MFI) units. 
Several o f  the mAbs used were directly labeled with PE (phyeoerythrin) and required 
only 1 incubation step whereas with mAbs 6.5E, KIM 185, SAM-1 and M ax68P, cells 
were first incubated with the primary mAbs and following 3 washes in FACS buffer 
where further incubated with a polyclonal anti-mouse Fc-PE labelled Ab. All mAbs 
were used at 20|ig/ml final concentration. The results shown above are representative o f 
3 or more independently performed experiments performed on different days.
As both the a  and (3 subunits are required for the binding of 6.5E, the ability of this mAb to bind 
to LFA-1 when it is expressed without the I domain supports previous work which showed that 
this form of the integrin is correctly folded and that the presence of the I domain is not required 
for the correct folding of the integrin. The capacity of 6.5E to bind to the same extent to all 
forms of cell surface-expressed LFA-1 also confirms data from Lu et al. (2001(b)) which 
showed that the 6.5E epitope is available for antibody binding in cell lines containing the 
287C294C mutation to the same extent as wild type LFA-1, even though its ability to block 
ligand binding in this mutation is reduced. Binding of KIM 185 also appears to be unaffected by 
the presence of mutations within the IDAS. Although there is a slightly higher than background 
level of binding of KIM 185 and mAb24 to J B 2 .? org , the lack of binding with the other p2  mAbs
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and aL mAbs suggests that this may reflect some low level cross-reactivity or non-speciflc 
binding. The mAb 24 epitope, which can be induced by divalent cations Mg^  ^or Mn^ ,^ reflects 
a conformational change in LFA-1 characteristic of a higher-afflnity receptor and is considered 
to act as an activation reporter (Dransfleld and Hogg, 1989; Dransfleld et aL, 1992(b), Stewart 
and Hogg, 1996). The mAb24 results shown in Figure 6.1 are similar to those reported by 
Leitinger and Hogg (2000) in that LFA-1 JB2.7AiDomain demonstrated higher binding in the 
presence of mAb24 compared with J B 2 .7 lfa-iw t and is consistent with the JB2.7AiDomain cell line 
being in a higher activation state than the wild type cell line. Interestingly, all the mutant cell 
lines showed even higher binding of mAb24 compared with the LFA-1 JB2.7AiDomain cell line, 
suggesting that the introduction of the IDAS mutations does enhance the activation state of the 
integrin.
6.3 Binding of JB2.7 Cell Lines to ICAM-1, -2 and -3
Although the mAb24 data suggested that the mutated forms of LFA-1 were more highly 
activated than LFA-1 wt and also that all mutated cell lines were in a slightly higher activation 
state than the JB2.7AiDomain cell line, we felt it was prudent to confirm this increased activation 
above wild type with ICAM binding assays. As expected, both cell lines lacking an aL I 
domain, J B 2 .7 org  and JB2.7AiDomain, exhibited only background binding to all ICAMs in the 
presence of Mn^  ^ (Figure 6.2). Ligand binding studies in the presence of media alone also 
showed that the JB2.7 cell line expressing wild type LFA-1 was unable to bind to any of the 
three ICAM ligands tested (See Figure 6,2 for ICAM-1 binding). In contrast to this result, and 
consistent with the K562 cell results, JB2.7 cells transfected with aL containing mutations at 
positions 287C294C, 294C and 235A did bind to ICAM-1 in media alone and this binding was 
increased up to 3-fold in the presence of Mn^ .^ Although J B 2 .7 lfa-iw t  binding to ICAM-1 also
157
C'hapter 6
increased approximately 4-fold on addition o f  Mn^ ,^ the level o f binding was still lower than that 
seen for some o f the mutant cell lines.
B in d in g  o f J B 2 .7  C e ll L in e s  to  
IC A M -1 h Fc  in M ed ia
B in d in g  o f J B 2 .7  C ell L in e s  to  
IC A M -1 h Fc  in th e  p re s e n c e  o f M n ^
B in d in g  o f J B 2 .7  C e ll L in e s  to  
IC A M -2  h Fc  in th e  p re s e n c e  o f M n
2 .0  -I
1^1.5
B in d in g  o f J B 2 .7  C ell L in e s  to  
IC A M -3  h Fc  in th e  p re s e n c e  o f  M n
2.0 -1
Figure 6.2 Binding of JB2.7 Cell Lines to ICAM  Ligands. The above graphs show the relative 
binding o f the various cell lines in media (DMEM) +/-Mn^^ in the case o f  ICA M -lhFc 
and +Mn^^ in the case o f ICAM-2hFc and ICAM-3hFc. The degree o f binding was 
assessed at 570nm using the Rose Bengal Assay. Each data point presented here 
represents the mean +/-SD (n=4) and is representative o f 3-8 independently performed 
experiments. Statistical analysis was performed to compare J B 2 . 7 l f a - i w t  binding with 
the other ICAM-1 binding JB2.7 cell lines under the same conditions. * indicates 
significance p< 0.01.
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Figure 6.3 Binding of JB2.7 Cell Lines to ICAM ligands in the presence of KIM 127. The
above graphs show the relative binding o f  the various cell lines in the presence o f 
M0PC21 (Control mAh) or 20pg/ml KIM 127 when the assay was carried out in media 
(DMEM) containing Mn^C The degree o f  binding was assessed at 570nm using the 
Rose Bengal Assay. Each data point represents mean +/-SD (n=3) and these data 
presented here are representative o f that obtained in three other independently perform ed 
experiments.
The JB2 .7292A cell line bound less than cells transfected with other mutated forms of LFA-1 but 
binding to ICAM-1 in media was still significantly higher than with cells expressing LFA-1 w t -  
Binding of the JB2 .7235A cell line to ICAM-1 did not increase as dramatically as the JB2 .7287C294C 
and JB2 .7294C cell lines in the presence of Mn^  ^ although all three cell lines showed equivalent
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binding in media alone. Binding of the J B 2 .7 lfa-iw t  and JB2.?292a cell lines to lCAM- 2  and 
1C AM-3 was lower than that seen for binding to lCAM-1, although this binding was still above 
background levels. The cell lines JB2 .7287C294c, JB2 .723sa and JB2 .7294C again showed a higher 
affinity for ICAM-2 and ICAM-3 over wild type suggesting that the introduction of these 
mutations has a positive effect on the activation state of the integrin.
On addition of the mAb KIM127 (Figure 6 .3 ) ,  the levels of binding of the J B 2 .7 lfa- iw t  and 
JB2 .7292A cell lines were greatly increased with all ligands tested. Although the cell lines 
expressing different forms of LFA-1 showed some variations in levels of binding no statistically 
significant differences between the ICAM-binding cell lines were observed. Although KIM 127 
did increase the level of binding of both JB2 .7287C294c and JB2 .7294C, this increase in binding was 
not as dramatic as seen with wild type.
Inhibition of ICAM ligand binding with a metal chelating agent and blocking LFA-1 mAbs 
confirmed that all ligand interactions were cation and LFA-1 dependent. DA36 was capable of 
blocking the interaction of all the JB2.7 cell lines with all ICAM ligands (Figure 6.4(a)), even in 
the presence of KIM 127. Similar to results seen for both soluble LFA-1 and K562-expressed 
LFA-1, 6.5E was unable to completely block ligand binding with some of the mutant forms of 
LFA-1. Figure 6.4(b) illustrates the binding of the JB2.7 cell lines in the presence of 6.5E. 
Adhesion of the J B 2 .7 lfa-iw t  and JB2 .7292A cell lines was completely blocked by 6.5E in the 
absence and presence of K1M127. However, binding of the JB2 .7287C294c cell line to ICAM-1 
was only reduced by ~50% in the presence of Mn^  ^ and the capacity to block was further 
reduced to ~20% in the presence of KIM 127. Similar blocking profiles were shown for lCAM-2 
and ICAM-3 (data not shown). Overall, all the cell lines behaved in a similar manner to their 
equivalent mutations in K562 cells although it does appear that cytoplasmic constraints may 
have a bigger role to play in JB2.7 cells.
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Figure 6.4 Binding of JB2.7 cell lines in the presence of LFA-1 blocking mAbs and EDTA.
Cells were washed and diluted to SxloVml in DMEM eontaining ImM  Mn^^ with or 
without 20pg/ml KIM 127 or M 0PC21 (control) to which was added 20|ig/ml DA36, 
20|ig/ml 6.5E or 20mM EDTA. The degree o f binding was assessed at 570nm using the 
Rose Bengal Assay. In experiment A, 100% represents the binding o f the individual cell 
lines in the presence o f KIM 127 and in experiment B, 100% represents the binding o f 
the individual cell lines in the presence o f M 0PC 2I or KIM 127. Each data point 
represents mean +!- SD (n=3) and the data presented here are representative o f 3 other 
independently performed experiments.
6.3.1. Binding of JB2.7 cells to ICAM-1 in the presence of PMA
The inability of PMA to influence the binding of LFA-1 expressed on K562 cells (Chapter 5, 
Figure 5.4) suggested that some of the integrin signalling mechanisms may be absent in K562 
cells. PMA is a known activator of the PKC pathway and its addition leads to enhanced 
clustering of integrins on the cell surface (Stewart et ai, 1996; Lub et a l, 1997; Chapter 1 
Section 5.1) and it has been shown in other cell lines (e.g. T cells and JB2.7 cells) to be a major 
regulator of LFA-1 activation. Before investigating the ability of the mutant cell lines to affect 
crosstalk in the JB2.7 cell system, the ability of PMA to activate LFA-1 in these cells was 
checked in order to confirm that a mechanism of LFA-1 activation through inside-out signalling 
was operational. In this study, addition of PMA to the JB2.7 cell lines did stimulate ligand
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binding above that seen for media alone (Figure 6.5). Similar to the data in the presence of 
Mn^ ,^ the cell lines JB2.7287C294C, JB2.7235A, and JB2.7294c showed significantly higher levels of 
binding when compared with wild type cells. Moreover, KIM 127 induced comparable levels of 
binding in all cell lines. This data shows that PMA-induced signalling pathways are operational 
in JB2.7 cells and that outside-in stimulation with Mn^  ^yields comparable results to inside-out 
signalling with PMA in media alone. Finally, in both cases, cells do not appear to be maximally 
activated since addition of KIM 127 can further increase ligand binding.
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Figure 6.5 B inding of JB2.7 Cell Lines to IC A M -lhF c in the presence of PMA. The above 
graphs show the relative binding o f various cell lines with or without K1M127 and with 
or without PMA when the assay was carried out in media (DMEM). The degree o f 
binding was assessed at 570nm using the Rose Bengal Assay. The data presented here 
are representative o f that obtained in two other independently performed experiments 
with each data point representing the mean -f-/-SD (n=4). Statistical analysis was 
performed to compare binding o f each cell line in the presence o f Media vs 
Media-hPMA and KIM 127 vs K1M127-KPMA. * indicates significance p< 0.05.
162
6.4 Binding of JB2.7 Cell Lines to Fibronectin and VCAM-1
Having established that the mutant forms of LFA-1 expressed in JB2.7 cells bind ICAM ligands 
in a similar manner to the K562 cell lines and that signalling pathways known to be relevant for 
LFA-1 activation were intact in the JB2.7 cell line, it was therefore of interest to determine if 
these mutated forms of LFA-1 could support LFA-1 cross talk. Although we demonstrated a 
statistically significant increase in binding with K562 cells expressing LFA-1 with IDAS 
mutations compared with KL4 cells, no other reports of crosstalk with K562 cells have been 
published and in this study only maximally activated LFA-1 was capable of supporting the 
increase in a5|3l ligand binding. Leitinger and Hogg (2000) reported that JB2.7 cells expressing 
an activated form of LFA-1 showed increased binding to both fibronectin and VCAM-1 relative 
to a cell line expressing wild type LFA-1. This finding suggests that an activated form of LFA-1 
is capable of influencing the ability of other integrins expressed on the same cell surface to bind 
ligand. In the present study the level of binding to fibronectin and VCAM-1 of all the JB2.7 
cells lines, including cell lines used by Leitinger et al., were compared using an assay which 
involved assessing colourimetrically the number of cells binding to immobilized ligand. As 
previously shown (Figure 6.1) levels ofa5pl  and a4pl expression were similar for all JB2.7 
cell lines, suggesting that any variation in binding to fibronectin or VCAM would be attributable 
to the activation state of LFA-1.
In this study, in the presence of media alone, the JB2.7AiDomain cell line did bind to fibronectin to 
a slightly greater extent than J B 2 .7 lfa-iw t  and J B 2 ,7 org but this was not statistically significant 
(Figure 6 .6 A). However, on binding to VCAM-1 the JB2.7AiDomain cell line did show a statistical 
difference from the parental cell line (Figure 6 .6 B). Surprisingly, while all the cell lines 
expressing mutated LFA-1 molecules exhibited higher mAb24 binding compared with the 
JB2.7AiDomain cells (Figure 6.1) their binding to both fibronectin and VCAM-1 was not 
statistically significantly different from cells expressing wild type LFA-1. This suggests that
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either the LFA-1 Aioomam is in a different activation state from the other forms o f  LFA-1, or due to 
the absence o f  an I domain, its ability to signal is different from that o f  a more physiological 
active form o f the integrin. In the presence o f  Mn^ ,^ variation between cell lines in terms o f  their 
binding to both VCAM-1 and fibronectin was again observed. However, whilst binding o f  
J B 2 .7 l f a - iw t  and JB2.?292a cells to VCAM-1 was significantly less than binding o f  the J B 2 .7 o r g  
cell line, this cannot be attributed to the activation state o f  LFA-1 since J B 2 .7 q r g  (which does 
not express LFA-1) showed a similar increase in binding compared with the other cell lines 
expressing LFA-1.
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Figure 6.6 Binding of JB2.7 Cell Lines to Fibronectin and VCAM-lhFc. Cells were washed 
and diluted in media (DMEM) in the presence or absence o f ImM Mn^^ The degree o f 
cell binding to fibronectin/VCAM -lhFe coated plates was assessed at 570nm using the 
Rose Bengal Assay. The data presented here are representative o f three independently 
performed experiments and each data point shows mean +/-SD (n=6). Statistical 
analysis was performed to compare J B 2 . 7 o r g  binding with the other JB2.7cell lines. * 
indicates significance p< 0.05.
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Further characterisation o f the binding o f  JB2.7 cells to fibronectin and VCAM-1 showed that 
the binding could be completely blocked by the anti-a5 mAb, SAM-1, and the anti-a4 mAb, 
Max68P respectively (Figure 6.7 & Figure 6.8). Although a4(31 has been shown to bind 
fibronectin (Chan et al., 1992; Hemler et a i ,  1990; Humphries et al., 1995), the ability o f SAM - 
1 to completely block this interaction suggests that binding is predominantly aSpl-dependent. 
The interaction o f  a5(3l with fibronectin was also completely blocked in the presence o f  EDTA  
confirming the requirement o f  cation for ligand binding (Figure 6.7).
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Figure 6.7 Binding of JB2.7 Cell Lines to Fibronectin in the presence of SAM-1 and EDTA. In
each experiment, 100% represents the binding o f the individual cell lines in the presence 
o f the control mAh, M0PC21 with ImM M n^f All mAbs were used at 20pg/ml and 
EDTA was used at 20mM. Each data point represents mean +SD (n=3) and the data 
presented here are representative o f 2 other independently performed experiments.
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Figure 6.8 Binding of JB2.7 Cell Lines to VCAM-lhFc in the presence of Max68P. In each 
experiment, 100% represents the binding o f  the individual cell lines in the presence o f 
the control mAh, M 0PC21 with or without the presence o f  M n^\ All mAbs were used 
at 20pg/ml. Each data point represents mean +/-SD (n=3) and the data presented are 
representative o f 2 other independently performed experiments.
The activating (31 mAb, TS2/16, was capable of activating both a5(3l and a4[3l which resulted 
in increased binding to their respective ligands (Figure 6.9 & Figure 6.10). Once again there is 
slight variation in the relative percentage increase of binding across all the mutants but this 
variation is unlikely to be attributable to the activation state of LFA-1 since the increase in 
binding of J B 2 .7 qrg is generally similar to that seen with the other cell lines. The ability of 
TS2/16 to further increase the binding of all cell lines to fibronectin in the presence of Mn^  ^also 
suggests that this integrin is not fully activated with divalent cations alone. In contrast to this 
result, Mn^  ^alone appears to be sufficient to fully activate a4(31 since binding to VCAM in the 
presence of TS2/16 is increased by only 10-15% for all cell lines relative to Mn^  ^alone.
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Figure 6.9 Binding of JB2.7 Cell Lines to Fibronectin in the presence of TS2/16. Cells were 
washed and diluted in media (DMEM) with or without ImM Mn^^. TS2/16 was used at 
a final concentration o f 20pg/ml. In each experiment, 100% represents the binding o f 
the individual cell lines without the presence o f mAbs. Each data point represents mean 
+/- SD (n=3) and the data presented here are representative o f 3 other independently 
performed experiments.
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Figure 6.10 Binding of JB2.7 Cell Lines to VCAM-lhFc in the presence of TS2/16. Cells were 
washed and diluted in media (DMEM) with or without ImM  M n^f TS2/16 was used at 
a final concentration o f 20pg/ml. In each experiment, 100% represents the binding o f 
the individual cell lines without the presence o f mAbs. Each data point represents mean 
+/- SD (n=3) and the data presented here are representative o f 3 other independently 
performed experiments.
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6.4.1. Binding of JB2.7 Cell Lines to Fibronectin in the presence of LFA-1 mAbs
In Chapter 5, addition of KIM127 was shown to increase the binding of LFA-1-expressing K562 
cells to fibronectin suggesting that fully activated LFA-1 could affect the activation state of 
another integrin expressed on the same cell surface. In this chapter we have already shown that, 
in the presence of KIM127, JB2.7 cells expressing LFA-1 demonstrated increased binding to 
ICAM ligands relative to cation alone (Figure 6.3). If crosstalk between the integrins was taking 
place, one might expect to see alterations in the capacity of both aSpi and a4(3l to bind their 
respective ligands. However, as seen from Figures 6.11 and 6.12, KIM 127 (and KIM 185 in the 
case of VCAM-1 binding) has no significant effect on the ability of either aSpi to bind 
fibronectin or a4|3l to bind VCAM-1 when the cells were incubated in media alone. Although 
there is slight variation between the cell lines in levels of binding in the presence and absence of 
KIM 127, the profile is similar to that seen in the presence of DA36. DA36 is a known blocker 
of LFA-1 activity and although it is unknown whether the binding of this mAb affects both the 
binding of ligand and the activation state of LFA-1, or solely the binding of ligand, in this 
instance it also acts as an isotype control for KIM 127. When assays were carried out in the 
presence of Mn^ ,^ KIM 127 also failed to show enhanced binding to fibronectin or VCAM-1 
(data not shown).
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Figure 6.11 Binding of JB2.7 cell lines to Fibronectin in the presence of LFA-1 mAbs. All
mAbs were used at 20pg/ml and diluted in media (DMEM) with ImM  Mn^^ (M 0PC21 
was used as the eontrol mAb). The degree o f binding was assessed at 570nm using the 
Rose Bengal Assay. Eaeh data point represents mean +/-SD (n=3). The data presented 
here are representative o f 3 other independently performed experiments.
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Figure 6.12 Binding of JB2.7 Cell Lines to VCAM-lhFc in the presence of LFA-1 mAbs. Cells 
were washed and diluted in media (DMEM) with ImM  Mn^^ and all mAbs were used at 
a final eoncentration o f 20pg/ml. (M 0PC21 was used as the control mAb). Each data 
point represents mean +/-SD (n=3) and the data presented here are representative o f  3 
other independently performed experiments.
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6.4.2. Binding of JB2.7 Cell Lines to ICAM-1 in the presence of aSpl and a4pl 
mAbs
Although there are no published reports of a5pl and a4pl crosstalk to aLp2, we also 
investigated the ability of both blocking and activating a5pl and a4pl mAbs to affect the 
binding of LFA-1 to ICAM-1 and to detennine if the activation state of LFA-1 would affect the 
extent of any possible crosstalk. However, similar to the results seen in the K562 system, no 
significant effects were observed, with both blocking and activating a5pl and a4pl mAbs 
exhibiting similar profiles. In all cases J B 2 .7 qrg , which lacks expression of LFA-1, gave similar 
results to the LFA-1-containing cell lines (Figure 6.13).
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Figure 6.13 Binding of JB2.7 Cell Lines to ICAM-1 in the presence of oSpi and a4pi mAbs.
Cells were washed and diluted in DMEM (media) with ImM Mn^^ followed by the 
addition o f one o f the following mAbs SAM-1: a5  blocking mAb; Max68P: a 4  
blocking mAb; TS2/16: activating p i mAb or M 0PC21 (eontrol mAb) (20pg/ml final 
concentration). 100% represents the binding o f the individual cell lines in the absence 
o f mAb. Each data point represents mean -F/-SD (n=3) and the data presented here are 
representative o f 2 other independently performed experiments.
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6.5 Discussion
The data presented in Chapter 5 suggested that under certain conditions activated forms of LFA- 
1 expressed in K562 cells could influence the ability of (x5pl to bind to fibronectin. The work 
presented in this chapter extends our investigations into LFA-1 crosstalk by looking at the ability 
of activated forms of LFA-1 to modulate the binding of both cx5pl and a4pl in the Jurkat 
derived cell line, JB2.7.
As predicted, the J B 2 .7 org and JB2.7AiDomain cell lines which lack fimctional LFA-1, were unable 
to support ICAM ligand binding even in the presence of activating mAbs. JB2.7 cells 
reconstituted with wild type LFA-1 ( J B 2 .7 lfa-iw t)  were also unable to support binding to the 
ICAM family members in the presence of media alone. Published data from Weber et al. 
(1997), Lupher et al. (2001) and Leitinger and Hogg (2000) support this finding. In all of these 
reports, stimulating agents such as PMA, Mn^  ^or activating mAbs were required to activate the 
integrin. Additions of Mn^  ^and PMA in this study were also shown to be capable of inducing 
wild type LFA-1 binding to lCAM-1 although, in both cases, the level of binding could be 
further increased in the presence of KIM 127. Addition of both KIM 127 and KIM 185 were also 
shown by Leitinger and Hogg (2000) to further increase binding of wild type LFA-1 to lCAM-1 
in the presence of PMA. While there is a statistically significant increase in the ligand binding 
of the JB2.7292A cell line over the J B 2 .7 lfa-iw t  cell line in the presence of media alone this 
binding is much reduced compared to the other mutated cell lines in the study. This cell line 
also showed comparable binding levels to the J B 2 .7 lfa- iw t  cell line in the presence of Mn^  ^
suggesting that in JB2.7 cells the controlling effects of the cytoplasmic domains play a more 
dominant role than in K562 cells and thus override the capacity of this mutation to activate LFA- 
1.
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Similar to the results seen for the mutated LFA-1-transfected K562 cell lines, the JB2.7294c, 
JB2.7235A and JB2.7287C294c cell lines showed constitutive LFA-1/ICAM-1 binding. This 
contrasts with work from Lupher et al. (2001), which showed that transfection of JB2.7 cells 
with otL containing the 235A mutation was unable to support ligand binding in the presence of 
media alone. While the JB2.7294c, JB2.7235A and JB2.728?c294c cell lines showed significantly 
enhanced binding relative to J B 2 .7 w tlfa-i , both in the presence of media alone and with ImM 
Mn^ ,^ the magnitude of the effects are lower than seen in the K562 cell system. As hypothesized 
for the 292A mutant, intracellular regular regulation may play a greater role in controlling 
integrin function in JB2.7 cells than in K562 cells.
Binding of all cell lines expressing LFA-1 was further increased in the presence of KIM 127 and, 
similar to the effects seen with the K562 cell system, the addition of the activating mAb 
conferred similar levels of binding to all the lCAM-1 binding cell lines. Binding of all the cell 
lines to ICAM-2 and 1C AM-3 followed similar trends to those seen for lCAM-1 binding. 
Results from blocking studies with 6.5E also support the findings from the K562 experiments.
PMA was capable of stimulating binding of LFA-1-expressing JB2.7 cells to lCAM-1 over and 
above that seen with media alone. PMA is known to act by inducing clustering of LFA-1 on the 
cell surface and this result suggests that, in the presence of media containing Mg^ ,^ clustering of 
the integrin also contributes to ligand binding through avidity changes in the integrin. The 
concentration of LFA-1 molecules in discreet regions on the cell surface appears to increase the 
number of interactions with ligand compared to the unclustered state. Since the hierarchy of 
binding between the various cell lines is maintained in the presence of PMA, it would appear 
that LFA-1 clusters to the same extent in all cell lines and that the same proportion of LFA-1 
molecules are in an active state regardless of whether PMA is present or not. Similar to our 
results on activation of the JB2.723sa cell line in the presence of PMA, Lupher et al. (2001) have 
also shown that JB2.7 cells expressing LFA-1 with an alanine substitution at 1235 demonstrate 
increased binding to lCAM-1 over wild type in the presence of PMA. Leitinger and Hogg
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(2000) have also shown that phorbol esters induce J B 2 .7 lfa- iw t  cells to bind ICAM-1 and that 
this binding can be further enhanced in the presence of KIM 127. In our studies, activation of all 
cell lines in the presence of PMA could also be further enhanced by the addition of KIM 127, and 
this mAb was capable of activating all cell lines to a similar extent.
Previously, Leitinger and Hogg (2000) showed that removal of the I domain from the aL subunit 
generates a form of LFA-1 that appears to be in an activated state (as indicated by the binding of 
activation state reporter mAbs) although its ability to bind ligand is abolished. Using this 
activated form of LFA-1, they showed that LFA-1 was capable of influencing the ability of other 
integrins (aSpi and a4pl) on the same cell surface to bind ligand. This binding could also be 
further enhanced by the addition of stimulating mAbs. By introducing select mutations within 
the IDAS, we have also been able to generate activated forms of LFA-1 in the JB2.7 cell system. 
These cell lines were shown to constitutively bind ligand and display enhanced mAb24 binding 
when compared with both JB2.7 l f a - i w t  and JB2.7AiDomain cell lines.
We investigated whether these mutated forms of LFA-1 could influence the binding of either 
aSpi or a4pi, which are both endogenously expressed on the cell surface of JB2.7 cells, to their 
respective ligands. The LFA-1 wild type ( J B 2 .7 lfa-iw t)  and the I domain-less LFA-1 
(JB2.7AiDomain) Cell lines generated in the Leitinger et al. studies were also included in our 
experiments. No significant differences were seen in the ability of any of the cell lines to bind to 
fibronectin either constitutively or following Mn^”^, KIM 127 or KIM185 activation. While a 
small but statistically significant increase in binding of oc4pl to VCAM-1 in media alone was 
noted in JB2.7AiDomam cells when compared with J B 2 .7 org  cells, overall, the crosstalk seen in the 
JB2.7 cells in the presence or absence of activating stimuli was small and based on this data 
must be considered of dubious physiological relevance.
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Whilst the data presented here therefore does not appear to support the conclusions drawn by 
Leitinger et al. there are some potential explanations for the discrepancy. It may be that removal 
of the I domain forces LFA-1 into a conformation that affects crosstalk signalling pathways and 
this conformation is not replicated by any of the forms of I domain containing LFA-1 used in 
this study. However this does not explain the failure of the work reported here to show a 
difference in fibronectin binding between the JB2.7 cells expressing wild type and the 
JB2.7AiDomam Cell Imc. It must be noted that the assay system used in the experiments described 
here does differ from that used by Leitinger et al. Their system involved counting ligand-coated 
beads that remained bound to individual cells after gentle washing and cell fixing. It is possible 
that this assay is more sensitive and capable of picking up small effects compared to the plate 
binding methods used in this study. Several attempts were made to carry out the bead-binding 
format for this study but results were too inconsistent for any firm conclusions to be drawn.
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Chapter 7 Discussion
The work reported in this thesis has investigated both the contribution of the IDAS site within the I 
domain to the activation state of LFA-1 and the effect activated LFA-1 molecules have on the 
activation state of other integrins expressed on the same cell surface. Through introduction of select 
mutations within the IDAS site, several activated forms of LFA-1 were generated that showed 
increased affinity for ligand relative to wild type when expressed both in a soluble form and on the 
cell surface. Having an activated form of LFA-1 also allowed us to investigate the capacity of 
LFA-1 to crosstalk with aSpi and a4pi on K562 and JB2.7 cells.
At the start of this work, several crystal structures of the aM and a2 I domains had been solved and, 
depending on the crystallization conditions used, were shown to take up two different 
conformations. The ‘open’, or high affinity conformation was observed in crystals that had Mg^^ at 
the MIDAS bound to a glutamate residue from either a ligand (oc2) or an adjacent 1 domain (aM) 
(Lee et aL, 1995; Emsley et aL, 2000). The ‘open’ conformation differed from the ‘closed’, ligand- 
free, low affinity structure in terms of the position of residues around the MIDAS but the most 
dramatic difference was a 10Â downward shift of the a7 helix distal to the MIDAS site. The a l  
helix is at the C-terminal end of the 1 domain and is connected by a flexible linker sequence to the 
p-propeller.
Through its connection to the main body of the integrin head piece, the IDAS site is now thought to 
be involved in propagating conformational change to and from the 1 domain ligand binding site as a 
result of ligand binding or through conformational change initiated within the cytoplasmic tails as a 
result of inside-out signalling. As part of this study residues along the length of the a l  helix 
contained within the IDAS site were mutated, based on the fact that their size and the reactivity of 
their side chains appeared to preferentially restrain LFA-1 in an inactive conformation. By
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substituting these residues with alanine or cysteine, we appeared to be able to artificially shift the 
equilibrium in favour of the active conformation.
During the course of this work several other groups had also shown that LFA-1 activity could be 
enhanced by introduction of mutations within the IDAS site. Huth et al. (2000) achieved this 
through the introduction of a series of alanine substitutions in the IDAS site and identified 1235 and 
1306 as residues that appear to preferentially hold the 1 domain in the ‘closed’ conformation as 
substitutions at these positions conferred constitutive activity to LFA-1 expressed on the cell 
surface. The novel introduction of select cysteine bonds within the IDAS site by Shimaoka et al. 
(2001) also allowed the ‘open’ and ‘closed’ conformations seen in the various crystal structures of 
the aM  and a2 1 domains to be mimicked within the aL 1 domain. Results from their ligand 
binding studies using these restrained 1 domains reinforced the idea that the downward shift of the 
al helix plays a major role in switching LFA-1 from an inactive to an active state. Indeed when 
these restraints were introduced into full length LFA-1 expressed on the cell surface, constitutive 
activity was conferred to the integrin with equivalent levels of binding in the presence of both Mn^  ^
and Mg^ "^  which could not be further enhanced by addition of the activating mAb, CRBLFA-1/2 (Lu 
et al., 2001, Shimaoka et al., 2001).
In the work reported in this thesis, all of the above mutations along with novel alanine substitutions 
at positions F292, L295, and F299 were introduced in the aL 1 domain and were evaluated for their 
contribution to the proposed conformational changes which take place on integrin activation. F292, 
L295, and F299 are contained within the loop that connects the p6 strand and al helix and it was 
reasoned that a downward shift of the al helix would be associated with radical structural change 
around these residues and their side chains within the loop in order to facilitate this conformational 
change. By substituting these residues for alanine residues we proposed that some of the side chain 
interactions would be removed and that the size change in the case of phenylalanine may introduce 
more flexibility into this region and therefore lower the energy barrier required to shift the I domain 
into the active state.
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Our findings support the theory that the IDAS site does indeed contribute to the overall activation 
state of LFA-1. However, we believe also that other factors including attachment to the cell 
membrane contribute to the activation state and act to restrain the integrin in an inactive form. In 
our soluble system where the extracellular region of LFA-1 was fused to a Fc moiety, encouraging 
stable heterodimerisation of the a  and P chains by the formation of disulphide bridges in the hinge 
region of the CH3 domains, LFA-1 constructs containing either the 287C294C double mutation, a 
single K—>C substitution at position 294 or alanine substitutions at F292 or K295 appeared to 
confer constitutive activity to LFA-1. This was confirmed by the inability of the KIM mAbs and 
MEM 148 to further increase the binding of these constructs to lCAM-1. The introduction of 
alanine substitutions at residues 1235 and 1306 also increased ligand binding above wild type but, 
interestingly, similar to the wild type LFA-1 construct, this binding was further increased by the 
addition of the activation mAbs. This suggested that even though these mutations shifted the 
equilibrium ftirther in favour of the active state compared to wild type, it was not sufficient to fully 
activate the integrin. Whilst alanine substitution of several of the amino acids along the a7-helix 
appeared to shift the equilibrium towards the active conformation, F299 appears to be essential for 
the maintenance of the integrity of the ligand binding interface regardless of whether it is in the 
‘open’ or ‘closed’ conformation. Substitution of this residue to alanine completely abolished the 
ligand binding capability of LFA-1 although, interestingly expression levels were double that of the 
wild type construct and antibody binding did not appear to be affected by its absence.
Results published by Lu et al. (2001) showed that introduction of a disulphide bond through 
cysteine substitutions at positions K289 and K294 locked the 1 domain in a ‘closed’ conformation, 
preventing the binding of ligand when expressed as an isolated I domain on the surface of 293T 
cells. In contrast, in our soluble system this construct behaved in a similar manner to wild type, 
with further increases in ligand binding shown on the addition of activating mAbs. Addition of a 
reducing agent such as DTT would have likely adverse affects on LFA-1 due to the presence of 
several other cysteine bonds in the structure so we were unable to ascertain if indeed the formation
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of any of the disulphide bonds did indeed occur. In our hands, single cysteine substitutions at 
positions 287 and 294 displayed either similar or better ligand binding affinities respectively 
compared to our wild type construct. This result suggests that, although the formation of the 
cysteine bond can contribute to the increased affinity for ligand, it is the nature and position of the 
substitution that is the deciding factor in altering the activation state of LFA-1.
It is widely accepted that the cytoplasmic domains play a central role in the regulation of the 
adhesive and signalling functions of LFA-1 and whilst the soluble system allowed analysis of the 
effect of affinity changes that mutations within the IDAS site might confer on LFA-1, the 
contribution of these domains in the regulation of the whole integrin could not be assessed. To 
address this, mutations that displayed higher binding activity relative to the wild type construct 
were introduced into two different cell lines, K562 and JB2.7, both of which have previously been 
used by other research groups to study the role of LFA-1.
As previously reported by Ortlepp et al. (1995) for KL4 cells, wild type LFA-1 expressed on the 
surface of both K562 and JB2.7 cell lines appeared to be in a low state of activation as judged by its 
low-level binding to immobilized ICAM ligands. Introduction of the activating mutations used in 
the soluble system did greatly enhance the capacity of LFA-1 to bind ligand both in media alone 
and in the presence of Mn^ .^ The hierarchy of binding of the various forms of cell surface 
expressed LFA-1 followed a similar pattern to that seen for the soluble constructs although, 
interestingly, the 294C and 287C294C mutations in both cell lines displayed similar levels of ligand 
binding in the presence of both Mn^  ^and Mg^ .^ This supports the hypothesis discussed above that 
it is the 294C substitution itself, and not the presence of the disulphide bond, that confers increased 
affinity to the LFA-1 molecule. In all cases, activating mAbs could further increase affinity for the 
ICAM ligands, suggesting that other factors were involved in regulating the affinity of LFA-1 for its 
ligands in the context of the whole integrin. This result also suggests that there is some flexibility 
in the overall structure of the integrin which is locked on binding of KIM127 into a state favourable 
for ICAM binding.
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By modelling LFA-1 on the crystal structure of aV|33, Lu et al. (2001) showed that the KIM 127 
epitope was obscured in the ‘closed’ bent conformation which suggested that it could only bind 
when the integrin was in the extended conformation. The overall implication is that mAbs such as 
KIM 185 and KIM 127 provide rigidity to the extended form of the integrin, and hold it in a 
conformation that allows ligand to bind.
Through the course of these studies it was noted that the LFA-1 blocking mAb, 6.5E, was unable to 
fully block ligand binding of some of the mutated forms of LFA-1 when expressed both in soluble 
and cell-expressed systems. The epitope of 6.5E has been mapped to the top of the P-chain I-like 
domain and binding studies have shown that both the a  and P subunits are required to be present for 
epitope presentation (Huang et al., 2000). Since flow cytometric analysis showed that the mAb 
bound to the same extent to all cell lines, the suggestion is that 6.5E inhibits ligand binding either 
through steric hindrance or through an allosteric mechanism since the epitope is not in the same 
vicinity as the 1 domain MIDAS site.
While some groups have reported the ability of PMA to activate LFA-1 expressed on K562 cells, 
results presented in this study together with data from S.Ortlepp (1997) in this laboratory and Lub et 
al. (1997) do not support this, at least in short term adhesion assays. Findings from Lub et al. 
(1997) suggest that some of the components in the signal transduction pathway linking PKC 
activation to integrin activation are absent or non-functional in K562 cells, but it must be noted that 
these components are integrin-specifîc since PMA can activate some, but not all integrins expressed 
on K562 cells. This result is in contrast to the results obtained from activation of the LFA-1 
expressing JB2.7 cell lines where PMA was able to activated cells transfected with wild type and 
mutated LFA-1 to a similar extent. The JB2.7 cell line was generated from a Jurkat cell line which, 
before treatment with EMS (ethylmethane sulphonate), expressed LFA-1 endogenously (Weber et 
al., 1997). Regardless of the initial activation state of the JB2.7 cell lines expressing different forms 
of LFA-1, PMA increased the binding of all LFA-1 expressing cell lines while maintaining the 
hierarchy seen in the presence of media alone. This result is consistent with previous data
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suggesting that PMA increases the avidity rather than affinity of LFA-1 for its ligand (Stewart et al, 
1996; Van Kooyk et al., 1991; Van Kooyk et al, 1999). The concentration of LFA-1 molecules in 
discrete regions on the cell surface appears to increase the number of interactions with ligand 
compared to the unclustered state. Since the hierarchy of binding between the various cell lines is 
maintained in the presence of PMA, it would appear that the activation state of LFA-1 does not 
dramatically change its ability to be clustered following PMA treatment.
As well as being one of the main players in the initiation and maintenance of adhesiveness during 
cell-cell and cell-endothelium contact, integrins are also signalling molecules and signalling 
pathways initiated through integrin ligand interactions have been shown to be involved in gene 
expression and cell growth, differentiation and survival (reviewed by Schwartz and Ginsberg, 
2003). Evidence is now also emerging which suggests that, in addition to the effects on other 
receptors on the cell surface, outside-in signals can also alter the activity of neighbouring integrins 
in a process termed ‘crosstalk’ (Blystone et a l, 1994; Leitinger and Hogg, 2000). Results to date 
suggest that both the hierarchy and the capacity of an integrin to positively or negatively regulate 
the function of other integrins is dependent to some extent on the levels of expression of the 
integrins involved (Diaz-Gonzalez et al, 1996) although further research is required to fully define 
how crosstalk is initiated and maintained. Work from N. Hoggs’s laboratory (Leitinger et al., 2001, 
Porter and Hogg, 1997) has suggested that LFA-1 can regulate both «4(31 and «5(31 in a positive 
and negative manner depending on the cell type and relative concentrations of each of the integrins 
involved.
Having identified that alanine or cysteine substitutions within the IDAS site could constitutively 
activate LFA-1 both in a soluble and cellular environment, further work in this thesis addressed 
whether activation of LFA-I in such a manner affected its ability to crosstalk. We showed that 
when LFA-1 was highly activated in the presence of KIM 127, regardless of its initial activation 
state, adhesion of «5(31 to fibronectin was increased. No increase in LFA-1 binding to ICAM-1 
was noted when «5pl was activated suggesting that LFA-1 is the dominant-integrin in the K562
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cell system and positively regulates «5(31 activation. Mean Fluorescence Intensity measurements 
showed that transfected LFA-I is as highly expressed or even more highly expressed, than «5^1. 
This is the first report of LFA-1 crosstalk in K562 cells and these cells may employ different 
control mechanisms relative to the T-cell cell types previously used to investigate crosstalk 
(Leitinger et a l, 2001, Porter and Hogg, 1997).
Whilst the K562 cell line crosstalk data suggests that LFA-I needs to be highly activated in order to 
influence the binding of other integrins, there remains the possibility that a reduced level of 
signalling in this cell line, as suggested by the lack of induced ligand binding in the presence of 
PMA, would lead to an underestimation of the effect of LFA-1 crosstalk. If this is the case, then, 
less activated forms of LFA-1 such as our mutated forms of LFA-1, without the presence of 
activating mAbs, may be sufficient to demonstrate crosstalk in another cell line. Leitinger et al.
(2001) have previously demonstrated enhanced a5pi- and «4pl- dependent adhesion using an 
activated form of LFA-1 generated by the deletion of the I domain in the JB2.7 cell line. They 
showed that, on deletion of the I domain, they could express correctly folded LFA-1 which 
displayed many of the attributes of an activated form of LFA-1 although it lacked the capacity to 
bind ligand. Analysis of the activation state of the mutated forms of LFA-1 by mAb24 binding 
showed that the mAb bound as well or better to our mutant cell lines as to this JB2.7AiDomam cell line.
Disappointingly, our studies did not fully replicate the crosstalk reports of Leitinger et al. While we 
were able to confirm that the JB2.7AiDomain cell line showed significantly more binding to VCAM-1 
than that seen for the parental cell line lacking LFA-1 expression ( J B 2 .7 qrg) ,  our data failed to 
show a significant increase in binding to fibronectin over the J B 2 .7 org cell line. Also, none of the 
activated forms of LFA-1 generated in this study showed increased binding to VCAM-1 or 
fibronectin over and above that seen for the J B 2 .7 org cell line even when further activated with 
KIM 127. Unlike the situation found in K562 cells, KIM 127 treatment of the JB2.7 cells did not 
stimulate fibronectin binding. Also it was noted that on Mn^  ^activation J B 2 .7 lfa-iw t  and JB2.7292a 
cells showed a marginal reduction in fibronectin binding when compared to J B 2 .7 qrg  cells. While
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the most convincing sign of crosstalk involved the increased binding of the JB2.7Amomain cell line to 
VCAM-1, the lack of crosstalk with the other cell lines does bring into question its physiological 
relevance in the JB2.7 cell line. Although it is possible that LFA-1 lacking an I domain does adopt 
the conformation of an active LFA-1 molecule and thus mimics real integrin/integrin interactions, 
our efforts to replicate this with molecules of more obvious physiological relevance were 
unsuccessful.
While work in this thesis has generated some evidence for integrin crosstalk (most convincingly for 
KIM 127 activated LFA-1 forms interacting with aSpi), it is clear that from the data presented here 
and the literature surrounding integrin crosstalk that the phenomenon is complicated and as yet 
poorly understood. It does not appear that mutations which activate the extracellular domain of 
LFA-1 can alone result in crosstalk (at least in the cells tested here). This may suggest that integrin 
clustering plays a key role in crosstalk. The ability of integrins to crosstalk may also be further 
complicated by cell line specific differences. This is highlighted in this work by what appears to be 
a clear case of crosstalk in K562 cells that cannot be replicated in JB2.7 cells.
While crosstalk between integrins remains a very attractive theory to explain the regulation of some 
cellular interactions, the complex nature of such pathways requires additional methodologies to be 
developed to analysis further the mechanisms involved. Such methodologies include:
1. The development of more sensitive assay systems, possibly using radio-labelling 
techniques, which could reliably detect small changes in integrin-ligand interactions.
2. Determination of the effects on crosstalk of altering the relative concentration of integrins 
on the cell surface. Diaz-Gonzalez et al. (1996) have previously shown that negative versus 
positive regulation is dependent on the levels of expression of the integrins involved, with 
negative regulation controlled by high expression of the dominant integrin. In the context 
of the work presented in this thesis, this could be investigated by selecting both JB2.7 and 
K562 wild type and mutated clones expressing different levels of LFA-1 and analysing 
whether such differences have an effect on the capacity of LFA-1 to regulate the activation
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state of other integrins expressed on the same cell surface. The activation state of LFA-1 
could also be manipulated in such a system. This may lead to an explanation for the 
differential ability of LFA-1 to crosstalk in the K562 cells compared with JB2.7 cells.
3. Analysis of the distribution of LFA-1 on the cell surface of the K562 and JB2.7 cell lines. 
Using confocal microscopy the effects of different activating agents such as PMA, 
antibodies and cations on the cellular distribution of the integrins involved may help to 
explain the differences seen in the ability of the two cell types used in this study to initiate 
crosstalk. Previous work by Leitinger et al. (2002) using a similar technique showed that, 
when activated, LFA-1 homed to lipid rafts which then initiated the entry of other integrins 
into the rafts through crosstalk.
4. Examination of the availability of adaptor proteins for cytoskeletal connections or 
components critical for signalling pathways. A detailed analysis of the concentration, 
activation state and integrin-associated intracellular and cytoskeletal proteins by 
intracellular staining and immunoprécipitation techniques may help to shed light on the 
fundamental processes involved in crosstalk. Of special interest would be a study of the 
phosphorylation profiles over time, not only of the integrin cytoplasmic domains, but also 
of protein kinases such as Lck, Fyn, and Fak which appear to play important roles in 
regulating integrin signalling (reviewed in Giancotti et al. 2003). The proteolytic state of 
talin (Valmu et al, 1999; Kupfer et al, 1990) and cytohesin (Geiger et al, 2000) during 
LFA-1 activation, and analysis of their association with the expressed integrin cytoplasmic 
tails may also be informative.
The IDAS mutations analysed during the course of these studies showed that this region of the I 
domain has a significant role to play in the activation state of LFA-1. Further structural analysis 
now suggests that the I domain may in fact be an intrinsic ligand for the p-I-like domain in I 
domain-containing integrins and bind in a similar manner to ligands of non I domain-containing
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integrins (Alonso et a l, 2002; Yang et al., 2004). The conformation of the (3-I-like domain appears 
to be directly influenced by the structural changes brought about by activation of integrins through 
inside-out signalling. It therefore may be more beneficial to use different activation conformations 
of the (3 I-like domain (which could be brought about by introduction of select mutations and 
activating mAbs) to elucidate the factors involved in LFA-1 crosstalk. Using this approach, a more 
direct influence of changes in the globular head of the integrin may lead to more defined and 
measurable changes in intracellular signalling and subsequent crosstalk to other integrins on the cell 
surface.
Another area of study which may lead to advancement in the understanding of LFA-1 activation 
and its effects on cellular signalling is the role of the various cation-binding sites that have recently 
been identified (Xiong et al, 2001; Xiong et al, 2002). Elucidation of the role of cation at each of 
these sites may help to identify a physiological mechanism of outside-in integrin activation leading 
possibly to novel signalling pathways and may highlight yet another level of control over the 
activation state of LFA-1 and integrins in general.
Much progress has been made over the last few years in our understanding of the changes integrins 
undergo to become functionally active. Nonetheless, further investigation of integrin signalling 
partners, modes of activation and structural rearrangement may help identify additional points of 
intervention at which therapeutic agents may be directed. For example, the generation of novel 
therapeutics that stabilize particular integrin conformations, or competitively interfere with ligand 
binding, or interfere with signalling pathways. This will be particularly important in the case of 
LFA-1, which is an important target in the pharmaceutical industry for blocking organ 
transplantation rejection and treating inflammatory diseases. While monoclonal antibodies have 
been shown to prolong graft survival in many animal models (Nicolls et al, 2002; Poston et al, 
2000; Samacki et al, 2000) and to alleviate symptoms of psoriasis in clinical trails (Gottlieb and 
Bos, 2002, Gottlieb et al, 2002), the identification of low molecular weight inhibitors that can be
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administered orally has remained elusive. The identification of further molecularly defined points of 
intervention, at which such inhibitors may be directed should help this drug discovery process.
Conclusions
The work presented in this thesis has confirmed that mutations in the IDAS of the I domain of LFA- 
1 can alter the ability of LFA-1 to bind to its ligands. A number of the mutations have confirmed 
previous literature reports and the results obtained with novel mutations are consistent with 
currently accepted theories of the interaction of I domains with integrin ligands. Our findings also 
indicate that alterations to the IDAS site do not cause any major changes in ligand specificity or 
divalent cation responsiveness.
Whilst the data presented here is consistent with the idea that under certain circumstances the 
activation state of one integrin can modify the ability of other integrins on the same cell to interact 
with their ligands it is apparent that the conditions under which crosstalk can occur varies between 
cell lines. Under the conditions used in this study the introduction of mutations into the LFA-1 I 
domain currently known to promote ligand binding were not sufficient alone to promote integrin 
crosstalk in either the K562 or JB2.7 cell systems but in the presence of mAh KIM 127, crosstalk 
between a5pl and all forms of K562 surface expressed LFA-1 was effectively induced.
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hCD18 DNA sequence and protein translation with highlighted regions indicating 
mutations and insertions required to generated a soluble form of CD18. All oligos 
and restriction sites used in the process are also highlighted.
Ab LEADER SEQUENCE OLIGO (B 6113)
GGC CAA GCT TCC GCC ACC ATG GGC ATC AAG ATG GAG TCA GAG ACC CAG
GCG GAG TGC AGG ACA CCG AGG GAG ATG CTG GGC CTG CGC CGC CCA CTG
CGC CTG AGG TCG TGT GGC TCC CTG TAG GAG CCG GAG GCG GGG GGT GAG
A D S S T P R D M L G L R P P L>
GTC TTT GTA TAG ATG TTG CTG TGG TTG TCT GGT GTT GAT GGA
CTC GCC CTG GTG.. GGG CTG CTC TCC CTC GGG TGC GTC CTC TCT CAG GAG
GAG CGG GAG CAC CGC GAG GAG AGG GAG CGC ACG GAG GAG AGA GTC CTC
L A L V G L L S L G C V L S Q E>
1 5 0 1 6 0 1 7 0 1 8 0 1 9 0
TGC ACG AAG TTC AAG GTC AGG AGG TGC CGG GAA TGC ATC GAG TCG GGG
ACG TGC TTC AAG TTC GAG TCG TCG ACG GCC CTT ACG TAG CTC AGG CGC
C T K F K V S S C R E C I E S G>
2 0 0 2 1 0 2 2 0 2 3 0 2 4 0
CGC GGC TGC ACC TGG TGC GAG AAG CTG AAC TTC ACA GGG CCG GGG GAT
GGG CCG ACG TGG ACC ACG GTC TTC GAG TTG AAG TGT CGC GGC CGC CTA
P G C T W C Q K L N F T G P G D:
2 5 0 2 6 0 2 7 0 2 8 0
CCT GAG TGC ATT CGC TGC GAG ACC CGG CCA GAG CTG CTC ATG AGG GGC
GGA CTG AGG TAA GCG ACG CTG TGG GCC GGT GTC GAG GAG TAG TCC CCG
P D S I R C D T R P Q L L M R G>
2 9 0 3 0 0 3 1 0 3 2 0 B 6 1 1 0
TGT GCG GCT GAG GAG ATC ATG GAG CGC ACA AGG CTC GCT GAA ACC CAG
ACA CGC CGA CTG CTG TAG TAG CTG GGG TGT TCG GAG CGA CTT TGG GTC
C A A D D I M D P T S L A E T Q>
3 4 0 3 5 0 3 6 0 3 7 0 3 8 0
GAA GAG CAC AAT GGG GGC GAG AAG GAG CTG TCC CCA CAA AAA GTG ACG
CTT CTG GTG TTA CGC CCG GTC TTC GTC GAG AGG GGT GTT TTT CAC TGC
E D H N G G Q K Q L S P Q K V T>
3 9 0 4 0 0 4 1 0 4 2 0 4 3 0
CTT TAG CTG CGA CCA GGC GAG GCA GCA GCG TTC AAC GTG ACC TTC CGG
GAA ATG GAG GCT GGT CCG GTC CGT CGT CGC AAG TTG CAC TGG AAG GCC
L Y L R P G Q A A A F N V T F R>
4 4 0 4 5 0 4 6 0 4 7 0 4 8 0
CGG GCC AAG GGC TAG CGC ATC GAG CTG TAG TAT CTG ATG GAG CTC TCC
GCC CGG TTC CCG ATG GGG TAG CTG GAG ATG ATA GAG TAG CTG GAG AGG
R A K G Y P I D L Y Y L M D L S>
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4 9 0  5 0 0  5 1 0  5 2 0
TAG TCC ATG CTT GAT GAC CTC AGG AAT GTC AAG AAG CTA GGT GGC GAC
ATG AGG TAG GAA CTA CTG GAG TCC TTA CAG TTC TTC GAT CCA CCG CTG
Y S M L D D L R N V K K L G G D>
5 3 0 5 4 0 5 5 0 5 6 0 5 7 0
CTG CTC CGG GCC CTC AAC GAG ATC ACC GAG TCC GGC CGC ATT GGC TTC
GAC GAG GCC CGG GAG TTG CTC TAG TGG CTC AGG CCG GCG TAA CCG AAG
L L R A L N E I T E S G R I G F>
5 8 0 5 9 0 6 0 0 6 1 0 6 2 0
GGG TCC TTC GTG GAC AAG ACC GTG CTG CCG TTC GTG AAC ACG CAC CCT
CGC AGG AAG CAC CTG TTC TGG CAC GAC GGC AAG CAC TTG TGC GTG GGA
G S F V D K T V L P F V N T H P>
6 3 0 6 4 0 6 5 0 6 6 0 6 7 0
GAT AAG CTG CGA AAC CCA TGC CCC AAC AAG GAG AAA GAG TGC CAG CCC
CTA TTC GAC GCT TTG GGT ACG GGG TTG TTC CTC TTT CTC ACG GTC GGG
D K L R N P C P N K E K E C Q P>
6 8 0 6 9 0 7 0 0 7 1 0 7 2 0
CCG TTT GCC TTC AGG CAC GTG CTG AAG CTG ACC AAC AAC TCC AAC CAG
GGC AAA CGG AAG TCC GTG CAC GAC TTC GAC TGG TTG TTG AGG TTG GTC
P F A F R H V L K L T N N S N Q>
7 3 0  7 4 0  7 5 0  7 6 0
TTT CAG ACC GAG GTC GGG AAG CAG CTG ATT TCC GGA AAC CTG GAT GCA
AAA GTC TGG CTC CAG CCC TTC GTC GAC TAA AGG CCT TTG GAC CTA CGT
F Q T E V G K Q L I S G N L D A>
7 7 0
CCC GAG GGT
GGG CTC CCA
P E G
8 2 0
GAA ATC GGC
CTT TAG CCG
E I G
8 7 0
GAC GGC TTC
CTG CCG AAG
D G F
9 2 0
CCC AAC GAC
GGG TTG CTG
P N D
7 8 0  7 9 0  8 0 0  8 1 0
GGG CTG GAG GCC ATG ATG CAG GTC GCC GCC TGC CCG GAG
CGC GAG CTG CGG TAG TAG GTC CAG CGG CGG ACG GGC CTC
G L D A M M Q V A A C P E >
8 3 0  8 4 0  8 5 0  8 6 0
TGG CGC AAC GTC ACG CGG CTG CTG GTG TTT GCC ACT GAT
ACC GCG TTG CAG TGC GCC GAC GAG CAC AAA CGG TGA CTA
W R N V T R L L V F A T D >
8 8 0  8 9 0  9 0 0  9 1 0
CAT TTC GCG GGC GAC GGA AAG CTG GGC GCC ATC CTG ACC
GTA AAG CGC CCG CTG CCT TTC GAC CCG CGG TAG GAC TGG
H F A G D G K L G A I L T >
9 3 0  9 4 0  9 5 0  9 6 0
GGC CGC TGT CAC CTG GAG GAC AAC TTG TAG AAG AGG AGG
CCG GCG ACA GTG GAC CTC CTG TTG AAC ATG TTC TCC TCG
G R C H L E D N L Y K R S >
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9 7 0  9 8 0  9 9 0  1 0 0 0
AAC GAA TTC GAC TAC CCA TCG GTG GGC CAG CTG GCG CAC AAG CTG GCT
TTG CTT AAG CTG ATG GGT AGG CAC CCG GTC GAC CGC GTG TTC GAC CGA
N E F D Y P S V G Q L A H K L A>
1 0 1 0 1 0 2 0 1 0 3 0 1 0 4 0 1 0 5 0
GAA AAC AAC ATC CAG CCC ATC TTC GCG GTG ACC AGT AGG ATG GTG AAG
CTT TTG TTG TAG GTC GGG TAG AAG CGC CAC TGG TCA TCC TAC CAC TTC
E N N I Q P I F A V T S R M V K>
1 0 6 0 1 0 7 0 1 0 8 0 1 0 9 0 1 1 0 0
ACC TAG GAG AAA CTC ACC GAG ATC ATC CCC AAG TCA GCC GTG GGG GAG
TGG ATG CTC TTT GAG TGG CTC TAG TAG GGG TTC AGT CGG CAC CCC CTC
T Y E K L T E I I P K S A V G E>
1 1 1 0 1 1 2 0 1 1 3 0 1 1 4 0 1 1 5 0
CTG TCT GAG GAC TCC AGG AAT GTG GTC CAT CTC ATT AAG AAT GCT TAC
GAC AGA CTC CTG AGG TCG TTA CAC CAG GTA GAG TAA TTC TTA CGA ATG
L S E D S S N V V H L I K N A Y>
1 1 6 0 1 1 7 0 1 1 8 0 1 1 9 0 1 2 0 0
AAT AAA CTC TCC TCC AGG GTC TTC CTG GAT CAC AAC GCC CTC CCC GAC
TTA TTT GAG AGG AGG TCC CAG AAG GAC CTA GTG TTG CGG GAG GGG CTG
N K L S S R V F L D H N A L P D>
1 2 1 0 1 2 2 0 1 2 3 0 1 2 4 0
ACC CTG AAA GTC ACC TAC GAC TCC TTC TGC AGG AAT GGA GTG ACG CAC
TGG GAC TTT CAG TGG ATG CTG AGG AAG ACG TCG TTA CCT CAC TGC GTG
T L K V T Y D S F C S N G V T H>
1 2 5 0 1 2 6 0 1 2 7 0 1 2 8 0 1 2 9 0
AGG AAC CAG CCC AGA GGT GAC TGT GAT GGC GTG CAG ATC AAT GTC CCG
TCC TTG GTC GGG TCT CCA CTG ACA CTA CCG CAC GTC TAG TTA CAG GGC
R N Q P R G D C D G V Q I N V P>
1 3 0 0 1 3 1 0 1 3 2 0 1 3 3 0 1 3 4 0
ATC ACC TTC CAG GTG AAG GTC ACG GCC ACA GAG TGC ATC CAG GAG CAG
TAG TGG AAG GTC CAC TTC CAG TGC CGG TGT CTC ACG TAG GTC CTC GTC
I T F Q V K V T A T E C I Q E Q>
1 3 5 0 1 3 6 0 1 3 7 0 1 3 8 0 1 3 9 0
TCG TTT GTC ATC CGG GCG CTG GGC TTC ACG GAC ATA GTG ACC GTG CAG
AGG AAA CAG TAG GCC CGC GAC CCG AAG TGC CTG TAT CAC TGG CAC GTC
S F V I R A L G F T D I V T V Q>
1 4 0 0 1 4 1 0 1 4 2 0 1 4 3 0 1 4 4 0
GTT CTT CCC CAG TGT GAG TGC CGG TGC CGG GAC CAG AGC AGA GAC CGC
CAA GAA GGG GTC ACA CTC ACG GCC ACG GCC CTG GTC TCG TCT CTG GCG
V L P Q C E C R C R D Q S R D R>
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1 4 5 0 1 4 6 0 1 4 7 0 1 4 8 0
AGC CTC TGC CAT GGC AAG GGC TTC TTG GAG TGC GGC ATC TGC AGG TGT
TCG GAG ACG GTA CCG TTC CCG AAG AAC CTC ACG CCG TAG ACG TCC ACA
S L C H G K G F L E C G I C R C>
1 4 9 0 1 5 0 0 1 5 1 0 1 5 2 0 1 5 3 0
GAG ACT GGC TAC ATT GGG AAA AAC TGT GAG TGC GAG ACA CAG GGC CGG
CTG TGA CCG ATG TAA CGC TTT TTG ACA CTC ACG GTC TGT GTC CCG GCC
D T G Y I G K N C E C Q T Q G R>
1 5 4 0 1 5 5 0 1 5 6 0 1 5 7 0 1 5 8 0
AGC AGC GAG GAG CTG GAA GGA AGC TGC CGG AAG GAG AAC AAC TCC ATC
TCG TCG GTC CTC GAG CTT CCT TCG ACG GCC TTC CTG TTG TTG AGG TAG
S S Q E L E G S C R K D N N s ' I>
1 5 9 0 1 6 0 0 1 6 1 0 1 6 2 0 1 6 3 0
ATC TGC TCA GGG CTG GGG GAG TGT GTC TGC GGG GAG TGC CTG TGC CAC
TAG ACG AGT CGC GAG CGC CTG ACA GAG ACG CGC GTC ACG GAG ACG GTG
I C S G L G D C V C G Q C L C H>
1 6 4 0 1 6 5 0 1 6 6 0 1 6 7 0 1 6 8 0
ACC AGC GAG GTC CGC GGC AAG CTG ATA TAG GGG GAG TAG TGC GAG TGT
TGG TCG CTG GAG GGG CCG TTC GAG TAT ATG CGC GTC ATG ACG CTC ACA
T S D V P G K L I Y G Q Y C E C>
1 6 9 0 1 7 0 0 1 7 1 0 1 7 2 0
GAG ACC ATC AAC TGT GAG CGC TAC AAC GGC GAG GTC TGC GGC GGC CCG
CTG TGG TAG TTG ACA CTC GCG ATG TTG CCG GTC GAG ACG CCG CCG GGC
D T I N C E R Y N G Q V C G G P:
1 7 3 0 1 7 4 0 1 7 5 0 1 7 6 0 1 7 7 0
GGG AGG GGG CTC TGC TTC TGC GGG AAG TGC CGC TGC CAC CCG GGC TTT
CGC TCC CGC GAG ACG AAG ACG CGC TTC ACG GCG ACG GTG GGC CCG AAA
G R G L C F C G K C R C H P G F>
1 7 8 0 1 7 9 0 1 8 0 0 1 8 1 0 1 8 2 0
GAG GGC TCA GGG TGC GAG TGC GAG AGG ACC ACT GAG GGC TGC CTG AAC
CTC CCG AGT CGC ACG GTC ACG CTC TCC TGG TGA CTC CCG ACG GAG TTG
E G S A C Q C E R T T E G C L N>
1 8 3 0 1 8 4 0 1 8 5 0 1 8 6 0 1 8 7 0
CCG CGG CGT GTT GAG TGT AGT GGT CGT GGC CGG TGC CGC TGC AAC GTA
GGC GCC GCA CAA CTC ACA TCA CCA GCA CCG GCC ACG GCG ACG TTG CAT
P R R V E C S G R G R C R C N V>
1 8 8 0 1 8 9 0 1 9 0 0 1 9 1 0 B 3610
TGC GAG TGC CAT TCA GGC TAC GAG CTG CCT CTG TGC CAG GAG TGC CCC
ACG CTC ACG GTA AGT CCG ATG GTC GAG GGA GAG ACG GTC CTC ACG GGG
C E C H S G Y Q L P L C Q E C P>
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1 9 3 0 1 9 4 0 1 9 5 0 1 9 6 0
GGC TGC CCC TCA CCC TGT GGC AAG TAC ATC TCC TGC GCC GAG TGC CTG
CCG ACG GGG AGT GGG ACA CCG TTC ATG TAG AGG ACG CGG CTC ACG GAC
G C P S P C G K Y I S C A E C L>
1 9 7 0  S f u  I 1 9 9 0 2 0 0 0 2 0 1 0
AAG TTC GAA AAG GGC CCC TTT GGG AAG AAC TGC AGC GCG GCG TGT CCG
TTC AAG CTT TTC CCG GGG AAA CCC TTC TTG ACG TCG CGC CGC ACA GGC
K F E K G P F G K N C S A A C P>
2 0 2 0 2 0 3 0 2 0 4 0 2 0 5 0 2 0 6 0
GGC CTG CAG CTG TCG AAC AAC CCC GTG AAG GGC AGG ACC TGC AAG GAG
CCG GAG GTC GAC AGC TTG TTG GGG CAC TTC CCG TCC TGG ACG TTC CTC
G L Q L S N N P V K G R T C K E>
2 0 7 0 2 0 8 0 2 0 9 0 2 1 0 0 2 1 1 0
AGG GAC TCA GAG GGC TGC TGG GTG GCC TAC ACG CTG GAG CAG CAG GAC
TCC CTG AGT CTC CCG ACG ACC CAC CGG ATG TGC GAC CTC GTC GTC CTG
R D S E G C W V A Y T L E Q Q D>
2 1 2 0 2 1 3 0 2 1 4 0 2 1 5 0 2 1 6 0
GGG ATG GAC CGC TAC CTC ATC TAT GTG GAT GAG AGC CGA GAG TGT GTG
CCC TAC CTG GCG ATG GAG TAG ATA CAC CTA CTC TCG GCT CTC ACA CAC
G M D R Y L I  Y V D E S R E C V>
2 1 7 0 2 1 8 0 2 1 9 0 2 2 0 0
GCA GGC CCC AAC ATC GCC GCC ATC GTC GGG GGC ACC GTG GCA GGC ATC
CGT CCG GGG TTG TAG CGG CGG TAG CAG CCC CCG TGG CAC CGT CCG TAG
A G P N I A A I V G G T V A G I>
CAG CTG GGA ACC OLIGO TO INTRODUCE S a l J  S I T E ( B 3 6 1 1 )
2 2 1 0 2 2 2 0 2 2 3 0 2 2 4 0 2 2 5 0
GTG CTG ATC GGC ATT CTC CTG CTG GTC ATC TGG AAG GCT CTG ATC CAC
CAC GAC TAG CCG TAA GAG GAC GAC CAG TAG ACC TTC CGA GAC TAG GTG
V L I G I L L L V I W K A L I H>
2 2 6 0 2 2 7 0 2 2 8 0 2 2 9 0 2 3 0 0
CTG AGC GAC CTC CGG GAG TAC AGG CGC TTT GAG AAG GAG AAG CTC AAG
GAC TCG CTG GAG GCC CTC ATG TCC GCG AAA CTC TTC CTC TTC GAG TTC
L S D L R E Y R R F E K E K L K>
2 3 1 0 2 3 2 0 2 3 3 0 2 3 4 0 2 3 5 0
TCC CAG TGG AAC AAT GAT AAT CCC CTT TTC AAG AGC GCC ACC ACG ACG
AGG GTC ACC TTG TTA CTA TTA GGG GAA AAG TTC TCG CGG TGG TGC TGC
S Q W N N D N P L F K S A T T T>
2 3 6 0 2 3 7 0 2 3 8 0
GTC ATG AAC CCC AAG TTT GCT GAG AGT TAG 
CAG TAG TTG GGG TTC AAA CGA CTC TCA ATC 
V M N P K F A E S *
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hCDlla DNA sequence and protein translation with highlighted regions indicating 
mutations and insertions required to generated a soluble form of CDlla. All oligos 
and restriction sites used in the process are also highlighted.
A b LEADER SEQUENCE OLIGO (B61 1 4 )
GGC CAA GCT TCC GCC ACC ATG GCT TGG GTG TGG AAC TTG
ATG AAG GAT TCC TGC ATC ACT GTG ATG GCC ATG GCG CTG
TAC TTC CTA AGG ACG TAG TGA CAC TAC CGG TAC CGC GAC
M K D S C I T V M A M A L
CTA TTC CTG ATG GCA GCT GCC CAA AGT GCC CAA GCA
CTG TCT GGG TTC TTT TTC TTC GCG CCG GCC TCG AGC TAC AAC CTG GAC
GAC AGA CCC AAG AAA AAG AAG CGC GGC CGG AGC TCG ATG TTG GAC CTG
L S G F F F F A P A S S Y N L D>
1 6 0 1 8 0 1 9 0 2 0 0 2 1 0
GTG CGG GGC GCG CGG AGC TTC TCC CCA CCG CGC GCC GGG AGG CAC TTT
CAC GCC CCG CGC GCC TCG AAG AGG GGT GGC GCG CGG CCC TCC GTG AAA
V R G A R S F S P P R A G R H F>
2 2 0 2 3 0 2 4 0 2 5 0 2 6 0 2 7 0
GGA TAC CGC GTC CTG CAG GTC GGA AAC GGG GTC ATC GTG GGA GCT CCA
CCT ATG GCG CAG GAC GTC CAG CCT TTG CCC CAG TAG CAC CCT CGA GGT
G Y R V L Q V G N G V I V G A P>
2 8 0 2 9 0 3 0 0 3 1 0 3 2 0
GGG GAG GGG AAC AGC ACA GGA AGC CTC TAT CAG TGC CAG TCG GGC ACA
CCC CTC CCC TTG TCG TGT CCT TCG GAG ATA GTC ACG GTC AGC CCG TGT
G E G N S T G S L Y Q C Q S G T>
3 3 0 3 4 0 3 5 0 3 6 0 3 7 0
GGA CAC TGC CTG CCA GTC ACC CTG AGA GGT TCC AAC TAT ACC TCC AAG
CCT GTG ACG GAC GGT CAG TGG GAC TCT CCA AGG TTG ATA TGG AGG TTC
G H C L P V T L R G S N Y T S K>
3 8 0 3 9 0 4 0 0 4 1 0 4 2 0
TAC TTG GGA ATG ACC TTG GCA ACA GAC CGC ACA GAT GGA AGC ATT TTG
ATG AAC CCT TAC TGG AAC CGT TGT CTG GGG TGT CTA CCT TCG TAA AAC
Y L G M T L A T D P T D G S I L>
4 3 0 4 4 0 4 5 0 4 6 0 4 7 0
GCC TGT GAC CCT GGG CTG TCT CGA ACG TGT GAC CAG AAC ACC TAT CTG
CGG ACA CTG GGA CCC GAC AGA GCT TGC ACA CTG GTC TTG TGG ATA GAC
A C D P G L S R T C D Q N T Y L>
4 8 0 B 6112 4 9 0 5 0 0 5 1 0 5 2 0
AGT GGC CTG TGT TAC CTC TTC CGC CAG AAT CTG CAG GGT CCC ATG CTG
TCA CCG GAC ACA ATG GAG AAG GCG GTC TTA GAC GTC CCA GGG TAC GAC
S G L C Y L F R Q N L Q G P M L>
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Nar 1 550 5 6 0  5 7 0
CAG GGG CGC CCT GGT TTT CAG GAA T G T ATC AAG GGC AAC G T A GAC CTG
GTC CCC GCG GGA CCA AAA GTC CTT ACA TAG TTC CCG TTG CAT CTG GAC
Q G R P G F Q E C I K G N V D L>
START OF I DOMAIN B 6 1 0 9
5 8 0 5 9 0 6 0 0 6 1 0 6 2 0
GTA TTT CTG TTT GAT GGT TCG ATG AGC T T G CAG CCA GAT GAA TTT CAG
CAT AAA GAC AAA CTA CCA AGC TAC TCG AAC GTC GGT CTA C T T AAA GTC
V F L F D G S M S L Q P D E F 0>
6 3 0 6 4 0 6 5 0 6 6 0 6 7 0
AAA A T T CTG GAC T T C ATG AAG GAT GTG ATG AAG AAA C T C AGC AAC A C T
T T T TAA GAC CTG AAG TAC TTC CTA CAC TAC T T C TTT GAG TCG T T G TGA
K I L D F M K D y M K K L S N T>
6 8 0 6 9 0 7 0 0 7 1 0 7 2 0
TCG T A C CAG T T T GCT GCT G T T CAG T T T TCC ACA AGC TAC AAA ACA GAA
AGC ATG GTC AAA CGA CGA CAA GTC AAA AGG TGT TCG ATG T T T T G T C T T
S y Q F A A V Q F S T S Y K T E>
7 3 0 7 4 0 7 5 0 7 6 0
TTT G A T TTC TCA GAT T A T G T T AAA T G G AAG GAC CCT GAT GCT CTG CTG
AAA CTA AAG AGT CTA ATA CAA T T T ACC T T C CTG GGA CTA CGA GAC GAC
F D F S D Y V K W K D P D A L L >
7 7 0 7 8 0 7 9 0 8 0 0 8 1 0
AAG C A T GTA AAG CAC ATG T T G CTG T T G ACC AAT ACC T T T GGT GCC ATC
T T C GTA C A T T T C GTG TAC AAC GAC AAC TGG T T A TGG AAA CCA CGG TAG
K H V K H M L L L T N T F G A I >
B 8 5 4 9 8 3 0 8 4 0 8 5 0 8 6 0
A A T T A T GTC GCG ACA GAG GTG T T C CGG GAG GAG CTG GGG GCC CGG CCA
TTA ATA CAG CGC T G T CTC CAC AAG GCC CTC CTC GAC CCC CGG GCC GGT
N Y V A T E V F R E E L G A R P >
8 7 0 B8553 8 9 0 9 0 0 9 1 0
G A T GCC ACC AAA GTG CTT ATC ATC ATC ACG GAT GGG GAG GCC ACT GAC
CTA CGG TGG T T T CAC GAA TAG TAG TAG TGC CTA CCC CTC CGG TGA CTG
D A T K V L I I I T D G E A T D >
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9 2 0 9 3 0 9 4 0 9 5 0 9 6 0
AGT GGC AAC ATC GAT GCG GCC AAA G A C ATC ATC CGC T A C ATC A T C G G G
TCA CCG TTG TAG CTA CGC CGG T T T CTG TAG TAG GCG ATG T A G T A G CCC
S G N I D A A K D I I R Y I I G >
9 7 0 9 8 0 9 9 0 1 0 0 0
ATT GGA AAG CAT T T T CAG ACC AAG GAG AGT CAG GAG ACC CTC CAC AAA
TAA CCT T T C GTA AAA GTC TGG T T C CTC TCA GTC CTC TGG GAG G T G T T T
I G K H F Q T K E S Q E T L H K >
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A P P E N D I X !
1 0 1 0  1 0 2 0  1 0 3 0  1 0 4 0  1 0 5 0
T T T  G C A  T C A  AAA C C C  G C G  A G C  G A G  T T T  G T G  AAA A T T  CTG G A C  A C A  TTT
AAA C G T  A G T  T T T  G G G  C G C  T C G  C T C  AAA C A C  TTT TAA GAC C T G  T G T  AAA
F A S K P A S E F V K I L D T F >
2 8 7  2 8 9  2 9 2
1 0 6 0  1 0 7 0  1 0 8 0  1 0 9 0  1 1 0 0
GAG AAG CTG A A A  G A T  C T A  TTC A C T  G A G  C T G  C A G  A A G  AAG ATC TAT G T C
C T C  TTC GAC T T T  C T A  G A T  AAG T G A  C T C  G A C  G T C  T T C  T T C  TAG ATA C A G
E K L K D L F T E  L  Q K K I Y V >  
2 9 4  2 9 5  2 9 9  3 0 6
1 1 2 0  1 1 3 0  1 1 4 0  1 1 5 0
A T T  G A G  G G C  ACA AGC AAA CAG GAC CTG ACT TCC TTC AAC ATG GAG CTG
T A A  C T C  C C G  TGT TCG T T T  GTC CTG GAC TGA AGG AAG TTG TAC CTC GAC
I  E  G  T S K Q D L T S F N M E L >  
END OF I  D O M AIN
1 1 6 0  1 1 7 0  1 1 8 0  1 1 9 0  1 2 0 0
TCC TCC AGC GGC ATC AGT GCT GAC CTC AGC AGG GGC CAT GCA GTC GTG
AGG AGG TCG CCG TAG TCA CGA CTG GAG TCG TCC CCG GTA CGT CAG CAC
S S S G I S A D L S R G H A V V >
B 8 5 5 0  1 2 2 0  1 2 3 0  1 2 4 0
GGG GCA GTA GGA GCC AAG GAC TGG GCT GGG GGC T T T  CTT GAC CTG AAG
CCC CGT CAT CCT CGG TTC CTG ACC CGA CCC CCG AAA GAA CTG GAC TTC
G A V G A K D W A G G F L D L K >
1 2 5 0  1 2 6 0  1 2 7 0  1 2 8 0  1 2 9 0
GCA GAC CTG CAG GAT GAC ACA TTT ATT GGG AAT GAA CCA TTG ACA CCA
CGT CTG GAC GTC CTA CTG TGT AAA TAA CCC TTA CTT GGT AAC TGT GGT
A D L Q D D T F I G N E P L T P >
B 8 5 5 4  1 3 1 0  1 3 2 0  1 3 3 0  1 3 4 0
GAA GTG AGA GCA GGC TAT TTG GGT TAC ACC GTG ACC TGG CTG CCC TCC
CTT CAC TCT CGT CCG ATA AAC CCA ATG TGG CAC TGG ACC GAC GGG AGG
E V R A G Y L G Y T V T W L P S >
1 3 5 0  1 3 6 0  1 3 7 0  1 3 8 0  1 3 9 0
CGG CAA AAG ACT TCG TTG CTG GCC TCG GGA GCC CCT CGA TAC CAG CAC
GCC GTT TTC TGA AGC AAC GAC CGG AGC CCT CGG GGA GCT ATG GTC GTG
R Q K T S L L A S G A P R Y Q H >
1 4 0 0  1 4 1 0  1 4 2 0  1 4 3 0  1 4 4 0
ATG GGC CGA GTG CTG CTG TTC CAA GAG CCA CAG GGC GGA GGA CAC TGG
TAC CCG GCT CAC GAC GAC AAG GTT CTC GGT GTC CCG CCT CCT GTG ACC
M G R V L L F Q E P Q G G G H W >
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A P P E N D I X !
1 4 5 0  1 4 6 0  1 4 7 0  1 4 8 0
AGC CAG GTC CAG ACA ATC CAT GGG 
TCG GTC CAG GTC TGT TAG GTA CCC 
S Q V Q T I H G
1 4 9 0  1 5 0 0  1 5 1 0
G E L C G V D V
1 5 4 0  1 5 5 0  1 5 6 0
CTG CTG A TT GGT GCC CCA CTG TTC
GAC GAC TAA CCA CGG GGT GAC AAG
L L I G A P L F
1 5 9 0  1 6 0 0  1 6 1 0
GTG T T T  ATC TAC CAG AGA AGA CAG 
CAC AAA TAG ATG GTC TCT TCT GTC 
V F I Y Q R R Q
1 6 4 0  1 6 5 0  1 6 6 0
CTG CAG GGG GAC CCC GGC TAC CCA
GAC GTC CCC CTG GGG CCG ATG GGT
L Q G D P G Y P
1 6 9 0  B 8 5 5 5
ACT GCT CTG ACA GAC ATC AAC GGC
TGA CGA GAC TGT CTG TAG TTG CCG
T A L T D I N G
1 7 3 0  1 7 4 0  1 7 5 0
GGG GCC CCT CTG GAG GAG CAG GGG
CCC CGG GGA GAC CTC CTC GTC CCC
G A P L E E Q G
1 7 8 0  1 7 9 0  1 8 0 0
CAC GGG GGG CTT AGT CCC CAG CCA
GTG CCC CCC GAA TCA GGG GTC GGT
H G  G L S P Q P
1 8 3 0  1 8 4 0  1 8 5 0
GTG CTC TCA GGA A TT CAG TGG TTT
CAC GAG AGT CCT TAA GTC ACC AAA
V L S G I Q W F
1 8 8 0  1 8 9 0  1 9 0 0
GAC CTT GAA GGG GAT GGC TTG GCA
CTG GAA CTT CCC CTA CCG AAC CGT
D L E G D G L A
ACC CAG AT T GGC TCT TAT TTC GGT
TGG GTC TAA CCG AGA AT A AAG CCA
T Q I G S Y F G>
1 5 2 0 1 5 3 0
GAC CAA GAT GGG GAG ACA GAG CTG
CTG GTT CTA CCC CTC TGT CTC GAC
D Q D G E T E L>
B 8 5 5 1 1 5 8 0
TAT GGG GAG CAG AGA GGA GGC CGG
ATA CCC CTC GTC TCT CCT CCG GCC
Y G E Q R G G R>
1 6 2 0 1 6 3 0
TTG GGG TTT GAA GAA GTC TCA GAG
AAC CCC AAA CTT CTT CAG AGT CTC
L G F E E V S E>
1 6 7 0 1 6 8 0
CTC GGG CGG TTT GGA GAA GCC ATC
GAG CCC GCC AAA CCT CTT CGG TAG
L G R F G E A I >
L 710 1 7 2 0
GAT GGG CTG GTA GAC GTG GCT GTG
CTA CCC GAC CAT CTG CAC CGA CAC
D G L V D V A V>
1 7 6 0 1 7 7 0
GCT GTG TAC ATC TTC AAT GGG AGG
CGA CAC ATG TAG AAG TTA CCC TCC
A V Y I F N G R>
1 1 8 1 0 1 8 2 0
AGT CAG CGG ATA GAA GGG ACC CAA
TCA GTC GCC TAT CTT CCC TGG GTT
S Q R I E G T Q>
1 8 6 0 1 8 7 0
GGA CGC TCC ATC CAT GGG GTG AAG
CCT GCG AGG TAG GTA CCC CAC TTC
G R S I H G V K>
1 9 1 0 1 9 2 0
GAT GTG GCT GTG GGG GCT GAG AGC
CTA CAC CGA CAC CCC CGA CTC TCG
D V A V G A E S >
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APPENDIX 2
1 9 3 0  1 9 4 0  1 9 5 0  1 9 6 0
CAG ATG ATC GTG CTG AGC TCC CGG CCC GTG GTG GAT ATG GTC ACC CTG
GTC TAC TAG CAC GAC TCG AGG GCC GGG CAC CAC CTA TAC CAG TGG GAC
Q M I V L S S R P V V D M V T L>
1 9 7 0 1 9 8 0 1 9 9 0 2 0 0 0 B 8 5 5 2
ATG TCC TTC TCT CCA GCT GAG ATC CCA GTG CAT GAA GTG GAG TGC TCC
TAC AGG AAG AGA GGT CGA CTC TAG GGT CAC GTA CTT CAC CTC ACG AGG
M S F S P A E I P V H E V E C S>
2 0 2 0 2 0 3 0 2 0 4 0 2 0 5 0 2 0 6 0
TAT TCA ACC AGT AAC AAG ATG AAA GAA GGA GTT AAT ATC ACA ATC TGT
ATA AGT TGG TCA TTG TTC TAC TTT CTT CCT CAA TTA TAG TGT TAG ACA
Y S T S N K M K E G V N I T I C>
2 0 7 0 2 0 8 0 2 0 9 0 B 8 5 5 6 2 1 1 0
TTC CAG ATC AAG TCT CTC TAC CCC CAG TTC CAA GGC CGC CTG GTT GCC
AAG GTC TAG TTC AGA GAG ATG GGG GTC AAG GTT CCG GCG GAC CAA CGG
F Q I K S L Y P Q F Q G R L V A>
2 1 2 0 2 1 3 0 2 1 4 0 2 1 5 0 2 1 6 0
AAT CTC ACT TAC ACT CTG CAG CTG GAT GGC CAC CGG ACC AGA AGA CGG
TTA GAG TGA ATG TGA GAC GTC GAC CTA CCG GTG GCC TGG TCT TCT GCC
N L T Y T L Q L D G H R T R R R>
2 1 7 0 2 1 8 0 2 1 9 0 2 2 0 0
GGG TTG TTC CCA GGA GGG AGA CAT GAA CTC AGA AGG AAT ATA GCT GTC
CCC AAC AAG GGT CCT CCC TCT GTA CTT GAG TCT TCC TTA TAT CGA CAG
G L F P G G R H E L R R N I A V>
2 2 1 0 2 2 2 0 2 2 3 0 2 2 4 0 2 2 5 0
ACC ACC AGC ATG TCA TGC ACT GAC TTC TCA TTT CAT TTC CCG GTA TGT
TGG TGG TCG TAC AGT ACG TGA CTG AAG AGT AAA GTA AAG GGC CAT ACA
T T S M S C T D F S F H F P V C>
2 2 6 0 2 2 7 0 2 2 8 0 2 2 9 0 2 3 0 0
GTT CAA GAC CTC ATC TCC CCC ATC AAT GTT TCC CTG AAT TTC TCT CTT
CAA GTT CTG GAG TAG AGG GGG TAG TTA CAA AGG GAC TTA AAG AGA GAA
V Q D L I S P I N V S L N F S L>
2 3 1 0 2 3 2 0 2 3 3 0 2 3 4 0 2 3 5 0
TGG GAG GAG GAA GGG ACA CCG AGG GAC CAA AGG GCG CAG GGC AAG GAC
ACC CTC CTC CTT CCC TGT GGC TCC CTG GTT TCC CGC GTC CCG TTC CTG
W E E E G T P R D Q R A Q G K D>
2 3 6 0 2 3 7 0 B 8 5 5 7 2 3 9 0 2 4 0 0
ATA CCG CCC ATC CTG AGA CCC TCC CTG CAC TCG GAA ACC TGG GAG ATC
TAT GGC GGG TAG GAC TCT GGG AGG GAC GTG AGC CTT TGG ACC CTC TAG
I  P P I  L R P S L H S E T W E I >
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2 4 1 0  2 4 2 0  2 4 3 0  2 4 4 0
CCT TTT GAG AAG AAC TGT GGG GAG GAC AAG AAG TGT GAG GCA AAC TTG
GGA AAA CTC TTC TTG ACA CCC CTC CTG TTC TTC ACA CTC CGT TTG AAC
P F E K N C G E D K K C E A N L>
2 4 5 0 2 4 6 0 2 4 7 0 B 8 5 5 9 2 4 9 0
AGA GTG TCC TTC TCT CCT GCA AGA TCC AGA GCC CTG CGT CTA ACT GCT
TCT CAC AGG AAG AGA GGA CGT TCT AGG TCT CGG GAC GCA GAT TGA CGA
R V S F S P A R S R A L R L T A>
2 5 0 0 2 5 1 0 2 5 2 0 2 5 3 0 2 5 4 0
TTT GCC AGC CTC TCT GTG GAG CTG AGC CTG AGT AAC TTG GAA GAA GAT
AAA CGG TCG GAG AGA CAC CTC GAC TCG GAC TCA TTG AAC CTT CTT CTA
F A S L S V E L S L S N L E E D>
2 5 5 0 2 5 6 0 2 5 7 0 2 5 8 0 2 5 9 0
GCT TAC TGG GTC CAG CTG GAC CTG CAC TTC CCC CCG GGA CTC TCC TTC
CGA ATG ACC CAG GTC GAC CTG GAC GTG AAG GGG GGC CCT GAG AGG AAG
A Y W V Q L D L H F P P G L S F>
2 6 0 0 2 6 1 0 2 6 2 0 2 6 3 0 2 6 4 0
CGC AAG GTG GAG ATG CTG AAG CCC CAT AGC CAG ATA CCT GTG AGC TGC
GCG TTC CAC CTC TAC GAC TTC GGG GTA TCG GTC TAT GGA CAC TCG ACG
R K V E M L K P H S Q I P V S C>
2 6 5 0 2 6 6 0 2 6 7 0 2 6 8 0
GAG GAG CTT CCT GAA GAG TCC AGG CTT CTG TCC AGG GCA TTA TCT TGC
CTC CTC GAA GGA CTT CTC AGG TCC GAA GAC AGG TCC CGT AAT AGA ACG
E E L P E E S R L L S R A L S C>
2 6 9 0 2 7 0 0 2 7 1 0 2 7 2 0 2 7 3 0
AAT GTG AGC TCT CCC ATC TTC AAA GCA GGC CAC TCG GTT GCT CTG CAG
TTA CAC TCG AGA GGG TAG AAG TTT CGT CCG GTG AGC CAA CGA GAC GTC
N V S S P I F K A G H S V A L Q>
2 7 4 0  B 8 5 5 8 2 7 6 0 2 7 7 0 2 7 8 0
ATG ATG TTT AAT ACA CTG GTA AAC AGC TCC TGG GGG GAC TCG GTT GAA
TAC TAC AAA TTA TGT GAC CAT TTG TCG AGG ACC CCC CTG AGC CAA CTT
M M , F N T L V N S S W G D S V E>
2 7 9 0 2 8 0 0 2 8 1 0 B 3 6 0 6 2 8 3 0
TTG CAC GCC AAT GTG ACC TGT AAC AAT GAG GAC TCA GAC CTC CTG GAG
AAC GTG CGG TTA CAC TGG ACA TTG TTA CTC CTG AGT CTG GAG GAC CTC
L H A N V T C N N E D S D L L E>
2 8 4 0 2 8 5 0 2 8 6 0 2 8 7 0 2 8 8 0
GAC AAC TCA GCC ACT ACC ATC ATC CCC ATC CTG TAC CCC ATC AAC ATC
CTG TTG AGT CGG TGA TGG TAG TAG GGG TAG GAC ATG GGG TAG TTG TAG
D N S A T T I I P I L Y P I N I >
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A PPENDIX 2
2 8 9 0  2 9 0 0  2 9 1 0  2 9 2 0
CTC ATC CAG GAC CAA GAA GAC TCC ACA CTC TAT GTC AGT TTC ACC CCC
GAG TAG GTC CTG GTT CTT CTG AGG TGT GAG ATA CAG TCA AAG TGG GGG
L I Q D Q E D S T L Y V S F T P >
2 9 3 0  2 9 4 0  2 9 5 0  2 9 6 0  BairiH I
AAA GGC CCC AAG ATC CAC CAA GTC AAG CAC ATG TAC CAG GTG AGG ATC
TTT CCG GGG TTC TAG GTG GTT CAG TTC GTG TAC ATG GTC CAC TCC TAG
K G P K I H Q V K H M Y Q V R I >
2 9 8 0  2 9 9 0  3 0 0 0  3 0 1 0  3 0 2 0
CAG CCT TCC ATC CAC GAC CAC AAC ATA CCC ACC CTG GAG GCT GTG GTT
GTC GGA AGG TAG GTG CTG GTG TTG TAT GGG TGG GAC CTC CGA CAC CAA
Q P S I H D H N I P T L E A V V >
3 0 3 0  3 0 4 0  3 0 5 0  3 0 6 0  3 0 7 0
GGG GTG CCA CAG CCT CCC AGC GAG GGG CCC ATC ACA CAC CAG TGG AGC
CCC CAC GGT GTC GGA GGG TCG CTC CCC GGG TAG TGT GTG GTC ACC TCG
G V P Q P P S E G P I T H Q W S >
3 0 8 0  3 0 9 0  3 1 0 0  3 1 1 0  B 3 6 0 7
GTG CAG ATG GAG CCT CCC GTG CCC TGC CAC TAT GAG GAT CTG GAG AGG
CAC GTC TAC CTC GGA GGG CAC GGG ACG GTG ATA CTC CTA GAC CTC TCC
V Q M E P P V P C H Y E D L E R >
3 1 3 0  3 1 4 0  3 1 5 0  3 1 6 0
CTC CCG GAT GCA GCT GAG CCT TGT CTC CCC GGA GCC CTG TTC CGC TGC
GAG GGC CTA CGT CGA CTC GGA ACA GAG GGG CCT CGG GAC AAG GCG ACG
L P D A A E P C L P G A L F R C >
3 1 7 0  3 1 8 0  3 1 9 0  3 2 0 0  B 3 6 0 8
CCT GTT GTC TTC AGG CAG GAG ATC CTC GTC CAA GTG ATC GGG ACT CTG
GGA CAA CAG AAG TCC GTC CTC TAG GAG CAG GTT CAC TAG CCC TGA GAC
P V V F R Q E I L V Q V I G T L >
3 2 2 0  3 2 3 0  3 2 4 0  3 2 5 0  3 2 6 0
GAG CTG GTG GGA GAG ATC GAG GCC TCT TCC ATG TTC AGC CTC TGC AGC
CTC GAC CAC CCT CTC TAG CTC CGG AGA AGG TAC AAG TCG GAG ACG TCG
E L V G E I E A S S M F S L C S >
3 2 7 0  3 2 8 0  3 2 9 0  3 3 0 0  3 3 1 0
TCC CTC TCC ATC TCC TTC AAC AGC AGC AAG CAT TTC CAC CTC TAT GGC
AGG GAG AGG TAG AGG AAG TTG TCG TCG TTC GTA AAG GTG GAG ATA CCG
S L S I S F N S S K H F H  L Y G >
3 3 2 0  3 3 3 0  3 3 4 0  3 3 5 0  3 3 6 0
AGC AAC GCC TCC CTG GCC CAG GTT GTC ATG AAG GTT GAC GTG GTG TAT
TCG TTG CGG AGG GAC CGG GTC CAA CAG TAC TTC CAA CTG CAC CAC ATA
S N A S L A Q V V M K V D V V Y >
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3 3 7 0  3 3 8 0  3 3 9 0  3 4 0 0
GAG AAG CAG ATG CTC TAC CTC TAC GTG CTG AGC GGC ATC GGG GGG CTG
CTC TTC GTC TAC GAG ATG GAG ATG CAC GAC TCG CCG TAG CCC CCC GAC
E K Q M L Y L Y V L S G I G G L >
TCC AGC TGA ATT O L IG O  TO IN T RO D U C E  S a l  I  S I T E ( B 3 6 0 9 )
3 4 1 0  3 4 2 0  3 4 3 0  3 4 4 0  3 4 5 0
CTG CTG CTG CTG CTC A TT TTC ATA GTG CTG TAC AAG GTT GGT TTC TTC
GAC GAC GAC GAC GAG TAA AAG TAT CAC GAC ATG TTC CAA CCA AAG AAG
L L L L L I F I V L Y K V G F F >
3 4 6 0  3 4 7 0  3 4 8 0  3 4 9 0  3 5 0 0
AAA CGG AAC CTG AAG GAG AAG ATG GAG GCT GGC AGA GGT GTC CCG AAT
TTT GCC TTG GAC TTC CTC TTC TAC CTC CGA CCG TCT CCA CAG GGC TTA
K R N L K E K M E A G R G V P N >
3 5 1 0  3 5 2 0  3 5 3 0  3 5 4 0  3 5 5 0
GGA ATC CCT GCA GAA GAC TCT GAG CAG CTG GCA TCT GGG CAA GAG GCT
CCT TAG GGA CGT CTT CTG AGA CTC GTC GAC CGT AGA CCC GTT CTC CGA
G I P A E D S E Q L A S G Q E A >
3 5 6 0  3 5 7 0  3 5 8 0  3 5 9 0  3 6 0 0
GGG GAT CCC GGC TGC CTG AAG CCC CTC CAT GAG AAG GAC TCT GAG AGT
CCC CTA GGG CCG ACG GAC TTC GGG GAG GTA CTC TTC CTG AGA CTC TCA
G D P G C L K P L H E K D S E S >
3 6 1 0
GGT GGT GGC AAG GAC TGA
CCA CCA CCG TTC CTG ACT
G G G K D *>
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